data_2m37_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m37 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 37.9 mt . . . . . 0 CA--C 1.513 -0.446 0 N-CA-C 109.277 -0.638 . . . . 72.150000000000006 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -160.76 -170.13 2.64 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 117.344 -1.313 . . . . 73.049999999999997 109.756 -170.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -119.86 51.51 1.18 Allowed 'General case' 0 C--N 1.36 1.062 0 CA-C-N 119.404 1.002 . . . . 71.120000000000005 110.956 -178.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.06 -141.99 1.41 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.763 . . . . 54.130000000000003 112.489 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.55 -30.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.801 0.334 . . . . 74.409999999999997 111.121 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -96.06 121.21 61.33 Favored Pre-proline 0 C--N 1.358 0.968 0 O-C-N 117.801 -3.062 . . . . 74.519999999999996 107.741 -175.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -78.56 168.12 21.72 Favored 'Trans proline' 0 C--N 1.362 1.269 0 CA-C-N 123.65 2.339 . . . . 74.409999999999997 111.328 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -102.21 -62.27 1.29 Allowed 'General case' 0 C--N 1.357 0.918 0 CA-C-O 117.915 -1.041 . . . . 74.519999999999996 108.351 174.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.1 mt -146.95 -64.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.092 0 CA-C-N 119.22 0.918 . . . . 75.310000000000002 109.293 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.57 -132.59 6.38 Favored Glycine 0 C--N 1.359 1.818 0 N-CA-C 107.918 -2.073 . . . . 73.310000000000002 107.918 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -93.99 62.51 3.11 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 120.131 1.966 . . . . 75.409999999999997 108.591 176.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.3 t -139.21 160.45 39.77 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 117.885 -1.055 . . . . 72.420000000000002 108.578 176.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -150.42 165.64 32.53 Favored 'General case' 0 C--N 1.352 0.697 0 CA-C-O 118.411 -0.804 . . . . 74.430000000000007 110.862 -170.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -81.97 174.98 10.75 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-N 119.004 0.82 . . . . 74.219999999999999 111.539 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 . . . . . 0 C--N 1.358 0.945 0 CA-C-O 117.767 -1.111 . . . . 61.240000000000002 109.893 -175.98 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.3 mt . . . . . 0 CA--C 1.514 -0.424 0 N-CA-C 108.806 -0.813 . . . . 70.129999999999995 108.806 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.6 m -157.56 -169.92 3.04 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 117.589 -1.196 . . . . 73.099999999999994 109.215 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -120.6 51.45 1.23 Allowed 'General case' 0 C--N 1.358 0.962 0 CA-C-N 119.096 0.862 . . . . 75.510000000000005 110.888 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -142.0 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.694 -0.765 . . . . 62.219999999999999 112.477 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.54 -30.05 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.819 0.342 . . . . 73.010000000000005 111.105 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.62 121.63 59.31 Favored Pre-proline 0 C--N 1.358 0.972 0 O-C-N 117.774 -3.079 . . . . 74.109999999999999 107.736 -175.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.14 167.95 22.57 Favored 'Trans proline' 0 C--N 1.363 1.334 0 CA-C-N 123.7 2.357 . . . . 75.400000000000006 111.459 -176.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.17 -62.13 1.28 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.119 -0.943 . . . . 65.299999999999997 108.666 174.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.5 mt -148.22 -64.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.055 0 CA-C-N 119.106 0.866 . . . . 74.209999999999994 110.155 -174.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.2 -95.12 1.18 Allowed Glycine 0 C--N 1.357 1.737 0 N-CA-C 108.798 -1.721 . . . . 54.530000000000001 108.798 -174.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -136.54 54.09 1.89 Allowed 'General case' 0 C--N 1.355 0.827 0 N-CA-C 107.019 -1.474 . . . . 72.129999999999995 107.019 -178.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.2 t -138.13 163.85 30.63 Favored 'General case' 0 C--N 1.356 0.875 0 N-CA-C 107.602 -1.258 . . . . 71.409999999999997 107.602 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -149.38 165.48 31.92 Favored 'General case' 0 C--N 1.351 0.673 0 CA-C-N 119.232 0.924 . . . . 74.230000000000004 110.941 -171.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -81.02 174.41 11.64 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 118.127 -0.939 . . . . 74.319999999999993 111.545 -176.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.359 0.997 0 CA-C-O 118.054 -0.974 . . . . 72.540000000000006 109.48 -175.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.0 mt . . . . . 0 CA--C 1.515 -0.401 0 N-CA-C 108.689 -0.856 . . . . 73.420000000000002 108.689 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -159.15 -171.6 3.43 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-O 117.397 -1.287 . . . . 70.340000000000003 109.576 -172.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -119.83 51.47 1.18 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-N 119.22 0.918 . . . . 74.510000000000005 110.901 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -141.99 1.37 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.744 -0.741 . . . . 62.140000000000001 112.513 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.58 -29.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.812 0.339 . . . . 75.109999999999999 111.107 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -97.52 120.65 60.27 Favored Pre-proline 0 C--N 1.359 1.018 0 O-C-N 117.568 -3.208 . . . . 60.409999999999997 107.773 -174.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.2 166.07 25.04 Favored 'Trans proline' 0 C--N 1.364 1.364 0 CA-C-N 123.653 2.34 . . . . 75.109999999999999 111.314 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -99.61 -62.2 1.27 Allowed 'General case' 0 C--N 1.358 0.953 0 N-CA-C 108.402 -0.962 . . . . 74.400000000000006 108.402 175.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.2 mt -148.03 -64.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.025 0 CA-C-O 118.39 -0.814 . . . . 65.230000000000004 109.683 -174.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.46 -114.25 1.89 Allowed Glycine 0 C--N 1.358 1.786 0 N-CA-C 108.488 -1.845 . . . . 74.310000000000002 108.488 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -114.37 55.89 0.73 Allowed 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.302 1.551 . . . . 74.530000000000001 106.966 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -137.23 162.11 34.38 Favored 'General case' 0 C--N 1.355 0.837 0 N-CA-C 108.117 -1.068 . . . . 71.510000000000005 108.117 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -149.27 165.62 31.37 Favored 'General case' 0 C--N 1.352 0.676 0 CA-C-O 118.309 -0.853 . . . . 73.409999999999997 110.407 -171.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -81.37 174.09 11.82 Favored 'General case' 0 C--N 1.358 0.962 0 CA-C-O 118.071 -0.966 . . . . 73.510000000000005 111.024 -177.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 . . . . . 0 C--N 1.358 0.939 0 CA-C-O 117.809 -1.091 . . . . 61.340000000000003 110.926 -176.344 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 51.7 mt . . . . . 0 CA--C 1.514 -0.41 0 N-CA-C 108.884 -0.784 . . . . 74.040000000000006 108.884 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 m -155.72 -170.56 3.46 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 117.419 -1.277 . . . . 55.420000000000002 109.195 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -119.86 51.57 1.17 Allowed 'General case' 0 C--N 1.359 0.993 0 CA-C-N 119.313 0.96 . . . . 74.109999999999999 110.896 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.99 -141.95 1.38 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 55.409999999999997 112.478 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.62 -30.21 2.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.807 0.337 . . . . 72.140000000000001 111.126 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.29 121.95 59.04 Favored Pre-proline 0 C--N 1.359 0.981 0 O-C-N 117.763 -3.086 . . . . 75.219999999999999 107.731 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -77.91 166.96 24.43 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.773 2.383 . . . . 75.129999999999995 111.233 -176.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -100.71 -61.79 1.32 Allowed 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.328 -0.989 . . . . 72.310000000000002 108.328 174.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.1 mt -147.53 -64.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.013 0 CA-C-N 119.005 0.82 . . . . 75.239999999999995 109.717 -175.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.65 -115.99 2.32 Favored Glycine 0 C--N 1.357 1.74 0 N-CA-C 108.396 -1.881 . . . . 63.039999999999999 108.396 -177.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -112.22 58.98 0.63 Allowed 'General case' 0 C--N 1.357 0.909 0 CA-C-N 119.324 1.562 . . . . 75.25 106.93 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -140.56 160.02 40.92 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 117.806 -1.092 . . . . 71.030000000000001 108.218 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -148.84 165.45 31.47 Favored 'General case' 0 C--N 1.352 0.675 0 CA-C-O 118.342 -0.837 . . . . 73.140000000000001 110.526 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -80.97 174.87 11.19 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 119.265 0.939 . . . . 75.319999999999993 111.44 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 . . . . . 0 C--N 1.358 0.977 0 CA-C-O 117.865 -1.064 . . . . 74.239999999999995 108.857 -174.926 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 40.7 mt . . . . . 0 CA--C 1.513 -0.455 0 N-CA-C 109.27 -0.641 . . . . 63.399999999999999 109.27 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 m -160.39 -169.92 2.62 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 117.181 -1.39 . . . . 75.409999999999997 110.092 -170.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -120.28 51.45 1.21 Allowed 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.483 1.038 . . . . 74.519999999999996 110.873 -178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.92 -142.0 1.36 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 64.040000000000006 112.493 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.56 -30.58 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.75 0.31 . . . . 70.349999999999994 111.103 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.05 120.98 61.92 Favored Pre-proline 0 C--N 1.358 0.978 0 O-C-N 117.921 -2.987 . . . . 71.329999999999998 107.656 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -78.22 167.74 22.76 Favored 'Trans proline' 0 C--N 1.363 1.318 0 CA-C-N 123.76 2.378 . . . . 74.25 111.115 -175.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -101.42 -61.48 1.37 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 108.556 -0.905 . . . . 74.109999999999999 108.556 175.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.1 mt -146.63 -64.45 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.983 0 CA-C-O 118.378 -0.82 . . . . 73.129999999999995 109.576 -175.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.8 -112.75 2.54 Favored Glycine 0 C--N 1.357 1.748 0 N-CA-C 108.733 -1.747 . . . . 41.43 108.733 -177.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -114.15 56.03 0.72 Allowed 'General case' 0 C--N 1.355 0.838 0 N-CA-C 106.789 -1.559 . . . . 73.129999999999995 106.789 -177.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.9 t -140.61 162.26 35.8 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 117.995 -1.002 . . . . 72.230000000000004 108.64 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -151.01 166.82 29.53 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-O 118.294 -0.86 . . . . 73.120000000000005 110.693 -170.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -83.37 173.56 11.44 Favored 'General case' 0 C--N 1.358 0.944 0 CA-C-N 119.41 1.005 . . . . 73.540000000000006 111.89 -176.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 . . . . . 0 C--N 1.36 1.04 0 CA-C-N 119.168 0.894 . . . . 72.299999999999997 109.764 -177.259 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.7 mt . . . . . 0 CA--C 1.513 -0.451 0 N-CA-C 108.78 -0.822 . . . . 74.129999999999995 108.78 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.6 m -160.23 -171.62 3.26 Favored 'General case' 0 C--N 1.354 0.77 0 CA-C-O 117.398 -1.287 . . . . 70.040000000000006 109.855 -172.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.96 51.52 1.18 Allowed 'General case' 0 C--N 1.359 0.981 0 CA-C-N 119.213 0.915 . . . . 74.200000000000003 110.904 -178.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.11 -141.8 1.4 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.756 . . . . 62.020000000000003 112.482 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.7 -30.57 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 73.430000000000007 111.13 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.17 121.47 60.49 Favored Pre-proline 0 C--N 1.359 0.992 0 O-C-N 117.845 -3.034 . . . . 74.140000000000001 107.758 -175.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -78.17 166.79 24.2 Favored 'Trans proline' 0 C--N 1.364 1.363 0 CA-C-N 123.803 2.394 . . . . 75.420000000000002 111.25 -175.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -99.61 -61.24 1.39 Allowed 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.296 -1.001 . . . . 64.129999999999995 108.296 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 mt -146.77 -64.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.309 -0.853 . . . . 74.409999999999997 109.506 -175.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.2 -110.48 2.41 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 108.902 -1.679 . . . . 55.229999999999997 108.902 -177.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 51.1 mt-30 -115.8 54.04 0.83 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 106.717 -1.586 . . . . 74.019999999999996 106.717 -176.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.5 t -139.83 160.87 38.91 Favored 'General case' 0 C--N 1.354 0.783 0 N-CA-C 108.312 -0.995 . . . . 74.109999999999999 108.312 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -149.98 166.23 30.28 Favored 'General case' 0 C--N 1.351 0.674 0 CA-C-O 118.309 -0.853 . . . . 74.120000000000005 110.669 -170.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -82.19 174.38 11.24 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.04 0.837 . . . . 64.439999999999998 111.472 -176.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 . . . . . 0 C--N 1.358 0.96 0 CA-C-O 118.007 -0.997 . . . . 54.329999999999998 108.65 -175.292 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.218 -0.896 . . . . 74.140000000000001 108.675 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.8 m -162.33 -168.21 1.8 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 116.594 -1.67 . . . . 74.340000000000003 109.577 -168.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -115.48 43.63 2.02 Favored 'General case' 0 C--N 1.362 1.12 0 CA-C-N 120.439 1.472 . . . . 74.299999999999997 110.925 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.57 1.0 Allowed Glycine 0 C--N 1.351 1.364 0 O-C-N 119.94 -1.725 . . . . 62.520000000000003 110.646 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.15 -21.96 4.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-N 117.659 0.73 . . . . 70.109999999999999 111.154 -173.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -98.37 115.8 65.67 Favored Pre-proline 0 C--N 1.361 1.098 0 O-C-N 117.543 -3.223 . . . . 74.299999999999997 108.044 -175.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -77.64 168.7 22.12 Favored 'Trans proline' 0 C--N 1.363 1.305 0 CA-C-N 124.07 2.489 . . . . 74.310000000000002 111.578 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.01 -61.42 1.66 Allowed 'General case' 0 C--N 1.359 0.979 0 N-CA-C 108.548 -0.908 . . . . 74.420000000000002 108.548 177.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.1 mt -146.37 -65.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.001 0 CA-C-O 118.397 -0.811 . . . . 74.319999999999993 109.271 -174.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.97 -107.81 1.27 Allowed Glycine 0 C--N 1.357 1.748 0 CA-C-O 117.457 -1.746 . . . . 71.439999999999998 109.124 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 tt0 -127.47 58.25 1.48 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 106.831 -1.544 . . . . 75.430000000000007 106.831 -178.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -139.02 159.57 41.84 Favored 'General case' 0 C--N 1.355 0.812 0 CA-C-O 117.023 -1.465 . . . . 73.140000000000001 107.871 -177.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.08 146.15 32.63 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-N 119.722 1.147 . . . . 75.129999999999995 110.881 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.13 160.16 32.93 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-N 120.135 1.334 . . . . 75.040000000000006 109.926 -178.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 . . . . . 0 C--N 1.356 0.866 0 N-CA-C 108.082 -1.081 . . . . 75.140000000000001 108.082 -178.798 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.2 mt . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.225 -0.893 . . . . 75.239999999999995 108.64 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.0 m -161.95 -170.12 2.43 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-O 116.76 -1.59 . . . . 75.349999999999994 109.852 -168.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -114.24 43.46 1.87 Allowed 'General case' 0 C--N 1.36 1.046 0 CA-C-N 120.119 1.327 . . . . 64.329999999999998 110.938 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.24 0.97 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 119.791 -1.818 . . . . 73.530000000000001 110.698 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.38 -22.77 4.33 Favored 'Isoleucine or valine' 0 C--N 1.357 0.892 0 CA-C-N 117.665 0.733 . . . . 72.519999999999996 111.164 -173.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.37 116.72 65.95 Favored Pre-proline 0 C--N 1.362 1.115 0 O-C-N 117.591 -3.193 . . . . 71.030000000000001 107.822 -174.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.11 168.79 21.37 Favored 'Trans proline' 0 C--N 1.363 1.338 0 CA-C-N 123.984 2.459 . . . . 70.430000000000007 111.593 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.48 -62.61 1.47 Allowed 'General case' 0 C--N 1.358 0.973 0 N-CA-C 108.419 -0.956 . . . . 74.109999999999999 108.419 177.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.3 mt -147.23 -66.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.979 0 CA-C-O 118.373 -0.822 . . . . 74.439999999999998 109.075 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.23 -105.26 1.09 Allowed Glycine 0 C--N 1.357 1.73 0 CA-C-O 117.637 -1.646 . . . . 74.019999999999996 109.338 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -129.29 60.19 1.57 Allowed 'General case' 0 C--N 1.357 0.92 0 N-CA-C 106.997 -1.483 . . . . 71.040000000000006 106.997 -177.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.95 163.7 32.08 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 117.117 -1.42 . . . . 75.319999999999993 108.445 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -146.6 148.06 31.72 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 117.885 -1.055 . . . . 75.420000000000002 111.005 -172.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -73.36 162.07 29.75 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-N 120.133 1.333 . . . . 75.510000000000005 110.041 -177.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 . . . . . 0 C--N 1.357 0.896 0 N-CA-C 108.023 -1.103 . . . . 74.439999999999998 108.023 -178.969 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 31.7 mt . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.217 -0.897 . . . . 74.439999999999998 109.171 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.4 m -158.64 -166.62 1.93 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-O 116.543 -1.694 . . . . 75.010000000000005 109.349 -169.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -115.37 43.57 2.01 Favored 'General case' 0 C--N 1.361 1.086 0 CA-C-N 120.553 1.524 . . . . 74.239999999999995 110.867 -177.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.2 -143.05 0.98 Allowed Glycine 0 C--N 1.351 1.395 0 O-C-N 120.076 -1.64 . . . . 72.349999999999994 110.713 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.94 -21.82 4.94 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 CA-C-N 117.634 0.717 . . . . 74.239999999999995 111.125 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.79 115.28 65.75 Favored Pre-proline 0 C--N 1.361 1.072 0 O-C-N 117.661 -3.149 . . . . 74.450000000000003 107.971 -175.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -77.34 168.5 22.85 Favored 'Trans proline' 0 C--N 1.363 1.297 0 CA-C-N 124.187 2.531 . . . . 75.150000000000006 111.58 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.12 -61.76 1.61 Allowed 'General case' 0 C--N 1.357 0.935 0 N-CA-C 108.328 -0.99 . . . . 75.340000000000003 108.328 177.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.4 mt -145.48 -65.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.971 0 CA-C-O 118.275 -0.869 . . . . 64.019999999999996 108.703 -174.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.82 -137.43 8.52 Favored Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.26 -1.855 . . . . 74.549999999999997 108.508 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -93.95 67.09 3.69 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.814 1.807 . . . . 74.430000000000007 107.854 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -141.91 154.6 45.22 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.057 -1.449 . . . . 75.409999999999997 108.228 177.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -144.0 143.58 31.27 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.592 1.087 . . . . 75.200000000000003 110.707 -171.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -69.07 161.14 29.66 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 120.072 1.305 . . . . 74.420000000000002 109.875 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 C--N 1.355 0.825 0 N-CA-C 107.327 -1.36 . . . . 71.150000000000006 107.327 -178.91 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 29.4 mt . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 118.259 -0.877 . . . . 75.430000000000007 108.719 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.7 m -159.11 -167.18 2.01 Favored 'General case' 0 C--N 1.357 0.935 0 CA-C-O 116.511 -1.709 . . . . 71.319999999999993 109.79 -169.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -115.18 43.44 2.01 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-N 120.499 1.5 . . . . 75.319999999999993 110.915 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.11 -142.95 0.94 Allowed Glycine 0 C--N 1.35 1.355 0 O-C-N 119.96 -1.713 . . . . 72.329999999999998 110.856 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.95 -22.19 4.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.857 0 CA-C-N 117.76 0.78 . . . . 74.519999999999996 111.161 -173.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -97.47 116.09 65.82 Favored Pre-proline 0 C--N 1.361 1.08 0 O-C-N 117.656 -3.153 . . . . 74.530000000000001 107.952 -175.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -78.05 168.93 21.23 Favored 'Trans proline' 0 C--N 1.361 1.209 0 CA-C-N 124.086 2.495 . . . . 75.519999999999996 111.426 -175.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -110.39 -61.75 1.62 Allowed 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.687 -0.857 . . . . 73.140000000000001 108.687 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.05 -65.29 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.371 -0.823 . . . . 74.140000000000001 109.173 -174.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.15 -109.78 1.56 Allowed Glycine 0 C--N 1.357 1.714 0 CA-C-O 117.567 -1.685 . . . . 60.229999999999997 109.044 -177.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.6 tt0 -124.86 61.64 1.16 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 106.571 -1.64 . . . . 73.430000000000007 106.571 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.04 158.52 43.67 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 116.941 -1.504 . . . . 73.230000000000004 107.952 -178.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -144.08 144.36 31.58 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.844 1.202 . . . . 74.439999999999998 110.86 -172.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -70.05 159.47 33.78 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.331 1.423 . . . . 74.129999999999995 109.913 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.354 0.804 0 N-CA-C 107.85 -1.167 . . . . 73.219999999999999 107.85 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.221 -0.396 0 CA-C-O 117.514 -1.231 . . . . 71.430000000000007 109.68 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.5 m -158.57 -164.27 1.42 Allowed 'General case' 0 C--N 1.358 0.969 0 CA-C-O 116.019 -1.944 . . . . 75.510000000000005 109.475 -169.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -116.05 43.36 2.16 Favored 'General case' 0 C--N 1.361 1.094 0 CA-C-N 121.269 1.85 . . . . 60.039999999999999 110.936 -174.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.8 -143.66 0.93 Allowed Glycine 0 C--N 1.35 1.349 0 O-C-N 120.149 -1.595 . . . . 75.209999999999994 110.738 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.42 -22.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-N 117.642 0.721 . . . . 72.439999999999998 111.14 -173.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.01 117.82 65.43 Favored Pre-proline 0 C--N 1.361 1.104 0 O-C-N 117.532 -3.23 . . . . 71.5 107.864 -175.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.08 170.41 18.81 Favored 'Trans proline' 0 C--N 1.363 1.296 0 CA-C-N 124.046 2.481 . . . . 75.319999999999993 111.325 -175.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.2 -62.14 1.61 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 108.524 -0.917 . . . . 74.299999999999997 108.524 177.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.28 -65.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.017 0 CA-C-O 118.336 -0.84 . . . . 72.230000000000004 108.972 -174.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.39 -109.19 1.57 Allowed Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.447 -1.752 . . . . 42.310000000000002 109.143 -177.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -124.66 61.33 1.15 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 106.931 -1.507 . . . . 70.519999999999996 106.931 -177.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -142.73 157.79 44.29 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 116.955 -1.498 . . . . 72.409999999999997 108.088 -178.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -144.36 143.67 31.07 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.782 1.174 . . . . 73.109999999999999 110.705 -171.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -70.68 157.67 37.58 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 120.034 1.288 . . . . 73.420000000000002 110.151 -176.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 C--N 1.355 0.847 0 CA-C-O 117.368 -1.301 . . . . 75.0 108.748 -179.497 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.3 mt . . . . . 0 C--O 1.221 -0.412 0 N-CA-C 108.613 -0.884 . . . . 73.439999999999998 108.613 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -161.78 -171.07 2.77 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 116.954 -1.498 . . . . 71.239999999999995 109.793 -169.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -114.2 43.36 1.88 Allowed 'General case' 0 C--N 1.36 1.044 0 CA-C-N 119.951 1.251 . . . . 74.409999999999997 110.89 -177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.6 -143.76 0.9 Allowed Glycine 0 C--N 1.351 1.415 0 O-C-N 120.211 -1.555 . . . . 73.030000000000001 110.786 178.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.35 -22.93 4.38 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 CA-C-N 117.579 0.689 . . . . 71.420000000000002 111.133 -173.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -97.41 116.52 65.9 Favored Pre-proline 0 C--N 1.362 1.119 0 O-C-N 117.515 -3.241 . . . . 75.129999999999995 107.844 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.97 166.91 24.38 Favored 'Trans proline' 0 C--N 1.363 1.31 0 CA-C-N 123.995 2.463 . . . . 70.510000000000005 111.33 -174.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.16 -60.96 1.58 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.365 -0.976 . . . . 75.439999999999998 108.365 177.223 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.0 mt -145.29 -65.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.016 0 CA-C-O 118.168 -0.92 . . . . 74.299999999999997 108.897 -174.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.61 -115.31 3.54 Favored Glycine 0 C--N 1.358 1.75 0 CA-C-O 117.433 -1.759 . . . . 73.049999999999997 109.216 -177.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -110.78 63.14 0.61 Allowed 'General case' 0 C--N 1.358 0.953 0 CA-C-N 119.28 1.54 . . . . 73.239999999999995 107.871 -178.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -145.59 155.7 43.21 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 117.358 -1.306 . . . . 71.409999999999997 108.518 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -143.58 147.44 34.41 Favored 'General case' 0 C--N 1.354 0.795 0 CA-C-O 117.609 -1.186 . . . . 75.319999999999993 110.071 -172.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -73.38 159.96 32.51 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 120.183 1.356 . . . . 74.439999999999998 109.89 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 . . . . . 0 C--N 1.356 0.85 0 CA-C-O 117.616 -1.183 . . . . 65.109999999999999 108.249 -179.407 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 43.8 mt . . . . . 0 C--O 1.221 -0.412 0 N-CA-C 108.618 -0.882 . . . . 74.439999999999998 108.618 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.8 m -161.25 -169.89 2.48 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 116.756 -1.592 . . . . 75.129999999999995 109.751 -169.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -114.9 43.39 1.98 Allowed 'General case' 0 C--N 1.359 1.001 0 CA-C-N 120.11 1.323 . . . . 74.530000000000001 110.864 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.99 -143.1 0.92 Allowed Glycine 0 C--N 1.351 1.404 0 O-C-N 120.033 -1.667 . . . . 62.229999999999997 110.776 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.82 -21.95 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.858 0 CA-C-N 117.667 0.733 . . . . 75.549999999999997 111.163 -173.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.89 115.31 65.76 Favored Pre-proline 0 C--N 1.361 1.097 0 O-C-N 117.612 -3.18 . . . . 74.099999999999994 107.837 -175.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -77.63 166.59 25.4 Favored 'Trans proline' 0 C--N 1.362 1.258 0 CA-C-N 124.143 2.515 . . . . 73.230000000000004 111.471 -175.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.95 -61.36 1.55 Allowed 'General case' 0 C--N 1.357 0.922 0 N-CA-C 108.573 -0.899 . . . . 74.049999999999997 108.573 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.7 mt -146.23 -65.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.946 0 N-CA-C 108.772 -0.825 . . . . 74.0 108.772 -174.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.81 -122.05 3.11 Favored Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.332 -1.815 . . . . 53.229999999999997 108.63 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -110.13 63.87 0.61 Allowed 'General case' 0 C--N 1.358 0.946 0 CA-C-N 119.365 1.582 . . . . 70.519999999999996 107.094 -179.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.0 t -142.53 157.07 45.12 Favored 'General case' 0 C--N 1.354 0.782 0 CA-C-O 117.088 -1.434 . . . . 74.120000000000005 108.118 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -144.13 146.79 32.99 Favored 'General case' 0 C--N 1.354 0.768 0 CA-C-O 117.694 -1.146 . . . . 75.219999999999999 110.541 -172.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -72.08 161.05 31.45 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-N 120.148 1.34 . . . . 75.349999999999994 109.961 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 . . . . . 0 C--N 1.355 0.834 0 N-CA-C 107.856 -1.164 . . . . 62.130000000000003 107.856 -179.471 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.2 mt . . . . . 0 C--O 1.221 -0.397 0 N-CA-C 108.613 -0.884 . . . . 75.510000000000005 108.613 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -158.19 -169.94 2.96 Favored 'General case' 0 C--N 1.357 0.929 0 CA-C-O 116.786 -1.578 . . . . 73.310000000000002 109.697 -170.219 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -114.45 43.48 1.9 Allowed 'General case' 0 C--N 1.36 1.045 0 CA-C-N 120.132 1.333 . . . . 74.530000000000001 110.891 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.06 -143.16 0.94 Allowed Glycine 0 C--N 1.352 1.425 0 O-C-N 120.007 -1.683 . . . . 73.420000000000002 110.723 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.86 -22.38 4.63 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.617 0.708 . . . . 73.530000000000001 111.098 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -97.72 115.51 65.75 Favored Pre-proline 0 C--N 1.362 1.143 0 O-C-N 117.73 -3.106 . . . . 74.319999999999993 107.934 -175.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -77.81 166.94 24.62 Favored 'Trans proline' 0 C--N 1.364 1.369 0 CA-C-N 124.076 2.491 . . . . 65.219999999999999 111.722 -175.01 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.1 -61.9 1.48 Allowed 'General case' 0 C--N 1.357 0.912 0 N-CA-C 108.532 -0.914 . . . . 75.340000000000003 108.532 178.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.5 mt -147.23 -65.08 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.395 -0.812 . . . . 64.340000000000003 109.216 -174.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.44 -110.25 1.45 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.402 -1.777 . . . . 71.219999999999999 109.139 -176.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -123.44 58.96 1.11 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.815 -1.55 . . . . 63.140000000000001 106.815 -177.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -140.8 162.71 34.79 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 117.033 -1.461 . . . . 74.310000000000002 108.607 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -147.48 146.12 29.4 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.771 -1.109 . . . . 74.310000000000002 111.078 -171.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -72.94 159.5 33.6 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 120.207 1.367 . . . . 73.420000000000002 109.951 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 . . . . . 0 C--N 1.356 0.869 0 CA-C-O 117.826 -1.083 . . . . 74.129999999999995 108.76 -179.724 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.8 mt . . . . . 0 C--O 1.221 -0.429 0 N-CA-C 108.678 -0.86 . . . . 65.120000000000005 108.678 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -158.05 -168.92 2.64 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-O 116.64 -1.647 . . . . 70.319999999999993 109.534 -170.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -114.96 43.61 1.94 Allowed 'General case' 0 C--N 1.36 1.06 0 CA-C-N 120.265 1.393 . . . . 74.340000000000003 110.869 -177.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.49 -143.9 0.89 Allowed Glycine 0 C--N 1.352 1.439 0 O-C-N 120.41 -1.431 . . . . 64.230000000000004 110.743 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.36 -22.24 4.79 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 117.554 0.677 . . . . 75.329999999999998 111.146 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.69 115.59 65.75 Favored Pre-proline 0 C--N 1.362 1.12 0 O-C-N 117.728 -3.107 . . . . 73.310000000000002 108.094 -175.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.26 167.14 25.2 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 124.122 2.508 . . . . 73.400000000000006 111.534 -175.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.96 -62.08 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 N-CA-C 108.393 -0.965 . . . . 71.209999999999994 108.393 177.123 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.9 mt -146.89 -64.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-O 118.409 -0.805 . . . . 61.32 108.867 -174.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.65 -122.72 2.57 Favored Glycine 0 C--N 1.359 1.817 0 CA-C-O 117.187 -1.896 . . . . 74.040000000000006 108.639 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.4 tt0 -111.04 61.5 0.61 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 119.437 1.618 . . . . 72.439999999999998 107.183 -179.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.9 t -139.78 157.48 45.67 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 117.132 -1.414 . . . . 64.409999999999997 108.101 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -144.57 142.83 30.46 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.815 -1.088 . . . . 71.450000000000003 110.603 -171.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -70.54 155.74 40.32 Favored 'General case' 0 C--N 1.359 1.004 0 CA-C-N 120.081 1.309 . . . . 75.25 109.513 -178.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--N 1.357 0.906 0 CA-C-O 118.028 -0.987 . . . . 71.140000000000001 108.935 -179.129 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.9 mt . . . . . 0 C--O 1.221 -0.406 0 N-CA-C 108.596 -0.89 . . . . 71.439999999999998 108.596 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.8 m -159.5 -167.22 1.97 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-O 116.674 -1.631 . . . . 54.210000000000001 109.814 -171.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.8 43.31 2.13 Favored 'General case' 0 C--N 1.362 1.123 0 CA-C-N 120.278 1.399 . . . . 71.5 110.915 -177.417 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.71 -142.97 0.85 Allowed Glycine 0 C--N 1.351 1.394 0 O-C-N 119.992 -1.693 . . . . 65.319999999999993 110.707 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.88 -21.94 4.88 Favored 'Isoleucine or valine' 0 C--N 1.357 0.902 0 CA-C-N 117.556 0.678 . . . . 74.329999999999998 111.134 -173.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -98.75 115.09 65.93 Favored Pre-proline 0 C--N 1.362 1.135 0 O-C-N 117.632 -3.167 . . . . 71.129999999999995 107.789 -174.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -77.78 167.27 24.16 Favored 'Trans proline' 0 C--N 1.362 1.24 0 CA-C-N 123.967 2.453 . . . . 74.329999999999998 111.364 -174.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.33 -62.2 1.45 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.314 -0.995 . . . . 74.439999999999998 108.314 177.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.5 mt -146.56 -66.11 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.968 0 N-CA-C 108.757 -0.831 . . . . 72.239999999999995 108.757 -174.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.98 -117.79 1.8 Allowed Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.366 -1.797 . . . . 73.310000000000002 108.798 -177.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -115.91 62.14 0.7 Allowed 'General case' 0 C--N 1.357 0.924 0 N-CA-C 106.828 -1.545 . . . . 73.0 106.828 -178.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -142.05 157.97 44.3 Favored 'General case' 0 C--N 1.354 0.776 0 CA-C-O 117.214 -1.374 . . . . 65.120000000000005 108.234 -178.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -144.72 146.55 32.24 Favored 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.797 -1.097 . . . . 63.219999999999999 110.444 -172.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -72.55 158.92 34.78 Favored 'General case' 0 C--N 1.357 0.896 0 CA-C-N 120.143 1.338 . . . . 74.450000000000003 110.15 -177.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 . . . . . 0 C--N 1.356 0.876 0 N-CA-C 107.437 -1.32 . . . . 73.030000000000001 107.437 178.359 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.7 mt . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.96 -1.019 . . . . 75.400000000000006 109.317 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -157.94 -164.29 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-O 116.223 -1.846 . . . . 74.420000000000002 109.557 -169.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -116.52 43.44 2.21 Favored 'General case' 0 C--N 1.361 1.089 0 CA-C-N 120.816 1.643 . . . . 71.349999999999994 110.917 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.59 -142.48 1.04 Allowed Glycine 0 C--N 1.35 1.326 0 O-C-N 119.859 -1.776 . . . . 61.219999999999999 110.682 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.13 -22.35 4.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 117.798 0.799 . . . . 73.519999999999996 111.16 -173.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -97.72 116.27 65.76 Favored Pre-proline 0 C--N 1.36 1.03 0 O-C-N 117.503 -3.248 . . . . 74.409999999999997 108.074 -174.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -77.71 169.42 20.84 Favored 'Trans proline' 0 C--N 1.362 1.26 0 CA-C-N 124.089 2.496 . . . . 73.310000000000002 111.6 -175.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.07 -61.99 1.61 Allowed 'General case' 0 C--N 1.357 0.932 0 N-CA-C 108.644 -0.872 . . . . 74.409999999999997 108.644 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.6 mt -146.71 -65.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.33 -0.843 . . . . 74.329999999999998 109.219 -174.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -107.81 1.28 Allowed Glycine 0 C--N 1.356 1.671 0 CA-C-O 117.492 -1.727 . . . . 74.400000000000006 109.112 -176.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -128.01 59.73 1.48 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 106.928 -1.508 . . . . 75.439999999999998 106.928 -177.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.4 t -140.83 159.93 41.14 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 116.898 -1.525 . . . . 72.040000000000006 107.733 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -144.61 142.77 30.39 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 120.052 1.296 . . . . 71.420000000000002 110.978 -171.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -68.14 161.08 27.74 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.99 1.268 . . . . 73.040000000000006 109.519 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 . . . . . 0 C--N 1.353 0.745 0 N-CA-C 107.921 -1.14 . . . . 74.439999999999998 107.921 -177.426 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 mt . . . . . 0 C--O 1.221 -0.431 0 N-CA-C 108.44 -0.948 . . . . 74.340000000000003 108.44 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.7 m -159.04 -169.35 2.64 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 116.857 -1.544 . . . . 65.340000000000003 109.622 -169.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -114.41 43.61 1.87 Allowed 'General case' 0 C--N 1.36 1.031 0 CA-C-N 120.081 1.31 . . . . 73.129999999999995 110.912 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.46 -142.29 0.99 Allowed Glycine 0 C--N 1.352 1.419 0 O-C-N 119.909 -1.745 . . . . 74.230000000000004 110.68 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.37 -22.67 4.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 117.69 0.745 . . . . 73.099999999999994 111.13 -173.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.38 117.07 65.92 Favored Pre-proline 0 C--N 1.362 1.122 0 O-C-N 117.62 -3.175 . . . . 74.420000000000002 108.012 -175.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -77.94 170.32 19.1 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 124.036 2.477 . . . . 74.140000000000001 111.541 -175.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.63 -62.19 1.59 Allowed 'General case' 0 C--N 1.359 0.995 0 N-CA-C 108.479 -0.934 . . . . 74.319999999999993 108.479 177.552 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt -146.71 -65.41 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.998 0 CA-C-O 118.375 -0.821 . . . . 75.409999999999997 109.213 -174.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.21 -108.39 1.16 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.407 -1.774 . . . . 74.510000000000005 108.96 -177.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -127.49 59.85 1.43 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.255 1.527 . . . . 75.25 106.909 -178.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -139.69 158.93 43.3 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 116.923 -1.513 . . . . 75.120000000000005 107.897 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -143.9 147.36 33.91 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-N 119.772 1.169 . . . . 71.329999999999998 110.738 -171.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-N 120.152 1.342 . . . . 74.299999999999997 110.43 -177.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 . . . . . 0 C--N 1.355 0.845 0 CA-C-O 117.774 -1.108 . . . . 73.340000000000003 108.988 -179.892 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.5 mt . . . . . 0 C--O 1.221 -0.431 0 N-CA-C 108.712 -0.848 . . . . 74.340000000000003 108.712 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.8 m -162.33 -168.96 2.0 Allowed 'General case' 0 C--N 1.358 0.936 0 CA-C-O 116.645 -1.645 . . . . 75.450000000000003 109.745 -167.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -115.09 43.56 1.97 Allowed 'General case' 0 C--N 1.36 1.058 0 CA-C-N 120.382 1.446 . . . . 72.530000000000001 110.906 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.41 -142.87 1.03 Allowed Glycine 0 C--N 1.351 1.373 0 O-C-N 119.963 -1.71 . . . . 74.140000000000001 110.682 179.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.01 -21.9 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.68 0.74 . . . . 74.239999999999995 111.124 -173.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -98.45 116.04 65.59 Favored Pre-proline 0 C--N 1.361 1.093 0 O-C-N 117.474 -3.266 . . . . 72.519999999999996 107.954 -175.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -77.83 168.63 21.97 Favored 'Trans proline' 0 C--N 1.363 1.341 0 CA-C-N 123.983 2.458 . . . . 75.219999999999999 111.577 -175.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.59 -61.41 1.64 Allowed 'General case' 0 C--N 1.357 0.911 0 N-CA-C 108.597 -0.89 . . . . 74.519999999999996 108.597 178.069 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.9 mt -145.8 -65.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.986 0 CA-C-O 118.513 -0.756 . . . . 74.120000000000005 109.065 -174.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.02 -110.18 1.75 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 117.519 -1.712 . . . . 62.149999999999999 109.001 -176.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -124.01 62.35 1.08 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.81 -1.552 . . . . 71.219999999999999 106.81 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.31 158.57 43.57 Favored 'General case' 0 C--N 1.354 0.801 0 CA-C-O 116.969 -1.491 . . . . 74.019999999999996 107.888 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -143.57 147.13 33.95 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-N 119.859 1.208 . . . . 74.420000000000002 110.711 -172.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.53 160.78 31.72 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 120.143 1.338 . . . . 74.430000000000007 109.963 -178.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--N 1.356 0.848 0 N-CA-C 108.13 -1.063 . . . . 73.239999999999995 108.13 -178.806 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.4 mt . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 118.347 -0.835 . . . . 74.150000000000006 108.996 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.9 m -157.31 -173.36 4.39 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 117.145 -1.407 . . . . 75.129999999999995 109.666 -170.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -109.08 41.48 1.61 Allowed 'General case' 0 C--N 1.359 1.011 0 CA-C-N 119.745 1.157 . . . . 75.150000000000006 110.917 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -72.1 -140.64 0.32 Allowed Glycine 0 C--N 1.35 1.337 0 O-C-N 120.181 -1.575 . . . . 73.200000000000003 110.767 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -118.47 -22.72 3.99 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-N 117.985 0.893 . . . . 64.409999999999997 111.138 -173.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.6 114.94 65.87 Favored Pre-proline 0 C--N 1.362 1.131 0 O-C-N 117.136 -3.478 . . . . 73.230000000000004 108.032 -174.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -76.92 167.19 25.64 Favored 'Trans proline' 0 C--N 1.364 1.39 0 CA-C-N 124.209 2.539 . . . . 74.420000000000002 112.016 -174.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.43 -61.56 1.62 Allowed 'General case' 0 C--N 1.357 0.934 0 N-CA-C 108.606 -0.887 . . . . 72.430000000000007 108.606 177.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.2 mt -146.32 -65.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.997 0 CA-C-O 118.435 -0.793 . . . . 74.510000000000005 108.896 -174.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.22 -120.64 2.71 Favored Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.236 -1.869 . . . . 72.140000000000001 108.761 -178.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -112.72 62.63 0.63 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-N 119.475 1.637 . . . . 75.200000000000003 107.258 -179.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.21 157.99 44.24 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 116.812 -1.566 . . . . 74.25 108.005 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -146.48 146.24 30.48 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.887 1.221 . . . . 65.530000000000001 110.425 -173.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -72.86 157.28 37.77 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.332 1.424 . . . . 73.439999999999998 110.015 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 . . . . . 0 C--N 1.356 0.876 0 CA-C-O 117.83 -1.081 . . . . 74.150000000000006 108.691 -178.54 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 N-CA-C 109.885 -1.286 . . . . 64.340000000000003 109.885 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 37.9 mt -129.2 39.46 3.76 Favored 'General case' 0 C--N 1.355 0.825 0 CA-C-N 117.855 0.827 . . . . 72.150000000000006 109.277 -175.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -160.76 -170.13 2.64 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 117.344 -1.313 . . . . 73.049999999999997 109.756 -170.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -119.86 51.51 1.18 Allowed 'General case' 0 C--N 1.36 1.062 0 CA-C-N 119.404 1.002 . . . . 71.120000000000005 110.956 -178.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.06 -141.99 1.41 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.763 . . . . 54.130000000000003 112.489 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.55 -30.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.801 0.334 . . . . 74.409999999999997 111.121 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -96.06 121.21 61.33 Favored Pre-proline 0 C--N 1.358 0.968 0 O-C-N 117.801 -3.062 . . . . 74.519999999999996 107.741 -175.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -78.56 168.12 21.72 Favored 'Trans proline' 0 C--N 1.362 1.269 0 CA-C-N 123.65 2.339 . . . . 74.409999999999997 111.328 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -102.21 -62.27 1.29 Allowed 'General case' 0 C--N 1.357 0.918 0 CA-C-O 117.915 -1.041 . . . . 74.519999999999996 108.351 174.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.1 mt -146.95 -64.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.092 0 CA-C-N 119.22 0.918 . . . . 75.310000000000002 109.293 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.57 -132.59 6.38 Favored Glycine 0 C--N 1.359 1.818 0 N-CA-C 107.918 -2.073 . . . . 73.310000000000002 107.918 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -93.99 62.51 3.11 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 120.131 1.966 . . . . 75.409999999999997 108.591 176.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.3 t -139.21 160.45 39.77 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 117.885 -1.055 . . . . 72.420000000000002 108.578 176.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -150.42 165.64 32.53 Favored 'General case' 0 C--N 1.352 0.697 0 CA-C-O 118.411 -0.804 . . . . 74.430000000000007 110.862 -170.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -81.97 174.98 10.75 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-N 119.004 0.82 . . . . 74.219999999999999 111.539 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -92.03 175.36 6.9 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-O 117.767 -1.111 . . . . 61.240000000000002 109.893 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -101.75 40.73 1.28 Allowed 'General case' 0 C--N 1.362 1.109 0 CA-C-N 119.371 0.987 . . . . 74.230000000000004 110.901 -178.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.88 158.18 36.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 53.229999999999997 110.876 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.501 -0.923 0 CA-C-N 116.143 -0.481 . . . . 74.510000000000005 110.908 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.766 0 N-CA-C 109.632 -1.387 . . . . 74.030000000000001 109.632 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.3 mt -132.49 41.43 3.2 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.996 0.898 . . . . 70.129999999999995 108.806 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.6 m -157.56 -169.92 3.04 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 117.589 -1.196 . . . . 73.099999999999994 109.215 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -120.6 51.45 1.23 Allowed 'General case' 0 C--N 1.358 0.962 0 CA-C-N 119.096 0.862 . . . . 75.510000000000005 110.888 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -142.0 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.694 -0.765 . . . . 62.219999999999999 112.477 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.54 -30.05 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.819 0.342 . . . . 73.010000000000005 111.105 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.62 121.63 59.31 Favored Pre-proline 0 C--N 1.358 0.972 0 O-C-N 117.774 -3.079 . . . . 74.109999999999999 107.736 -175.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.14 167.95 22.57 Favored 'Trans proline' 0 C--N 1.363 1.334 0 CA-C-N 123.7 2.357 . . . . 75.400000000000006 111.459 -176.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.17 -62.13 1.28 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.119 -0.943 . . . . 65.299999999999997 108.666 174.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.5 mt -148.22 -64.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.055 0 CA-C-N 119.106 0.866 . . . . 74.209999999999994 110.155 -174.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.2 -95.12 1.18 Allowed Glycine 0 C--N 1.357 1.737 0 N-CA-C 108.798 -1.721 . . . . 54.530000000000001 108.798 -174.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -136.54 54.09 1.89 Allowed 'General case' 0 C--N 1.355 0.827 0 N-CA-C 107.019 -1.474 . . . . 72.129999999999995 107.019 -178.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.2 t -138.13 163.85 30.63 Favored 'General case' 0 C--N 1.356 0.875 0 N-CA-C 107.602 -1.258 . . . . 71.409999999999997 107.602 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -149.38 165.48 31.92 Favored 'General case' 0 C--N 1.351 0.673 0 CA-C-N 119.232 0.924 . . . . 74.230000000000004 110.941 -171.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -81.02 174.41 11.64 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 118.127 -0.939 . . . . 74.319999999999993 111.545 -176.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.44 -179.35 5.57 Favored 'General case' 0 C--N 1.359 0.997 0 CA-C-O 118.054 -0.974 . . . . 72.540000000000006 109.48 -175.582 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -99.77 40.25 1.25 Allowed 'General case' 0 C--N 1.36 1.05 0 CA-C-N 119.108 0.867 . . . . 71.310000000000002 110.871 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.7 p -69.86 149.53 47.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 75.230000000000004 110.883 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.501 -0.929 0 CA-C-N 116.156 -0.475 . . . . 74.310000000000002 110.87 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.723 0 CA-C-O 118.241 -1.311 . . . . 55.119999999999997 109.915 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.0 mt -132.48 43.1 3.04 Favored 'General case' 0 C--N 1.355 0.81 0 CA-C-N 118.397 1.098 . . . . 73.420000000000002 108.689 -178.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -159.15 -171.6 3.43 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-O 117.397 -1.287 . . . . 70.340000000000003 109.576 -172.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -119.83 51.47 1.18 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-N 119.22 0.918 . . . . 74.510000000000005 110.901 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -141.99 1.37 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.744 -0.741 . . . . 62.140000000000001 112.513 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.58 -29.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.812 0.339 . . . . 75.109999999999999 111.107 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -97.52 120.65 60.27 Favored Pre-proline 0 C--N 1.359 1.018 0 O-C-N 117.568 -3.208 . . . . 60.409999999999997 107.773 -174.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.2 166.07 25.04 Favored 'Trans proline' 0 C--N 1.364 1.364 0 CA-C-N 123.653 2.34 . . . . 75.109999999999999 111.314 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -99.61 -62.2 1.27 Allowed 'General case' 0 C--N 1.358 0.953 0 N-CA-C 108.402 -0.962 . . . . 74.400000000000006 108.402 175.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.2 mt -148.03 -64.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.025 0 CA-C-O 118.39 -0.814 . . . . 65.230000000000004 109.683 -174.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.46 -114.25 1.89 Allowed Glycine 0 C--N 1.358 1.786 0 N-CA-C 108.488 -1.845 . . . . 74.310000000000002 108.488 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -114.37 55.89 0.73 Allowed 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.302 1.551 . . . . 74.530000000000001 106.966 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -137.23 162.11 34.38 Favored 'General case' 0 C--N 1.355 0.837 0 N-CA-C 108.117 -1.068 . . . . 71.510000000000005 108.117 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -149.27 165.62 31.37 Favored 'General case' 0 C--N 1.352 0.676 0 CA-C-O 118.309 -0.853 . . . . 73.409999999999997 110.407 -171.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -81.37 174.09 11.82 Favored 'General case' 0 C--N 1.358 0.962 0 CA-C-O 118.071 -0.966 . . . . 73.510000000000005 111.024 -177.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -89.59 159.7 17.04 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 117.809 -1.091 . . . . 61.340000000000003 110.926 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.26 40.44 1.53 Allowed 'General case' 0 C--N 1.362 1.124 0 CA-C-N 118.779 0.718 . . . . 54.130000000000003 110.88 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 51.9 m -69.86 163.76 25.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 65.439999999999998 110.886 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.501 -0.942 0 CA-C-N 116.122 -0.49 . . . . 74.409999999999997 110.882 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.557 -1.417 . . . . 63.439999999999998 109.557 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 51.7 mt -131.49 40.75 3.38 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 118.371 1.086 . . . . 74.040000000000006 108.884 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 m -155.72 -170.56 3.46 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 117.419 -1.277 . . . . 55.420000000000002 109.195 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -119.86 51.57 1.17 Allowed 'General case' 0 C--N 1.359 0.993 0 CA-C-N 119.313 0.96 . . . . 74.109999999999999 110.896 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.99 -141.95 1.38 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 55.409999999999997 112.478 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.62 -30.21 2.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.807 0.337 . . . . 72.140000000000001 111.126 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.29 121.95 59.04 Favored Pre-proline 0 C--N 1.359 0.981 0 O-C-N 117.763 -3.086 . . . . 75.219999999999999 107.731 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -77.91 166.96 24.43 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.773 2.383 . . . . 75.129999999999995 111.233 -176.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -100.71 -61.79 1.32 Allowed 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.328 -0.989 . . . . 72.310000000000002 108.328 174.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.1 mt -147.53 -64.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.013 0 CA-C-N 119.005 0.82 . . . . 75.239999999999995 109.717 -175.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.65 -115.99 2.32 Favored Glycine 0 C--N 1.357 1.74 0 N-CA-C 108.396 -1.881 . . . . 63.039999999999999 108.396 -177.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -112.22 58.98 0.63 Allowed 'General case' 0 C--N 1.357 0.909 0 CA-C-N 119.324 1.562 . . . . 75.25 106.93 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -140.56 160.02 40.92 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 117.806 -1.092 . . . . 71.030000000000001 108.218 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -148.84 165.45 31.47 Favored 'General case' 0 C--N 1.352 0.675 0 CA-C-O 118.342 -0.837 . . . . 73.140000000000001 110.526 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -80.97 174.87 11.19 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 119.265 0.939 . . . . 75.319999999999993 111.44 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -92.13 -177.16 4.6 Favored 'General case' 0 C--N 1.358 0.977 0 CA-C-O 117.865 -1.064 . . . . 74.239999999999995 108.857 -174.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -100.39 40.49 1.25 Allowed 'General case' 0 C--N 1.36 1.059 0 CA-C-N 119.546 1.066 . . . . 74.450000000000003 110.901 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -69.87 156.08 39.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 75.310000000000002 110.837 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.5 mtt180 . . . . . 0 CA--C 1.501 -0.939 0 CA-C-N 116.118 -0.492 . . . . 75.140000000000001 110.877 -179.952 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.776 0 N-CA-C 109.802 -1.319 . . . . 72.129999999999995 109.802 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 40.7 mt -126.73 39.27 3.96 Favored 'General case' 0 C--N 1.353 0.734 0 CA-C-N 118.17 0.985 . . . . 63.399999999999999 109.27 -175.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 m -160.39 -169.92 2.62 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 117.181 -1.39 . . . . 75.409999999999997 110.092 -170.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -120.28 51.45 1.21 Allowed 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.483 1.038 . . . . 74.519999999999996 110.873 -178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.92 -142.0 1.36 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 64.040000000000006 112.493 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.56 -30.58 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.75 0.31 . . . . 70.349999999999994 111.103 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.05 120.98 61.92 Favored Pre-proline 0 C--N 1.358 0.978 0 O-C-N 117.921 -2.987 . . . . 71.329999999999998 107.656 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -78.22 167.74 22.76 Favored 'Trans proline' 0 C--N 1.363 1.318 0 CA-C-N 123.76 2.378 . . . . 74.25 111.115 -175.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -101.42 -61.48 1.37 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 108.556 -0.905 . . . . 74.109999999999999 108.556 175.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.1 mt -146.63 -64.45 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.983 0 CA-C-O 118.378 -0.82 . . . . 73.129999999999995 109.576 -175.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.8 -112.75 2.54 Favored Glycine 0 C--N 1.357 1.748 0 N-CA-C 108.733 -1.747 . . . . 41.43 108.733 -177.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -114.15 56.03 0.72 Allowed 'General case' 0 C--N 1.355 0.838 0 N-CA-C 106.789 -1.559 . . . . 73.129999999999995 106.789 -177.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.9 t -140.61 162.26 35.8 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 117.995 -1.002 . . . . 72.230000000000004 108.64 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -151.01 166.82 29.53 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-O 118.294 -0.86 . . . . 73.120000000000005 110.693 -170.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -83.37 173.56 11.44 Favored 'General case' 0 C--N 1.358 0.944 0 CA-C-N 119.41 1.005 . . . . 73.540000000000006 111.89 -176.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -85.53 -178.05 6.58 Favored 'General case' 0 C--N 1.36 1.04 0 CA-C-N 119.168 0.894 . . . . 72.299999999999997 109.764 -177.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.9 pt-20 -103.27 40.34 1.42 Allowed 'General case' 0 C--N 1.361 1.093 0 C-N-CA 123.75 0.82 . . . . 71.310000000000002 110.855 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.95 150.64 46.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 74.109999999999999 110.808 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.906 0 CA-C-N 116.109 -0.496 . . . . 74.230000000000004 110.878 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.753 0 N-CA-C 109.855 -1.298 . . . . 53.32 109.855 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.7 mt -129.85 43.55 3.11 Favored 'General case' 0 C--N 1.353 0.722 0 CA-C-N 118.141 0.97 . . . . 74.129999999999995 108.78 -177.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.6 m -160.23 -171.62 3.26 Favored 'General case' 0 C--N 1.354 0.77 0 CA-C-O 117.398 -1.287 . . . . 70.040000000000006 109.855 -172.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.96 51.52 1.18 Allowed 'General case' 0 C--N 1.359 0.981 0 CA-C-N 119.213 0.915 . . . . 74.200000000000003 110.904 -178.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.11 -141.8 1.4 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.756 . . . . 62.020000000000003 112.482 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.7 -30.57 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 73.430000000000007 111.13 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.17 121.47 60.49 Favored Pre-proline 0 C--N 1.359 0.992 0 O-C-N 117.845 -3.034 . . . . 74.140000000000001 107.758 -175.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -78.17 166.79 24.2 Favored 'Trans proline' 0 C--N 1.364 1.363 0 CA-C-N 123.803 2.394 . . . . 75.420000000000002 111.25 -175.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -99.61 -61.24 1.39 Allowed 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.296 -1.001 . . . . 64.129999999999995 108.296 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 mt -146.77 -64.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.309 -0.853 . . . . 74.409999999999997 109.506 -175.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.2 -110.48 2.41 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 108.902 -1.679 . . . . 55.229999999999997 108.902 -177.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 51.1 mt-30 -115.8 54.04 0.83 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 106.717 -1.586 . . . . 74.019999999999996 106.717 -176.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.5 t -139.83 160.87 38.91 Favored 'General case' 0 C--N 1.354 0.783 0 N-CA-C 108.312 -0.995 . . . . 74.109999999999999 108.312 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -149.98 166.23 30.28 Favored 'General case' 0 C--N 1.351 0.674 0 CA-C-O 118.309 -0.853 . . . . 74.120000000000005 110.669 -170.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -82.19 174.38 11.24 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.04 0.837 . . . . 64.439999999999998 111.472 -176.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -91.55 -176.62 4.56 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.007 -0.997 . . . . 54.329999999999998 108.65 -175.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -102.16 40.5 1.33 Allowed 'General case' 0 C--N 1.359 1.0 0 CA-C-N 119.22 0.918 . . . . 73.430000000000007 110.906 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.9 m -69.88 155.17 40.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 70.030000000000001 110.891 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.927 0 CA-C-N 116.124 -0.489 . . . . 74.510000000000005 110.859 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.794 0 CA-C-O 118.525 -1.153 . . . . 75.519999999999996 113.872 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.0 mt -127.48 25.46 6.09 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.218 -0.896 . . . . 74.140000000000001 108.675 173.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.8 m -162.33 -168.21 1.8 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 116.594 -1.67 . . . . 74.340000000000003 109.577 -168.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -115.48 43.63 2.02 Favored 'General case' 0 C--N 1.362 1.12 0 CA-C-N 120.439 1.472 . . . . 74.299999999999997 110.925 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.57 1.0 Allowed Glycine 0 C--N 1.351 1.364 0 O-C-N 119.94 -1.725 . . . . 62.520000000000003 110.646 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.15 -21.96 4.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-N 117.659 0.73 . . . . 70.109999999999999 111.154 -173.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -98.37 115.8 65.67 Favored Pre-proline 0 C--N 1.361 1.098 0 O-C-N 117.543 -3.223 . . . . 74.299999999999997 108.044 -175.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -77.64 168.7 22.12 Favored 'Trans proline' 0 C--N 1.363 1.305 0 CA-C-N 124.07 2.489 . . . . 74.310000000000002 111.578 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.01 -61.42 1.66 Allowed 'General case' 0 C--N 1.359 0.979 0 N-CA-C 108.548 -0.908 . . . . 74.420000000000002 108.548 177.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.1 mt -146.37 -65.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.001 0 CA-C-O 118.397 -0.811 . . . . 74.319999999999993 109.271 -174.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.97 -107.81 1.27 Allowed Glycine 0 C--N 1.357 1.748 0 CA-C-O 117.457 -1.746 . . . . 71.439999999999998 109.124 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 tt0 -127.47 58.25 1.48 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 106.831 -1.544 . . . . 75.430000000000007 106.831 -178.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -139.02 159.57 41.84 Favored 'General case' 0 C--N 1.355 0.812 0 CA-C-O 117.023 -1.465 . . . . 73.140000000000001 107.871 -177.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.08 146.15 32.63 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-N 119.722 1.147 . . . . 75.129999999999995 110.881 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.13 160.16 32.93 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-N 120.135 1.334 . . . . 75.040000000000006 109.926 -178.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -91.53 169.52 10.69 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.082 -1.081 . . . . 75.140000000000001 108.082 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -100.04 40.0 1.28 Allowed 'General case' 0 C--N 1.357 0.91 0 CA-C-N 118.704 0.683 . . . . 74.530000000000001 110.897 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.93 166.53 19.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 74.299999999999997 110.845 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.8 ttt-85 . . . . . 0 CA--C 1.501 -0.91 0 CA-C-N 116.18 -0.464 . . . . 75.340000000000003 110.865 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.742 0 CA-C-O 118.398 -1.224 . . . . 61.25 114.48 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.2 mt -125.48 26.72 6.72 Favored 'General case' 0 C--N 1.354 0.773 0 CA-C-O 118.225 -0.893 . . . . 75.239999999999995 108.64 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.0 m -161.95 -170.12 2.43 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-O 116.76 -1.59 . . . . 75.349999999999994 109.852 -168.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -114.24 43.46 1.87 Allowed 'General case' 0 C--N 1.36 1.046 0 CA-C-N 120.119 1.327 . . . . 64.329999999999998 110.938 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.24 0.97 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 119.791 -1.818 . . . . 73.530000000000001 110.698 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.38 -22.77 4.33 Favored 'Isoleucine or valine' 0 C--N 1.357 0.892 0 CA-C-N 117.665 0.733 . . . . 72.519999999999996 111.164 -173.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.37 116.72 65.95 Favored Pre-proline 0 C--N 1.362 1.115 0 O-C-N 117.591 -3.193 . . . . 71.030000000000001 107.822 -174.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.11 168.79 21.37 Favored 'Trans proline' 0 C--N 1.363 1.338 0 CA-C-N 123.984 2.459 . . . . 70.430000000000007 111.593 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.48 -62.61 1.47 Allowed 'General case' 0 C--N 1.358 0.973 0 N-CA-C 108.419 -0.956 . . . . 74.109999999999999 108.419 177.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.3 mt -147.23 -66.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.979 0 CA-C-O 118.373 -0.822 . . . . 74.439999999999998 109.075 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.23 -105.26 1.09 Allowed Glycine 0 C--N 1.357 1.73 0 CA-C-O 117.637 -1.646 . . . . 74.019999999999996 109.338 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -129.29 60.19 1.57 Allowed 'General case' 0 C--N 1.357 0.92 0 N-CA-C 106.997 -1.483 . . . . 71.040000000000006 106.997 -177.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.95 163.7 32.08 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 117.117 -1.42 . . . . 75.319999999999993 108.445 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -146.6 148.06 31.72 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 117.885 -1.055 . . . . 75.420000000000002 111.005 -172.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -73.36 162.07 29.75 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-N 120.133 1.333 . . . . 75.510000000000005 110.041 -177.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.52 169.76 11.46 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 108.023 -1.103 . . . . 74.439999999999998 108.023 -178.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.1 pt-20 -99.81 40.96 1.19 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.049 0.84 . . . . 73.519999999999996 110.872 176.257 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.9 t -69.87 151.34 45.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 55.229999999999997 110.824 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.915 0 CA-C-N 116.14 -0.482 . . . . 74.109999999999999 110.879 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.685 0 CA-C-O 118.721 -1.044 . . . . 62.229999999999997 113.821 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 31.7 mt -129.35 23.12 5.55 Favored 'General case' 0 C--N 1.353 0.746 0 CA-C-O 118.217 -0.897 . . . . 74.439999999999998 109.171 172.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.4 m -158.64 -166.62 1.93 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-O 116.543 -1.694 . . . . 75.010000000000005 109.349 -169.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -115.37 43.57 2.01 Favored 'General case' 0 C--N 1.361 1.086 0 CA-C-N 120.553 1.524 . . . . 74.239999999999995 110.867 -177.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.2 -143.05 0.98 Allowed Glycine 0 C--N 1.351 1.395 0 O-C-N 120.076 -1.64 . . . . 72.349999999999994 110.713 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.94 -21.82 4.94 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 CA-C-N 117.634 0.717 . . . . 74.239999999999995 111.125 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.79 115.28 65.75 Favored Pre-proline 0 C--N 1.361 1.072 0 O-C-N 117.661 -3.149 . . . . 74.450000000000003 107.971 -175.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -77.34 168.5 22.85 Favored 'Trans proline' 0 C--N 1.363 1.297 0 CA-C-N 124.187 2.531 . . . . 75.150000000000006 111.58 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.12 -61.76 1.61 Allowed 'General case' 0 C--N 1.357 0.935 0 N-CA-C 108.328 -0.99 . . . . 75.340000000000003 108.328 177.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.4 mt -145.48 -65.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.971 0 CA-C-O 118.275 -0.869 . . . . 64.019999999999996 108.703 -174.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.82 -137.43 8.52 Favored Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.26 -1.855 . . . . 74.549999999999997 108.508 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -93.95 67.09 3.69 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.814 1.807 . . . . 74.430000000000007 107.854 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -141.91 154.6 45.22 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.057 -1.449 . . . . 75.409999999999997 108.228 177.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -144.0 143.58 31.27 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.592 1.087 . . . . 75.200000000000003 110.707 -171.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -69.07 161.14 29.66 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 120.072 1.305 . . . . 74.420000000000002 109.875 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -92.25 -179.44 5.24 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 107.327 -1.36 . . . . 71.150000000000006 107.327 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -100.67 40.81 1.23 Allowed 'General case' 0 C--N 1.356 0.856 0 CA-C-N 118.567 0.621 . . . . 73.430000000000007 110.883 177.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -69.98 140.14 52.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 73.239999999999995 110.822 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.3 ttm-85 . . . . . 0 CA--C 1.501 -0.933 0 CA-C-N 116.111 -0.495 . . . . 63.530000000000001 110.875 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.742 0 CA-C-O 118.682 -1.065 . . . . 51.340000000000003 113.87 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 29.4 mt -127.52 23.59 6.3 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.259 -0.877 . . . . 75.430000000000007 108.719 172.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.7 m -159.11 -167.18 2.01 Favored 'General case' 0 C--N 1.357 0.935 0 CA-C-O 116.511 -1.709 . . . . 71.319999999999993 109.79 -169.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -115.18 43.44 2.01 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-N 120.499 1.5 . . . . 75.319999999999993 110.915 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.11 -142.95 0.94 Allowed Glycine 0 C--N 1.35 1.355 0 O-C-N 119.96 -1.713 . . . . 72.329999999999998 110.856 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.95 -22.19 4.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.857 0 CA-C-N 117.76 0.78 . . . . 74.519999999999996 111.161 -173.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -97.47 116.09 65.82 Favored Pre-proline 0 C--N 1.361 1.08 0 O-C-N 117.656 -3.153 . . . . 74.530000000000001 107.952 -175.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -78.05 168.93 21.23 Favored 'Trans proline' 0 C--N 1.361 1.209 0 CA-C-N 124.086 2.495 . . . . 75.519999999999996 111.426 -175.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -110.39 -61.75 1.62 Allowed 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.687 -0.857 . . . . 73.140000000000001 108.687 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.05 -65.29 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.371 -0.823 . . . . 74.140000000000001 109.173 -174.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.15 -109.78 1.56 Allowed Glycine 0 C--N 1.357 1.714 0 CA-C-O 117.567 -1.685 . . . . 60.229999999999997 109.044 -177.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.6 tt0 -124.86 61.64 1.16 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 106.571 -1.64 . . . . 73.430000000000007 106.571 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.04 158.52 43.67 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 116.941 -1.504 . . . . 73.230000000000004 107.952 -178.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -144.08 144.36 31.58 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.844 1.202 . . . . 74.439999999999998 110.86 -172.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -70.05 159.47 33.78 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.331 1.423 . . . . 74.129999999999995 109.913 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.91 -178.56 5.5 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 107.85 -1.167 . . . . 73.219999999999999 107.85 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 20.8 pt-20 -101.15 40.11 1.33 Allowed 'General case' 0 C--N 1.356 0.882 0 CA-C-N 118.299 0.499 . . . . 73.329999999999998 110.874 176.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.9 t -69.94 172.3 8.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 64.519999999999996 110.832 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 11.1 mtt180 . . . . . 0 CA--C 1.501 -0.912 0 CA-C-N 116.105 -0.498 . . . . 74.230000000000004 110.92 -179.976 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.765 0 CA-C-O 118.667 -1.074 . . . . 41.140000000000001 113.145 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.4 mt -125.52 18.93 8.1 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 117.514 -1.231 . . . . 71.430000000000007 109.68 173.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.5 m -158.57 -164.27 1.42 Allowed 'General case' 0 C--N 1.358 0.969 0 CA-C-O 116.019 -1.944 . . . . 75.510000000000005 109.475 -169.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -116.05 43.36 2.16 Favored 'General case' 0 C--N 1.361 1.094 0 CA-C-N 121.269 1.85 . . . . 60.039999999999999 110.936 -174.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.8 -143.66 0.93 Allowed Glycine 0 C--N 1.35 1.349 0 O-C-N 120.149 -1.595 . . . . 75.209999999999994 110.738 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.42 -22.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-N 117.642 0.721 . . . . 72.439999999999998 111.14 -173.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.01 117.82 65.43 Favored Pre-proline 0 C--N 1.361 1.104 0 O-C-N 117.532 -3.23 . . . . 71.5 107.864 -175.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.08 170.41 18.81 Favored 'Trans proline' 0 C--N 1.363 1.296 0 CA-C-N 124.046 2.481 . . . . 75.319999999999993 111.325 -175.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.2 -62.14 1.61 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 108.524 -0.917 . . . . 74.299999999999997 108.524 177.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.28 -65.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.017 0 CA-C-O 118.336 -0.84 . . . . 72.230000000000004 108.972 -174.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.39 -109.19 1.57 Allowed Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.447 -1.752 . . . . 42.310000000000002 109.143 -177.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -124.66 61.33 1.15 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 106.931 -1.507 . . . . 70.519999999999996 106.931 -177.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -142.73 157.79 44.29 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 116.955 -1.498 . . . . 72.409999999999997 108.088 -178.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -144.36 143.67 31.07 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.782 1.174 . . . . 73.109999999999999 110.705 -171.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -70.68 157.67 37.58 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 120.034 1.288 . . . . 73.420000000000002 110.151 -176.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -83.66 152.87 24.55 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 117.368 -1.301 . . . . 75.0 108.748 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -103.98 39.9 1.55 Allowed 'General case' 0 C--N 1.358 0.967 0 CA-C-N 119.158 0.89 . . . . 74.040000000000006 110.842 176.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -69.88 169.21 13.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.19 -0.459 . . . . 74.310000000000002 110.87 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.7 ttt85 . . . . . 0 CA--C 1.501 -0.929 0 CA-C-N 116.138 -0.483 . . . . 73.140000000000001 110.897 -179.919 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.98 -0.9 . . . . 74.150000000000006 114.128 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.3 mt -131.29 28.81 4.67 Favored 'General case' 0 C--N 1.353 0.738 0 N-CA-C 108.613 -0.884 . . . . 73.439999999999998 108.613 171.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -161.78 -171.07 2.77 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 116.954 -1.498 . . . . 71.239999999999995 109.793 -169.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -114.2 43.36 1.88 Allowed 'General case' 0 C--N 1.36 1.044 0 CA-C-N 119.951 1.251 . . . . 74.409999999999997 110.89 -177.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.6 -143.76 0.9 Allowed Glycine 0 C--N 1.351 1.415 0 O-C-N 120.211 -1.555 . . . . 73.030000000000001 110.786 178.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.35 -22.93 4.38 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 CA-C-N 117.579 0.689 . . . . 71.420000000000002 111.133 -173.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -97.41 116.52 65.9 Favored Pre-proline 0 C--N 1.362 1.119 0 O-C-N 117.515 -3.241 . . . . 75.129999999999995 107.844 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.97 166.91 24.38 Favored 'Trans proline' 0 C--N 1.363 1.31 0 CA-C-N 123.995 2.463 . . . . 70.510000000000005 111.33 -174.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.16 -60.96 1.58 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.365 -0.976 . . . . 75.439999999999998 108.365 177.223 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.0 mt -145.29 -65.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.016 0 CA-C-O 118.168 -0.92 . . . . 74.299999999999997 108.897 -174.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.61 -115.31 3.54 Favored Glycine 0 C--N 1.358 1.75 0 CA-C-O 117.433 -1.759 . . . . 73.049999999999997 109.216 -177.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -110.78 63.14 0.61 Allowed 'General case' 0 C--N 1.358 0.953 0 CA-C-N 119.28 1.54 . . . . 73.239999999999995 107.871 -178.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -145.59 155.7 43.21 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 117.358 -1.306 . . . . 71.409999999999997 108.518 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -143.58 147.44 34.41 Favored 'General case' 0 C--N 1.354 0.795 0 CA-C-O 117.609 -1.186 . . . . 75.319999999999993 110.071 -172.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -73.38 159.96 32.51 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 120.183 1.356 . . . . 74.439999999999998 109.89 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -90.69 165.47 13.68 Favored 'General case' 0 C--N 1.356 0.85 0 CA-C-O 117.616 -1.183 . . . . 65.109999999999999 108.249 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -101.59 40.07 1.36 Allowed 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.076 0.853 . . . . 73.310000000000002 110.888 176.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 88.3 p -69.87 158.69 35.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.114 -0.493 . . . . 73.510000000000005 110.831 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.4 ttm-85 . . . . . 0 CA--C 1.501 -0.927 0 CA-C-N 116.119 -0.491 . . . . 73.329999999999998 110.855 -179.961 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.78 -1.011 . . . . 73.239999999999995 114.064 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 43.8 mt -130.32 28.51 4.97 Favored 'General case' 0 C--N 1.354 0.775 0 N-CA-C 108.618 -0.882 . . . . 74.439999999999998 108.618 171.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.8 m -161.25 -169.89 2.48 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 116.756 -1.592 . . . . 75.129999999999995 109.751 -169.662 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -114.9 43.39 1.98 Allowed 'General case' 0 C--N 1.359 1.001 0 CA-C-N 120.11 1.323 . . . . 74.530000000000001 110.864 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.99 -143.1 0.92 Allowed Glycine 0 C--N 1.351 1.404 0 O-C-N 120.033 -1.667 . . . . 62.229999999999997 110.776 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.82 -21.95 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.858 0 CA-C-N 117.667 0.733 . . . . 75.549999999999997 111.163 -173.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.89 115.31 65.76 Favored Pre-proline 0 C--N 1.361 1.097 0 O-C-N 117.612 -3.18 . . . . 74.099999999999994 107.837 -175.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -77.63 166.59 25.4 Favored 'Trans proline' 0 C--N 1.362 1.258 0 CA-C-N 124.143 2.515 . . . . 73.230000000000004 111.471 -175.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.95 -61.36 1.55 Allowed 'General case' 0 C--N 1.357 0.922 0 N-CA-C 108.573 -0.899 . . . . 74.049999999999997 108.573 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.7 mt -146.23 -65.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.946 0 N-CA-C 108.772 -0.825 . . . . 74.0 108.772 -174.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.81 -122.05 3.11 Favored Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.332 -1.815 . . . . 53.229999999999997 108.63 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -110.13 63.87 0.61 Allowed 'General case' 0 C--N 1.358 0.946 0 CA-C-N 119.365 1.582 . . . . 70.519999999999996 107.094 -179.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.0 t -142.53 157.07 45.12 Favored 'General case' 0 C--N 1.354 0.782 0 CA-C-O 117.088 -1.434 . . . . 74.120000000000005 108.118 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -144.13 146.79 32.99 Favored 'General case' 0 C--N 1.354 0.768 0 CA-C-O 117.694 -1.146 . . . . 75.219999999999999 110.541 -172.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -72.08 161.05 31.45 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-N 120.148 1.34 . . . . 75.349999999999994 109.961 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -91.49 169.78 10.49 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 107.856 -1.164 . . . . 62.130000000000003 107.856 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -101.12 40.0 1.34 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.967 0.803 . . . . 73.219999999999999 110.904 176.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 p -69.87 135.07 49.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 71.219999999999999 110.87 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 21.5 ttm180 . . . . . 0 CA--C 1.501 -0.923 0 CA-C-N 116.107 -0.497 . . . . 72.129999999999995 110.92 -179.948 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 118.618 -1.101 . . . . 73.150000000000006 114.048 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.2 mt -127.36 27.37 5.87 Favored 'General case' 0 C--N 1.353 0.754 0 N-CA-C 108.613 -0.884 . . . . 75.510000000000005 108.613 171.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -158.19 -169.94 2.96 Favored 'General case' 0 C--N 1.357 0.929 0 CA-C-O 116.786 -1.578 . . . . 73.310000000000002 109.697 -170.219 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -114.45 43.48 1.9 Allowed 'General case' 0 C--N 1.36 1.045 0 CA-C-N 120.132 1.333 . . . . 74.530000000000001 110.891 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.06 -143.16 0.94 Allowed Glycine 0 C--N 1.352 1.425 0 O-C-N 120.007 -1.683 . . . . 73.420000000000002 110.723 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.86 -22.38 4.63 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.617 0.708 . . . . 73.530000000000001 111.098 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -97.72 115.51 65.75 Favored Pre-proline 0 C--N 1.362 1.143 0 O-C-N 117.73 -3.106 . . . . 74.319999999999993 107.934 -175.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -77.81 166.94 24.62 Favored 'Trans proline' 0 C--N 1.364 1.369 0 CA-C-N 124.076 2.491 . . . . 65.219999999999999 111.722 -175.01 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.1 -61.9 1.48 Allowed 'General case' 0 C--N 1.357 0.912 0 N-CA-C 108.532 -0.914 . . . . 75.340000000000003 108.532 178.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.5 mt -147.23 -65.08 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.395 -0.812 . . . . 64.340000000000003 109.216 -174.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.44 -110.25 1.45 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.402 -1.777 . . . . 71.219999999999999 109.139 -176.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -123.44 58.96 1.11 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.815 -1.55 . . . . 63.140000000000001 106.815 -177.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -140.8 162.71 34.79 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 117.033 -1.461 . . . . 74.310000000000002 108.607 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -147.48 146.12 29.4 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.771 -1.109 . . . . 74.310000000000002 111.078 -171.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -72.94 159.5 33.6 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 120.207 1.367 . . . . 73.420000000000002 109.951 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -87.21 163.22 17.03 Favored 'General case' 0 C--N 1.356 0.869 0 CA-C-O 117.826 -1.083 . . . . 74.129999999999995 108.76 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.4 pt-20 -102.04 39.91 1.41 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 118.608 0.64 . . . . 54.0 110.856 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -69.87 171.23 9.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 72.400000000000006 110.876 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 63.7 mtt180 . . . . . 0 CA--C 1.501 -0.916 0 CA-C-N 116.14 -0.482 . . . . 70.420000000000002 110.886 -179.962 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 118.851 -0.972 . . . . 64.409999999999997 113.815 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.8 mt -129.91 26.73 5.22 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.678 -0.86 . . . . 65.120000000000005 108.678 171.014 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -158.05 -168.92 2.64 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-O 116.64 -1.647 . . . . 70.319999999999993 109.534 -170.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -114.96 43.61 1.94 Allowed 'General case' 0 C--N 1.36 1.06 0 CA-C-N 120.265 1.393 . . . . 74.340000000000003 110.869 -177.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.49 -143.9 0.89 Allowed Glycine 0 C--N 1.352 1.439 0 O-C-N 120.41 -1.431 . . . . 64.230000000000004 110.743 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.36 -22.24 4.79 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 117.554 0.677 . . . . 75.329999999999998 111.146 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.69 115.59 65.75 Favored Pre-proline 0 C--N 1.362 1.12 0 O-C-N 117.728 -3.107 . . . . 73.310000000000002 108.094 -175.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.26 167.14 25.2 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 124.122 2.508 . . . . 73.400000000000006 111.534 -175.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.96 -62.08 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 N-CA-C 108.393 -0.965 . . . . 71.209999999999994 108.393 177.123 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.9 mt -146.89 -64.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-O 118.409 -0.805 . . . . 61.32 108.867 -174.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.65 -122.72 2.57 Favored Glycine 0 C--N 1.359 1.817 0 CA-C-O 117.187 -1.896 . . . . 74.040000000000006 108.639 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.4 tt0 -111.04 61.5 0.61 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 119.437 1.618 . . . . 72.439999999999998 107.183 -179.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.9 t -139.78 157.48 45.67 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 117.132 -1.414 . . . . 64.409999999999997 108.101 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -144.57 142.83 30.46 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.815 -1.088 . . . . 71.450000000000003 110.603 -171.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -70.54 155.74 40.32 Favored 'General case' 0 C--N 1.359 1.004 0 CA-C-N 120.081 1.309 . . . . 75.25 109.513 -178.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -88.07 156.43 19.29 Favored 'General case' 0 C--N 1.357 0.906 0 CA-C-O 118.028 -0.987 . . . . 71.140000000000001 108.935 -179.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -105.62 39.97 1.65 Allowed 'General case' 0 C--N 1.357 0.933 0 O-C-N 123.76 0.663 . . . . 74.430000000000007 110.855 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.94 160.27 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 73.239999999999995 110.831 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.6 ttp180 . . . . . 0 CA--C 1.501 -0.91 0 CA-C-N 116.077 -0.51 . . . . 74.219999999999999 110.905 -179.951 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.776 0 CA-C-O 118.878 -0.957 . . . . 72.319999999999993 113.863 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.9 mt -129.59 27.61 5.24 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 108.596 -0.89 . . . . 71.439999999999998 108.596 170.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.8 m -159.5 -167.22 1.97 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-O 116.674 -1.631 . . . . 54.210000000000001 109.814 -171.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.8 43.31 2.13 Favored 'General case' 0 C--N 1.362 1.123 0 CA-C-N 120.278 1.399 . . . . 71.5 110.915 -177.417 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.71 -142.97 0.85 Allowed Glycine 0 C--N 1.351 1.394 0 O-C-N 119.992 -1.693 . . . . 65.319999999999993 110.707 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.88 -21.94 4.88 Favored 'Isoleucine or valine' 0 C--N 1.357 0.902 0 CA-C-N 117.556 0.678 . . . . 74.329999999999998 111.134 -173.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -98.75 115.09 65.93 Favored Pre-proline 0 C--N 1.362 1.135 0 O-C-N 117.632 -3.167 . . . . 71.129999999999995 107.789 -174.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -77.78 167.27 24.16 Favored 'Trans proline' 0 C--N 1.362 1.24 0 CA-C-N 123.967 2.453 . . . . 74.329999999999998 111.364 -174.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.33 -62.2 1.45 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.314 -0.995 . . . . 74.439999999999998 108.314 177.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.5 mt -146.56 -66.11 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.968 0 N-CA-C 108.757 -0.831 . . . . 72.239999999999995 108.757 -174.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.98 -117.79 1.8 Allowed Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.366 -1.797 . . . . 73.310000000000002 108.798 -177.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -115.91 62.14 0.7 Allowed 'General case' 0 C--N 1.357 0.924 0 N-CA-C 106.828 -1.545 . . . . 73.0 106.828 -178.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -142.05 157.97 44.3 Favored 'General case' 0 C--N 1.354 0.776 0 CA-C-O 117.214 -1.374 . . . . 65.120000000000005 108.234 -178.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -144.72 146.55 32.24 Favored 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.797 -1.097 . . . . 63.219999999999999 110.444 -172.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -72.55 158.92 34.78 Favored 'General case' 0 C--N 1.357 0.896 0 CA-C-N 120.143 1.338 . . . . 74.450000000000003 110.15 -177.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -87.66 174.0 8.69 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 107.437 -1.32 . . . . 73.030000000000001 107.437 178.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -101.68 40.08 1.36 Allowed 'General case' 0 C--N 1.356 0.868 0 C-N-CA 123.577 0.751 . . . . 74.129999999999995 110.857 174.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.85 159.35 33.8 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 64.319999999999993 110.905 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 . . . . . 0 CA--C 1.501 -0.931 0 CA-C-N 116.163 -0.471 . . . . 73.400000000000006 110.843 -179.924 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.45 -1.194 . . . . 74.010000000000005 113.499 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.7 mt -124.44 20.65 8.74 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.96 -1.019 . . . . 75.400000000000006 109.317 172.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -157.94 -164.29 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-O 116.223 -1.846 . . . . 74.420000000000002 109.557 -169.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -116.52 43.44 2.21 Favored 'General case' 0 C--N 1.361 1.089 0 CA-C-N 120.816 1.643 . . . . 71.349999999999994 110.917 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.59 -142.48 1.04 Allowed Glycine 0 C--N 1.35 1.326 0 O-C-N 119.859 -1.776 . . . . 61.219999999999999 110.682 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.13 -22.35 4.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 117.798 0.799 . . . . 73.519999999999996 111.16 -173.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -97.72 116.27 65.76 Favored Pre-proline 0 C--N 1.36 1.03 0 O-C-N 117.503 -3.248 . . . . 74.409999999999997 108.074 -174.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -77.71 169.42 20.84 Favored 'Trans proline' 0 C--N 1.362 1.26 0 CA-C-N 124.089 2.496 . . . . 73.310000000000002 111.6 -175.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.07 -61.99 1.61 Allowed 'General case' 0 C--N 1.357 0.932 0 N-CA-C 108.644 -0.872 . . . . 74.409999999999997 108.644 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.6 mt -146.71 -65.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.33 -0.843 . . . . 74.329999999999998 109.219 -174.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -107.81 1.28 Allowed Glycine 0 C--N 1.356 1.671 0 CA-C-O 117.492 -1.727 . . . . 74.400000000000006 109.112 -176.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -128.01 59.73 1.48 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 106.928 -1.508 . . . . 75.439999999999998 106.928 -177.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.4 t -140.83 159.93 41.14 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 116.898 -1.525 . . . . 72.040000000000006 107.733 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -144.61 142.77 30.39 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 120.052 1.296 . . . . 71.420000000000002 110.978 -171.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -68.14 161.08 27.74 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.99 1.268 . . . . 73.040000000000006 109.519 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -92.78 177.48 6.08 Favored 'General case' 0 C--N 1.353 0.745 0 N-CA-C 107.921 -1.14 . . . . 74.439999999999998 107.921 -177.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -101.95 40.75 1.29 Allowed 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.239 0.927 . . . . 73.209999999999994 110.903 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 73.3 m -69.91 163.12 26.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 73.439999999999998 110.865 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.8 ttp85 . . . . . 0 CA--C 1.501 -0.928 0 CA-C-N 116.118 -0.492 . . . . 74.030000000000001 110.89 -179.938 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.741 0 CA-C-O 118.647 -1.085 . . . . 70.150000000000006 113.751 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 mt -126.82 25.76 6.29 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 108.44 -0.948 . . . . 74.340000000000003 108.44 172.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.7 m -159.04 -169.35 2.64 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 116.857 -1.544 . . . . 65.340000000000003 109.622 -169.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -114.41 43.61 1.87 Allowed 'General case' 0 C--N 1.36 1.031 0 CA-C-N 120.081 1.31 . . . . 73.129999999999995 110.912 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.46 -142.29 0.99 Allowed Glycine 0 C--N 1.352 1.419 0 O-C-N 119.909 -1.745 . . . . 74.230000000000004 110.68 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.37 -22.67 4.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 117.69 0.745 . . . . 73.099999999999994 111.13 -173.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.38 117.07 65.92 Favored Pre-proline 0 C--N 1.362 1.122 0 O-C-N 117.62 -3.175 . . . . 74.420000000000002 108.012 -175.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -77.94 170.32 19.1 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 124.036 2.477 . . . . 74.140000000000001 111.541 -175.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.63 -62.19 1.59 Allowed 'General case' 0 C--N 1.359 0.995 0 N-CA-C 108.479 -0.934 . . . . 74.319999999999993 108.479 177.552 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt -146.71 -65.41 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.998 0 CA-C-O 118.375 -0.821 . . . . 75.409999999999997 109.213 -174.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.21 -108.39 1.16 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.407 -1.774 . . . . 74.510000000000005 108.96 -177.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -127.49 59.85 1.43 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.255 1.527 . . . . 75.25 106.909 -178.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -139.69 158.93 43.3 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 116.923 -1.513 . . . . 75.120000000000005 107.897 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -143.9 147.36 33.91 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-N 119.772 1.169 . . . . 71.329999999999998 110.738 -171.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-N 120.152 1.342 . . . . 74.299999999999997 110.43 -177.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -80.48 161.91 24.64 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 117.774 -1.108 . . . . 73.340000000000003 108.988 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -100.57 40.33 1.27 Allowed 'General case' 0 C--N 1.358 0.942 0 CA-C-N 118.821 0.737 . . . . 71.319999999999993 110.916 175.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.4 p -69.85 126.86 30.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.125 -0.489 . . . . 75.200000000000003 110.902 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 . . . . . 0 CA--C 1.501 -0.92 0 CA-C-N 116.152 -0.476 . . . . 74.329999999999998 110.91 -179.946 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.763 0 CA-C-O 118.688 -1.062 . . . . 73.019999999999996 114.032 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.5 mt -128.29 25.49 5.81 Favored 'General case' 0 C--N 1.354 0.774 0 N-CA-C 108.712 -0.848 . . . . 74.340000000000003 108.712 172.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.8 m -162.33 -168.96 2.0 Allowed 'General case' 0 C--N 1.358 0.936 0 CA-C-O 116.645 -1.645 . . . . 75.450000000000003 109.745 -167.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -115.09 43.56 1.97 Allowed 'General case' 0 C--N 1.36 1.058 0 CA-C-N 120.382 1.446 . . . . 72.530000000000001 110.906 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.41 -142.87 1.03 Allowed Glycine 0 C--N 1.351 1.373 0 O-C-N 119.963 -1.71 . . . . 74.140000000000001 110.682 179.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.01 -21.9 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.68 0.74 . . . . 74.239999999999995 111.124 -173.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -98.45 116.04 65.59 Favored Pre-proline 0 C--N 1.361 1.093 0 O-C-N 117.474 -3.266 . . . . 72.519999999999996 107.954 -175.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -77.83 168.63 21.97 Favored 'Trans proline' 0 C--N 1.363 1.341 0 CA-C-N 123.983 2.458 . . . . 75.219999999999999 111.577 -175.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.59 -61.41 1.64 Allowed 'General case' 0 C--N 1.357 0.911 0 N-CA-C 108.597 -0.89 . . . . 74.519999999999996 108.597 178.069 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.9 mt -145.8 -65.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.986 0 CA-C-O 118.513 -0.756 . . . . 74.120000000000005 109.065 -174.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.02 -110.18 1.75 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 117.519 -1.712 . . . . 62.149999999999999 109.001 -176.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -124.01 62.35 1.08 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.81 -1.552 . . . . 71.219999999999999 106.81 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.31 158.57 43.57 Favored 'General case' 0 C--N 1.354 0.801 0 CA-C-O 116.969 -1.491 . . . . 74.019999999999996 107.888 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -143.57 147.13 33.95 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-N 119.859 1.208 . . . . 74.420000000000002 110.711 -172.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.53 160.78 31.72 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 120.143 1.338 . . . . 74.430000000000007 109.963 -178.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -88.76 173.71 8.41 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 108.13 -1.063 . . . . 73.239999999999995 108.13 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -100.41 40.76 1.22 Allowed 'General case' 0 C--N 1.356 0.884 0 CA-C-N 118.812 0.733 . . . . 55.43 110.872 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.92 149.01 48.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 75.299999999999997 110.843 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.925 0 CA-C-N 116.173 -0.467 . . . . 73.340000000000003 110.879 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.78 0 CA-C-O 118.738 -1.035 . . . . 70.310000000000002 113.596 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.4 mt -127.39 25.51 6.11 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.347 -0.835 . . . . 74.150000000000006 108.996 170.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.9 m -157.31 -173.36 4.39 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 117.145 -1.407 . . . . 75.129999999999995 109.666 -170.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -109.08 41.48 1.61 Allowed 'General case' 0 C--N 1.359 1.011 0 CA-C-N 119.745 1.157 . . . . 75.150000000000006 110.917 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -72.1 -140.64 0.32 Allowed Glycine 0 C--N 1.35 1.337 0 O-C-N 120.181 -1.575 . . . . 73.200000000000003 110.767 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -118.47 -22.72 3.99 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-N 117.985 0.893 . . . . 64.409999999999997 111.138 -173.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.6 114.94 65.87 Favored Pre-proline 0 C--N 1.362 1.131 0 O-C-N 117.136 -3.478 . . . . 73.230000000000004 108.032 -174.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -76.92 167.19 25.64 Favored 'Trans proline' 0 C--N 1.364 1.39 0 CA-C-N 124.209 2.539 . . . . 74.420000000000002 112.016 -174.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.43 -61.56 1.62 Allowed 'General case' 0 C--N 1.357 0.934 0 N-CA-C 108.606 -0.887 . . . . 72.430000000000007 108.606 177.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.2 mt -146.32 -65.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.997 0 CA-C-O 118.435 -0.793 . . . . 74.510000000000005 108.896 -174.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.22 -120.64 2.71 Favored Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.236 -1.869 . . . . 72.140000000000001 108.761 -178.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -112.72 62.63 0.63 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-N 119.475 1.637 . . . . 75.200000000000003 107.258 -179.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.21 157.99 44.24 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 116.812 -1.566 . . . . 74.25 108.005 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -146.48 146.24 30.48 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.887 1.221 . . . . 65.530000000000001 110.425 -173.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -72.86 157.28 37.77 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.332 1.424 . . . . 73.439999999999998 110.015 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -86.68 170.06 12.12 Favored 'General case' 0 C--N 1.356 0.876 0 CA-C-O 117.83 -1.081 . . . . 74.150000000000006 108.691 -178.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -99.98 40.36 1.25 Allowed 'General case' 0 C--N 1.358 0.937 0 CA-C-N 119.021 0.828 . . . . 74.140000000000001 110.918 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.6 m -69.86 147.32 50.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 73.140000000000001 110.89 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 . . . . . 0 CA--C 1.501 -0.922 0 CA-C-N 116.163 -0.472 . . . . 74.409999999999997 110.888 -179.953 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 37.9 mt . . . . . 0 CA--C 1.513 -0.446 0 N-CA-C 109.277 -0.638 . . . . 72.150000000000006 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -160.76 -170.13 2.64 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 117.344 -1.313 . . . . 73.049999999999997 109.756 -170.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -119.86 51.51 1.18 Allowed 'General case' 0 C--N 1.36 1.062 0 CA-C-N 119.404 1.002 . . . . 71.120000000000005 110.956 -178.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.06 -141.99 1.41 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.763 . . . . 50.240000000000002 112.489 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.55 -30.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.801 0.334 . . . . 63.420000000000002 111.121 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -96.06 121.21 61.33 Favored Pre-proline 0 C--N 1.358 0.968 0 O-C-N 117.801 -3.062 . . . . 74.519999999999996 107.741 -175.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -78.56 168.12 21.72 Favored 'Trans proline' 0 C--N 1.362 1.269 0 CA-C-N 123.65 2.339 . . . . 74.219999999999999 111.328 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -102.21 -62.27 1.29 Allowed 'General case' 0 C--N 1.357 0.918 0 CA-C-O 117.915 -1.041 . . . . 72.349999999999994 108.351 174.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.1 mt -146.95 -64.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.092 0 CA-C-N 119.22 0.918 . . . . 75.310000000000002 109.293 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.57 -132.59 6.38 Favored Glycine 0 C--N 1.359 1.818 0 N-CA-C 107.918 -2.073 . . . . 50.420000000000002 107.918 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -93.99 62.51 3.11 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 120.131 1.966 . . . . 73.219999999999999 108.591 176.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.3 t -139.21 160.45 39.77 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 117.885 -1.055 . . . . 72.420000000000002 108.578 176.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -150.42 165.64 32.53 Favored 'General case' 0 C--N 1.352 0.697 0 CA-C-O 118.411 -0.804 . . . . 74.430000000000007 110.862 -170.312 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -81.97 174.98 10.75 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-N 119.004 0.82 . . . . 74.219999999999999 111.539 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 . . . . . 0 C--N 1.358 0.945 0 CA-C-O 117.767 -1.111 . . . . 61.240000000000002 109.893 -175.98 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.3 mt . . . . . 0 CA--C 1.514 -0.424 0 N-CA-C 108.806 -0.813 . . . . 63.200000000000003 108.806 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.6 m -157.56 -169.92 3.04 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 117.589 -1.196 . . . . 63.100000000000001 109.215 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -120.6 51.45 1.23 Allowed 'General case' 0 C--N 1.358 0.962 0 CA-C-N 119.096 0.862 . . . . 72.319999999999993 110.888 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -142.0 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.694 -0.765 . . . . 62.009999999999998 112.477 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.54 -30.05 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.819 0.342 . . . . 71.519999999999996 111.105 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.62 121.63 59.31 Favored Pre-proline 0 C--N 1.358 0.972 0 O-C-N 117.774 -3.079 . . . . 74.109999999999999 107.736 -175.344 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.14 167.95 22.57 Favored 'Trans proline' 0 C--N 1.363 1.334 0 CA-C-N 123.7 2.357 . . . . 61.450000000000003 111.459 -176.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.17 -62.13 1.28 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.119 -0.943 . . . . 65.299999999999997 108.666 174.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.5 mt -148.22 -64.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.055 0 CA-C-N 119.106 0.866 . . . . 64.239999999999995 110.155 -174.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.2 -95.12 1.18 Allowed Glycine 0 C--N 1.357 1.737 0 N-CA-C 108.798 -1.721 . . . . 54.530000000000001 108.798 -174.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -136.54 54.09 1.89 Allowed 'General case' 0 C--N 1.355 0.827 0 N-CA-C 107.019 -1.474 . . . . 72.129999999999995 107.019 -178.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.2 t -138.13 163.85 30.63 Favored 'General case' 0 C--N 1.356 0.875 0 N-CA-C 107.602 -1.258 . . . . 70.519999999999996 107.602 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -149.38 165.48 31.92 Favored 'General case' 0 C--N 1.351 0.673 0 CA-C-N 119.232 0.924 . . . . 74.230000000000004 110.941 -171.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -81.02 174.41 11.64 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 118.127 -0.939 . . . . 74.319999999999993 111.545 -176.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.359 0.997 0 CA-C-O 118.054 -0.974 . . . . 72.540000000000006 109.48 -175.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.0 mt . . . . . 0 CA--C 1.515 -0.401 0 N-CA-C 108.689 -0.856 . . . . 73.420000000000002 108.689 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -159.15 -171.6 3.43 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-O 117.397 -1.287 . . . . 52.520000000000003 109.576 -172.393 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -119.83 51.47 1.18 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-N 119.22 0.918 . . . . 74.439999999999998 110.901 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -141.99 1.37 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.744 -0.741 . . . . 62.140000000000001 112.513 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.58 -29.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.812 0.339 . . . . 62.32 111.107 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -97.52 120.65 60.27 Favored Pre-proline 0 C--N 1.359 1.018 0 O-C-N 117.568 -3.208 . . . . 60.409999999999997 107.773 -174.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.2 166.07 25.04 Favored 'Trans proline' 0 C--N 1.364 1.364 0 CA-C-N 123.653 2.34 . . . . 72.140000000000001 111.314 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -99.61 -62.2 1.27 Allowed 'General case' 0 C--N 1.358 0.953 0 N-CA-C 108.402 -0.962 . . . . 53.100000000000001 108.402 175.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.2 mt -148.03 -64.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.025 0 CA-C-O 118.39 -0.814 . . . . 55.299999999999997 109.683 -174.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.46 -114.25 1.89 Allowed Glycine 0 C--N 1.358 1.786 0 N-CA-C 108.488 -1.845 . . . . 74.310000000000002 108.488 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -114.37 55.89 0.73 Allowed 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.302 1.551 . . . . 74.530000000000001 106.966 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -137.23 162.11 34.38 Favored 'General case' 0 C--N 1.355 0.837 0 N-CA-C 108.117 -1.068 . . . . 54.149999999999999 108.117 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -149.27 165.62 31.37 Favored 'General case' 0 C--N 1.352 0.676 0 CA-C-O 118.309 -0.853 . . . . 73.409999999999997 110.407 -171.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -81.37 174.09 11.82 Favored 'General case' 0 C--N 1.358 0.962 0 CA-C-O 118.071 -0.966 . . . . 71.140000000000001 111.024 -177.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 . . . . . 0 C--N 1.358 0.939 0 CA-C-O 117.809 -1.091 . . . . 61.340000000000003 110.926 -176.344 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 51.7 mt . . . . . 0 CA--C 1.514 -0.41 0 N-CA-C 108.884 -0.784 . . . . 65.230000000000004 108.884 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 m -155.72 -170.56 3.46 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 117.419 -1.277 . . . . 55.420000000000002 109.195 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -119.86 51.57 1.17 Allowed 'General case' 0 C--N 1.359 0.993 0 CA-C-N 119.313 0.96 . . . . 52.020000000000003 110.896 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.99 -141.95 1.38 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 55.409999999999997 112.478 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.62 -30.21 2.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.807 0.337 . . . . 72.140000000000001 111.126 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.29 121.95 59.04 Favored Pre-proline 0 C--N 1.359 0.981 0 O-C-N 117.763 -3.086 . . . . 73.030000000000001 107.731 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -77.91 166.96 24.43 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.773 2.383 . . . . 70.239999999999995 111.233 -176.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -100.71 -61.79 1.32 Allowed 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.328 -0.989 . . . . 62.140000000000001 108.328 174.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.1 mt -147.53 -64.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.013 0 CA-C-N 119.005 0.82 . . . . 71.519999999999996 109.717 -175.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.65 -115.99 2.32 Favored Glycine 0 C--N 1.357 1.74 0 N-CA-C 108.396 -1.881 . . . . 52.539999999999999 108.396 -177.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -112.22 58.98 0.63 Allowed 'General case' 0 C--N 1.357 0.909 0 CA-C-N 119.324 1.562 . . . . 74.5 106.93 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -140.56 160.02 40.92 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 117.806 -1.092 . . . . 70.349999999999994 108.218 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -148.84 165.45 31.47 Favored 'General case' 0 C--N 1.352 0.675 0 CA-C-O 118.342 -0.837 . . . . 64.510000000000005 110.526 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -80.97 174.87 11.19 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 119.265 0.939 . . . . 74.030000000000001 111.44 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 . . . . . 0 C--N 1.358 0.977 0 CA-C-O 117.865 -1.064 . . . . 74.239999999999995 108.857 -174.926 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 40.7 mt . . . . . 0 CA--C 1.513 -0.455 0 N-CA-C 109.27 -0.641 . . . . 63.399999999999999 109.27 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 m -160.39 -169.92 2.62 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 117.181 -1.39 . . . . 75.409999999999997 110.092 -170.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -120.28 51.45 1.21 Allowed 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.483 1.038 . . . . 63.340000000000003 110.873 -178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.92 -142.0 1.36 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 41.310000000000002 112.493 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.56 -30.58 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.75 0.31 . . . . 70.349999999999994 111.103 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.05 120.98 61.92 Favored Pre-proline 0 C--N 1.358 0.978 0 O-C-N 117.921 -2.987 . . . . 55.340000000000003 107.656 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -78.22 167.74 22.76 Favored 'Trans proline' 0 C--N 1.363 1.318 0 CA-C-N 123.76 2.378 . . . . 74.25 111.115 -175.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -101.42 -61.48 1.37 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 108.556 -0.905 . . . . 74.109999999999999 108.556 175.162 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.1 mt -146.63 -64.45 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.983 0 CA-C-O 118.378 -0.82 . . . . 70.430000000000007 109.576 -175.425 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.8 -112.75 2.54 Favored Glycine 0 C--N 1.357 1.748 0 N-CA-C 108.733 -1.747 . . . . 41.43 108.733 -177.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -114.15 56.03 0.72 Allowed 'General case' 0 C--N 1.355 0.838 0 N-CA-C 106.789 -1.559 . . . . 71.200000000000003 106.789 -177.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.9 t -140.61 162.26 35.8 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 117.995 -1.002 . . . . 72.230000000000004 108.64 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -151.01 166.82 29.53 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-O 118.294 -0.86 . . . . 73.120000000000005 110.693 -170.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -83.37 173.56 11.44 Favored 'General case' 0 C--N 1.358 0.944 0 CA-C-N 119.41 1.005 . . . . 73.540000000000006 111.89 -176.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 . . . . . 0 C--N 1.36 1.04 0 CA-C-N 119.168 0.894 . . . . 62.200000000000003 109.764 -177.259 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.7 mt . . . . . 0 CA--C 1.513 -0.451 0 N-CA-C 108.78 -0.822 . . . . 63.210000000000001 108.78 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.6 m -160.23 -171.62 3.26 Favored 'General case' 0 C--N 1.354 0.77 0 CA-C-O 117.398 -1.287 . . . . 35.439999999999998 109.855 -172.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.96 51.52 1.18 Allowed 'General case' 0 C--N 1.359 0.981 0 CA-C-N 119.213 0.915 . . . . 63.130000000000003 110.904 -178.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.11 -141.8 1.4 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.756 . . . . 62.020000000000003 112.482 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.7 -30.57 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 55.350000000000001 111.13 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.17 121.47 60.49 Favored Pre-proline 0 C--N 1.359 0.992 0 O-C-N 117.845 -3.034 . . . . 74.140000000000001 107.758 -175.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -78.17 166.79 24.2 Favored 'Trans proline' 0 C--N 1.364 1.363 0 CA-C-N 123.803 2.394 . . . . 75.420000000000002 111.25 -175.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -99.61 -61.24 1.39 Allowed 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.296 -1.001 . . . . 64.129999999999995 108.296 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 mt -146.77 -64.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.309 -0.853 . . . . 74.409999999999997 109.506 -175.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.2 -110.48 2.41 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 108.902 -1.679 . . . . 45.119999999999997 108.902 -177.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 51.1 mt-30 -115.8 54.04 0.83 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 106.717 -1.586 . . . . 74.019999999999996 106.717 -176.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.5 t -139.83 160.87 38.91 Favored 'General case' 0 C--N 1.354 0.783 0 N-CA-C 108.312 -0.995 . . . . 64.540000000000006 108.312 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -149.98 166.23 30.28 Favored 'General case' 0 C--N 1.351 0.674 0 CA-C-O 118.309 -0.853 . . . . 74.120000000000005 110.669 -170.014 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -82.19 174.38 11.24 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.04 0.837 . . . . 64.439999999999998 111.472 -176.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 . . . . . 0 C--N 1.358 0.96 0 CA-C-O 118.007 -0.997 . . . . 54.329999999999998 108.65 -175.292 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.218 -0.896 . . . . 55.340000000000003 108.675 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.8 m -162.33 -168.21 1.8 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 116.594 -1.67 . . . . 73.030000000000001 109.577 -168.137 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -115.48 43.63 2.02 Favored 'General case' 0 C--N 1.362 1.12 0 CA-C-N 120.439 1.472 . . . . 61.329999999999998 110.925 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.57 1.0 Allowed Glycine 0 C--N 1.351 1.364 0 O-C-N 119.94 -1.725 . . . . 50.420000000000002 110.646 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.15 -21.96 4.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-N 117.659 0.73 . . . . 70.109999999999999 111.154 -173.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -98.37 115.8 65.67 Favored Pre-proline 0 C--N 1.361 1.098 0 O-C-N 117.543 -3.223 . . . . 74.299999999999997 108.044 -175.141 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -77.64 168.7 22.12 Favored 'Trans proline' 0 C--N 1.363 1.305 0 CA-C-N 124.07 2.489 . . . . 74.310000000000002 111.578 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.01 -61.42 1.66 Allowed 'General case' 0 C--N 1.359 0.979 0 N-CA-C 108.548 -0.908 . . . . 74.420000000000002 108.548 177.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.1 mt -146.37 -65.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.001 0 CA-C-O 118.397 -0.811 . . . . 63.450000000000003 109.271 -174.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.97 -107.81 1.27 Allowed Glycine 0 C--N 1.357 1.748 0 CA-C-O 117.457 -1.746 . . . . 71.439999999999998 109.124 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 tt0 -127.47 58.25 1.48 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 106.831 -1.544 . . . . 75.430000000000007 106.831 -178.084 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -139.02 159.57 41.84 Favored 'General case' 0 C--N 1.355 0.812 0 CA-C-O 117.023 -1.465 . . . . 62.340000000000003 107.871 -177.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.08 146.15 32.63 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-N 119.722 1.147 . . . . 75.129999999999995 110.881 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.13 160.16 32.93 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-N 120.135 1.334 . . . . 75.040000000000006 109.926 -178.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 . . . . . 0 C--N 1.356 0.866 0 N-CA-C 108.082 -1.081 . . . . 75.140000000000001 108.082 -178.798 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.2 mt . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.225 -0.893 . . . . 71.040000000000006 108.64 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.0 m -161.95 -170.12 2.43 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-O 116.76 -1.59 . . . . 75.349999999999994 109.852 -168.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -114.24 43.46 1.87 Allowed 'General case' 0 C--N 1.36 1.046 0 CA-C-N 120.119 1.327 . . . . 64.329999999999998 110.938 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.24 0.97 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 119.791 -1.818 . . . . 72.099999999999994 110.698 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.38 -22.77 4.33 Favored 'Isoleucine or valine' 0 C--N 1.357 0.892 0 CA-C-N 117.665 0.733 . . . . 72.239999999999995 111.164 -173.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.37 116.72 65.95 Favored Pre-proline 0 C--N 1.362 1.115 0 O-C-N 117.591 -3.193 . . . . 71.019999999999996 107.822 -174.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.11 168.79 21.37 Favored 'Trans proline' 0 C--N 1.363 1.338 0 CA-C-N 123.984 2.459 . . . . 70.430000000000007 111.593 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.48 -62.61 1.47 Allowed 'General case' 0 C--N 1.358 0.973 0 N-CA-C 108.419 -0.956 . . . . 74.109999999999999 108.419 177.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.3 mt -147.23 -66.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.979 0 CA-C-O 118.373 -0.822 . . . . 74.439999999999998 109.075 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.23 -105.26 1.09 Allowed Glycine 0 C--N 1.357 1.73 0 CA-C-O 117.637 -1.646 . . . . 74.019999999999996 109.338 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -129.29 60.19 1.57 Allowed 'General case' 0 C--N 1.357 0.92 0 N-CA-C 106.997 -1.483 . . . . 54.140000000000001 106.997 -177.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.95 163.7 32.08 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 117.117 -1.42 . . . . 73.140000000000001 108.445 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -146.6 148.06 31.72 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 117.885 -1.055 . . . . 52.32 111.005 -172.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -73.36 162.07 29.75 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-N 120.133 1.333 . . . . 75.510000000000005 110.041 -177.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 . . . . . 0 C--N 1.357 0.896 0 N-CA-C 108.023 -1.103 . . . . 73.129999999999995 108.023 -178.969 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 31.7 mt . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.217 -0.897 . . . . 71.519999999999996 109.171 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.4 m -158.64 -166.62 1.93 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-O 116.543 -1.694 . . . . 71.319999999999993 109.349 -169.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -115.37 43.57 2.01 Favored 'General case' 0 C--N 1.361 1.086 0 CA-C-N 120.553 1.524 . . . . 74.239999999999995 110.867 -177.08 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.2 -143.05 0.98 Allowed Glycine 0 C--N 1.351 1.395 0 O-C-N 120.076 -1.64 . . . . 72.349999999999994 110.713 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.94 -21.82 4.94 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 CA-C-N 117.634 0.717 . . . . 74.239999999999995 111.125 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.79 115.28 65.75 Favored Pre-proline 0 C--N 1.361 1.072 0 O-C-N 117.661 -3.149 . . . . 65.540000000000006 107.971 -175.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -77.34 168.5 22.85 Favored 'Trans proline' 0 C--N 1.363 1.297 0 CA-C-N 124.187 2.531 . . . . 75.150000000000006 111.58 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.12 -61.76 1.61 Allowed 'General case' 0 C--N 1.357 0.935 0 N-CA-C 108.328 -0.99 . . . . 75.340000000000003 108.328 177.012 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.4 mt -145.48 -65.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.971 0 CA-C-O 118.275 -0.869 . . . . 54.210000000000001 108.703 -174.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.82 -137.43 8.52 Favored Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.26 -1.855 . . . . 72.150000000000006 108.508 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -93.95 67.09 3.69 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.814 1.807 . . . . 74.430000000000007 107.854 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -141.91 154.6 45.22 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.057 -1.449 . . . . 75.409999999999997 108.228 177.664 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -144.0 143.58 31.27 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.592 1.087 . . . . 74.219999999999999 110.707 -171.563 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -69.07 161.14 29.66 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 120.072 1.305 . . . . 74.420000000000002 109.875 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 C--N 1.355 0.825 0 N-CA-C 107.327 -1.36 . . . . 71.150000000000006 107.327 -178.91 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 29.4 mt . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 118.259 -0.877 . . . . 44.420000000000002 108.719 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.7 m -159.11 -167.18 2.01 Favored 'General case' 0 C--N 1.357 0.935 0 CA-C-O 116.511 -1.709 . . . . 40.240000000000002 109.79 -169.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -115.18 43.44 2.01 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-N 120.499 1.5 . . . . 75.319999999999993 110.915 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.11 -142.95 0.94 Allowed Glycine 0 C--N 1.35 1.355 0 O-C-N 119.96 -1.713 . . . . 54.409999999999997 110.856 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.95 -22.19 4.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.857 0 CA-C-N 117.76 0.78 . . . . 74.519999999999996 111.161 -173.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -97.47 116.09 65.82 Favored Pre-proline 0 C--N 1.361 1.08 0 O-C-N 117.656 -3.153 . . . . 74.439999999999998 107.952 -175.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -78.05 168.93 21.23 Favored 'Trans proline' 0 C--N 1.361 1.209 0 CA-C-N 124.086 2.495 . . . . 75.519999999999996 111.426 -175.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -110.39 -61.75 1.62 Allowed 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.687 -0.857 . . . . 64.239999999999995 108.687 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.05 -65.29 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.371 -0.823 . . . . 72.409999999999997 109.173 -174.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.15 -109.78 1.56 Allowed Glycine 0 C--N 1.357 1.714 0 CA-C-O 117.567 -1.685 . . . . 60.229999999999997 109.044 -177.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.6 tt0 -124.86 61.64 1.16 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 106.571 -1.64 . . . . 64.310000000000002 106.571 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.04 158.52 43.67 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 116.941 -1.504 . . . . 73.230000000000004 107.952 -178.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -144.08 144.36 31.58 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.844 1.202 . . . . 70.140000000000001 110.86 -172.076 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -70.05 159.47 33.78 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.331 1.423 . . . . 74.129999999999995 109.913 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.354 0.804 0 N-CA-C 107.85 -1.167 . . . . 73.219999999999999 107.85 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.221 -0.396 0 CA-C-O 117.514 -1.231 . . . . 52.450000000000003 109.68 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.5 m -158.57 -164.27 1.42 Allowed 'General case' 0 C--N 1.358 0.969 0 CA-C-O 116.019 -1.944 . . . . 75.510000000000005 109.475 -169.218 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -116.05 43.36 2.16 Favored 'General case' 0 C--N 1.361 1.094 0 CA-C-N 121.269 1.85 . . . . 60.039999999999999 110.936 -174.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.8 -143.66 0.93 Allowed Glycine 0 C--N 1.35 1.349 0 O-C-N 120.149 -1.595 . . . . 73.349999999999994 110.738 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.42 -22.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-N 117.642 0.721 . . . . 65.0 111.14 -173.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.01 117.82 65.43 Favored Pre-proline 0 C--N 1.361 1.104 0 O-C-N 117.532 -3.23 . . . . 71.5 107.864 -175.163 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.08 170.41 18.81 Favored 'Trans proline' 0 C--N 1.363 1.296 0 CA-C-N 124.046 2.481 . . . . 75.319999999999993 111.325 -175.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.2 -62.14 1.61 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 108.524 -0.917 . . . . 74.299999999999997 108.524 177.3 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.28 -65.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.017 0 CA-C-O 118.336 -0.84 . . . . 72.230000000000004 108.972 -174.537 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.39 -109.19 1.57 Allowed Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.447 -1.752 . . . . 42.310000000000002 109.143 -177.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -124.66 61.33 1.15 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 106.931 -1.507 . . . . 63.240000000000002 106.931 -177.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -142.73 157.79 44.29 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 116.955 -1.498 . . . . 72.409999999999997 108.088 -178.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -144.36 143.67 31.07 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.782 1.174 . . . . 72.219999999999999 110.705 -171.478 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -70.68 157.67 37.58 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 120.034 1.288 . . . . 63.009999999999998 110.151 -176.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 C--N 1.355 0.847 0 CA-C-O 117.368 -1.301 . . . . 75.0 108.748 -179.497 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.3 mt . . . . . 0 C--O 1.221 -0.412 0 N-CA-C 108.613 -0.884 . . . . 63.450000000000003 108.613 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -161.78 -171.07 2.77 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 116.954 -1.498 . . . . 53.340000000000003 109.793 -169.237 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -114.2 43.36 1.88 Allowed 'General case' 0 C--N 1.36 1.044 0 CA-C-N 119.951 1.251 . . . . 74.409999999999997 110.89 -177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.6 -143.76 0.9 Allowed Glycine 0 C--N 1.351 1.415 0 O-C-N 120.211 -1.555 . . . . 73.030000000000001 110.786 178.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.35 -22.93 4.38 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 CA-C-N 117.579 0.689 . . . . 71.420000000000002 111.133 -173.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -97.41 116.52 65.9 Favored Pre-proline 0 C--N 1.362 1.119 0 O-C-N 117.515 -3.241 . . . . 65.019999999999996 107.844 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.97 166.91 24.38 Favored 'Trans proline' 0 C--N 1.363 1.31 0 CA-C-N 123.995 2.463 . . . . 62.119999999999997 111.33 -174.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.16 -60.96 1.58 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.365 -0.976 . . . . 70.040000000000006 108.365 177.223 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.0 mt -145.29 -65.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.016 0 CA-C-O 118.168 -0.92 . . . . 74.299999999999997 108.897 -174.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.61 -115.31 3.54 Favored Glycine 0 C--N 1.358 1.75 0 CA-C-O 117.433 -1.759 . . . . 73.049999999999997 109.216 -177.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -110.78 63.14 0.61 Allowed 'General case' 0 C--N 1.358 0.953 0 CA-C-N 119.28 1.54 . . . . 63.210000000000001 107.871 -178.188 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -145.59 155.7 43.21 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 117.358 -1.306 . . . . 71.409999999999997 108.518 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -143.58 147.44 34.41 Favored 'General case' 0 C--N 1.354 0.795 0 CA-C-O 117.609 -1.186 . . . . 75.120000000000005 110.071 -172.496 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -73.38 159.96 32.51 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 120.183 1.356 . . . . 74.25 109.89 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 . . . . . 0 C--N 1.356 0.85 0 CA-C-O 117.616 -1.183 . . . . 65.109999999999999 108.249 -179.407 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 43.8 mt . . . . . 0 C--O 1.221 -0.412 0 N-CA-C 108.618 -0.882 . . . . 74.439999999999998 108.618 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.8 m -161.25 -169.89 2.48 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 116.756 -1.592 . . . . 73.450000000000003 109.751 -169.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -114.9 43.39 1.98 Allowed 'General case' 0 C--N 1.359 1.001 0 CA-C-N 120.11 1.323 . . . . 72.030000000000001 110.864 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.99 -143.1 0.92 Allowed Glycine 0 C--N 1.351 1.404 0 O-C-N 120.033 -1.667 . . . . 62.229999999999997 110.776 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.82 -21.95 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.858 0 CA-C-N 117.667 0.733 . . . . 75.549999999999997 111.163 -173.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.89 115.31 65.76 Favored Pre-proline 0 C--N 1.361 1.097 0 O-C-N 117.612 -3.18 . . . . 74.099999999999994 107.837 -175.33 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -77.63 166.59 25.4 Favored 'Trans proline' 0 C--N 1.362 1.258 0 CA-C-N 124.143 2.515 . . . . 62.100000000000001 111.471 -175.329 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.95 -61.36 1.55 Allowed 'General case' 0 C--N 1.357 0.922 0 N-CA-C 108.573 -0.899 . . . . 62.130000000000003 108.573 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.7 mt -146.23 -65.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.946 0 N-CA-C 108.772 -0.825 . . . . 74.0 108.772 -174.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.81 -122.05 3.11 Favored Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.332 -1.815 . . . . 53.030000000000001 108.63 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -110.13 63.87 0.61 Allowed 'General case' 0 C--N 1.358 0.946 0 CA-C-N 119.365 1.582 . . . . 64.299999999999997 107.094 -179.021 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.0 t -142.53 157.07 45.12 Favored 'General case' 0 C--N 1.354 0.782 0 CA-C-O 117.088 -1.434 . . . . 73.120000000000005 108.118 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -144.13 146.79 32.99 Favored 'General case' 0 C--N 1.354 0.768 0 CA-C-O 117.694 -1.146 . . . . 75.219999999999999 110.541 -172.343 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -72.08 161.05 31.45 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-N 120.148 1.34 . . . . 71.420000000000002 109.961 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 . . . . . 0 C--N 1.355 0.834 0 N-CA-C 107.856 -1.164 . . . . 61.219999999999999 107.856 -179.471 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.2 mt . . . . . 0 C--O 1.221 -0.397 0 N-CA-C 108.613 -0.884 . . . . 74.310000000000002 108.613 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -158.19 -169.94 2.96 Favored 'General case' 0 C--N 1.357 0.929 0 CA-C-O 116.786 -1.578 . . . . 32.450000000000003 109.697 -170.219 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -114.45 43.48 1.9 Allowed 'General case' 0 C--N 1.36 1.045 0 CA-C-N 120.132 1.333 . . . . 74.530000000000001 110.891 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.06 -143.16 0.94 Allowed Glycine 0 C--N 1.352 1.425 0 O-C-N 120.007 -1.683 . . . . 73.420000000000002 110.723 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.86 -22.38 4.63 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.617 0.708 . . . . 73.530000000000001 111.098 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -97.72 115.51 65.75 Favored Pre-proline 0 C--N 1.362 1.143 0 O-C-N 117.73 -3.106 . . . . 74.319999999999993 107.934 -175.129 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -77.81 166.94 24.62 Favored 'Trans proline' 0 C--N 1.364 1.369 0 CA-C-N 124.076 2.491 . . . . 60.409999999999997 111.722 -175.01 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.1 -61.9 1.48 Allowed 'General case' 0 C--N 1.357 0.912 0 N-CA-C 108.532 -0.914 . . . . 75.340000000000003 108.532 178.039 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.5 mt -147.23 -65.08 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.395 -0.812 . . . . 64.340000000000003 109.216 -174.186 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.44 -110.25 1.45 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.402 -1.777 . . . . 71.219999999999999 109.139 -176.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -123.44 58.96 1.11 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.815 -1.55 . . . . 61.329999999999998 106.815 -177.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -140.8 162.71 34.79 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 117.033 -1.461 . . . . 65.310000000000002 108.607 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -147.48 146.12 29.4 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.771 -1.109 . . . . 74.310000000000002 111.078 -171.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -72.94 159.5 33.6 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 120.207 1.367 . . . . 64.010000000000005 109.951 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 . . . . . 0 C--N 1.356 0.869 0 CA-C-O 117.826 -1.083 . . . . 74.129999999999995 108.76 -179.724 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.8 mt . . . . . 0 C--O 1.221 -0.429 0 N-CA-C 108.678 -0.86 . . . . 55.219999999999999 108.678 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -158.05 -168.92 2.64 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-O 116.64 -1.647 . . . . 70.319999999999993 109.534 -170.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -114.96 43.61 1.94 Allowed 'General case' 0 C--N 1.36 1.06 0 CA-C-N 120.265 1.393 . . . . 74.340000000000003 110.869 -177.475 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.49 -143.9 0.89 Allowed Glycine 0 C--N 1.352 1.439 0 O-C-N 120.41 -1.431 . . . . 64.230000000000004 110.743 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.36 -22.24 4.79 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 117.554 0.677 . . . . 74.140000000000001 111.146 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.69 115.59 65.75 Favored Pre-proline 0 C--N 1.362 1.12 0 O-C-N 117.728 -3.107 . . . . 73.019999999999996 108.094 -175.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.26 167.14 25.2 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 124.122 2.508 . . . . 73.400000000000006 111.534 -175.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.96 -62.08 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 N-CA-C 108.393 -0.965 . . . . 71.099999999999994 108.393 177.123 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.9 mt -146.89 -64.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-O 118.409 -0.805 . . . . 45.43 108.867 -174.616 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.65 -122.72 2.57 Favored Glycine 0 C--N 1.359 1.817 0 CA-C-O 117.187 -1.896 . . . . 74.040000000000006 108.639 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.4 tt0 -111.04 61.5 0.61 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 119.437 1.618 . . . . 72.439999999999998 107.183 -179.407 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.9 t -139.78 157.48 45.67 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 117.132 -1.414 . . . . 64.409999999999997 108.101 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -144.57 142.83 30.46 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.815 -1.088 . . . . 71.450000000000003 110.603 -171.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -70.54 155.74 40.32 Favored 'General case' 0 C--N 1.359 1.004 0 CA-C-N 120.081 1.309 . . . . 62.450000000000003 109.513 -178.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--N 1.357 0.906 0 CA-C-O 118.028 -0.987 . . . . 71.140000000000001 108.935 -179.129 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.9 mt . . . . . 0 C--O 1.221 -0.406 0 N-CA-C 108.596 -0.89 . . . . 42.049999999999997 108.596 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.8 m -159.5 -167.22 1.97 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-O 116.674 -1.631 . . . . 54.210000000000001 109.814 -171.549 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.8 43.31 2.13 Favored 'General case' 0 C--N 1.362 1.123 0 CA-C-N 120.278 1.399 . . . . 71.5 110.915 -177.417 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.71 -142.97 0.85 Allowed Glycine 0 C--N 1.351 1.394 0 O-C-N 119.992 -1.693 . . . . 65.319999999999993 110.707 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.88 -21.94 4.88 Favored 'Isoleucine or valine' 0 C--N 1.357 0.902 0 CA-C-N 117.556 0.678 . . . . 65.209999999999994 111.134 -173.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -98.75 115.09 65.93 Favored Pre-proline 0 C--N 1.362 1.135 0 O-C-N 117.632 -3.167 . . . . 71.129999999999995 107.789 -174.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -77.78 167.27 24.16 Favored 'Trans proline' 0 C--N 1.362 1.24 0 CA-C-N 123.967 2.453 . . . . 74.329999999999998 111.364 -174.664 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.33 -62.2 1.45 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.314 -0.995 . . . . 74.439999999999998 108.314 177.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.5 mt -146.56 -66.11 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.968 0 N-CA-C 108.757 -0.831 . . . . 54.439999999999998 108.757 -174.387 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.98 -117.79 1.8 Allowed Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.366 -1.797 . . . . 65.230000000000004 108.798 -177.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -115.91 62.14 0.7 Allowed 'General case' 0 C--N 1.357 0.924 0 N-CA-C 106.828 -1.545 . . . . 73.0 106.828 -178.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -142.05 157.97 44.3 Favored 'General case' 0 C--N 1.354 0.776 0 CA-C-O 117.214 -1.374 . . . . 65.120000000000005 108.234 -178.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -144.72 146.55 32.24 Favored 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.797 -1.097 . . . . 63.219999999999999 110.444 -172.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -72.55 158.92 34.78 Favored 'General case' 0 C--N 1.357 0.896 0 CA-C-N 120.143 1.338 . . . . 73.319999999999993 110.15 -177.525 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 . . . . . 0 C--N 1.356 0.876 0 N-CA-C 107.437 -1.32 . . . . 73.030000000000001 107.437 178.359 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.7 mt . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.96 -1.019 . . . . 75.400000000000006 109.317 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -157.94 -164.29 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-O 116.223 -1.846 . . . . 74.420000000000002 109.557 -169.448 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -116.52 43.44 2.21 Favored 'General case' 0 C--N 1.361 1.089 0 CA-C-N 120.816 1.643 . . . . 71.349999999999994 110.917 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.59 -142.48 1.04 Allowed Glycine 0 C--N 1.35 1.326 0 O-C-N 119.859 -1.776 . . . . 61.219999999999999 110.682 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.13 -22.35 4.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 117.798 0.799 . . . . 63.310000000000002 111.16 -173.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -97.72 116.27 65.76 Favored Pre-proline 0 C--N 1.36 1.03 0 O-C-N 117.503 -3.248 . . . . 74.409999999999997 108.074 -174.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -77.71 169.42 20.84 Favored 'Trans proline' 0 C--N 1.362 1.26 0 CA-C-N 124.089 2.496 . . . . 73.310000000000002 111.6 -175.205 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.07 -61.99 1.61 Allowed 'General case' 0 C--N 1.357 0.932 0 N-CA-C 108.644 -0.872 . . . . 64.209999999999994 108.644 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.6 mt -146.71 -65.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.33 -0.843 . . . . 74.329999999999998 109.219 -174.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -107.81 1.28 Allowed Glycine 0 C--N 1.356 1.671 0 CA-C-O 117.492 -1.727 . . . . 74.400000000000006 109.112 -176.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -128.01 59.73 1.48 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 106.928 -1.508 . . . . 71.010000000000005 106.928 -177.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.4 t -140.83 159.93 41.14 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 116.898 -1.525 . . . . 54.009999999999998 107.733 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -144.61 142.77 30.39 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 120.052 1.296 . . . . 71.420000000000002 110.978 -171.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -68.14 161.08 27.74 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.99 1.268 . . . . 64.510000000000005 109.519 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 . . . . . 0 C--N 1.353 0.745 0 N-CA-C 107.921 -1.14 . . . . 74.439999999999998 107.921 -177.426 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 mt . . . . . 0 C--O 1.221 -0.431 0 N-CA-C 108.44 -0.948 . . . . 71.430000000000007 108.44 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.7 m -159.04 -169.35 2.64 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 116.857 -1.544 . . . . 55.109999999999999 109.622 -169.003 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -114.41 43.61 1.87 Allowed 'General case' 0 C--N 1.36 1.031 0 CA-C-N 120.081 1.31 . . . . 51.140000000000001 110.912 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.46 -142.29 0.99 Allowed Glycine 0 C--N 1.352 1.419 0 O-C-N 119.909 -1.745 . . . . 74.230000000000004 110.68 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.37 -22.67 4.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 117.69 0.745 . . . . 42.109999999999999 111.13 -173.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.38 117.07 65.92 Favored Pre-proline 0 C--N 1.362 1.122 0 O-C-N 117.62 -3.175 . . . . 61.240000000000002 108.012 -175.259 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -77.94 170.32 19.1 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 124.036 2.477 . . . . 54.119999999999997 111.541 -175.294 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.63 -62.19 1.59 Allowed 'General case' 0 C--N 1.359 0.995 0 N-CA-C 108.479 -0.934 . . . . 53.119999999999997 108.479 177.552 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt -146.71 -65.41 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.998 0 CA-C-O 118.375 -0.821 . . . . 75.409999999999997 109.213 -174.446 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.21 -108.39 1.16 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.407 -1.774 . . . . 63.130000000000003 108.96 -177.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -127.49 59.85 1.43 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.255 1.527 . . . . 75.25 106.909 -178.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -139.69 158.93 43.3 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 116.923 -1.513 . . . . 65.230000000000004 107.897 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -143.9 147.36 33.91 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-N 119.772 1.169 . . . . 71.329999999999998 110.738 -171.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-N 120.152 1.342 . . . . 74.299999999999997 110.43 -177.201 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 . . . . . 0 C--N 1.355 0.845 0 CA-C-O 117.774 -1.108 . . . . 73.340000000000003 108.988 -179.892 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.5 mt . . . . . 0 C--O 1.221 -0.431 0 N-CA-C 108.712 -0.848 . . . . 74.340000000000003 108.712 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.8 m -162.33 -168.96 2.0 Allowed 'General case' 0 C--N 1.358 0.936 0 CA-C-O 116.645 -1.645 . . . . 62.32 109.745 -167.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -115.09 43.56 1.97 Allowed 'General case' 0 C--N 1.36 1.058 0 CA-C-N 120.382 1.446 . . . . 72.329999999999998 110.906 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.41 -142.87 1.03 Allowed Glycine 0 C--N 1.351 1.373 0 O-C-N 119.963 -1.71 . . . . 73.239999999999995 110.682 179.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.01 -21.9 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.68 0.74 . . . . 61.340000000000003 111.124 -173.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -98.45 116.04 65.59 Favored Pre-proline 0 C--N 1.361 1.093 0 O-C-N 117.474 -3.266 . . . . 72.030000000000001 107.954 -175.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -77.83 168.63 21.97 Favored 'Trans proline' 0 C--N 1.363 1.341 0 CA-C-N 123.983 2.458 . . . . 52.119999999999997 111.577 -175.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.59 -61.41 1.64 Allowed 'General case' 0 C--N 1.357 0.911 0 N-CA-C 108.597 -0.89 . . . . 74.519999999999996 108.597 178.069 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.9 mt -145.8 -65.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.986 0 CA-C-O 118.513 -0.756 . . . . 64.209999999999994 109.065 -174.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.02 -110.18 1.75 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 117.519 -1.712 . . . . 52.509999999999998 109.001 -176.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -124.01 62.35 1.08 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.81 -1.552 . . . . 71.219999999999999 106.81 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.31 158.57 43.57 Favored 'General case' 0 C--N 1.354 0.801 0 CA-C-O 116.969 -1.491 . . . . 72.299999999999997 107.888 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -143.57 147.13 33.95 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-N 119.859 1.208 . . . . 73.310000000000002 110.711 -172.441 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.53 160.78 31.72 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 120.143 1.338 . . . . 74.430000000000007 109.963 -178.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--N 1.356 0.848 0 N-CA-C 108.13 -1.063 . . . . 64.409999999999997 108.13 -178.806 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.4 mt . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 118.347 -0.835 . . . . 74.150000000000006 108.996 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.9 m -157.31 -173.36 4.39 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 117.145 -1.407 . . . . 75.129999999999995 109.666 -170.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -109.08 41.48 1.61 Allowed 'General case' 0 C--N 1.359 1.011 0 CA-C-N 119.745 1.157 . . . . 71.329999999999998 110.917 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -72.1 -140.64 0.32 Allowed Glycine 0 C--N 1.35 1.337 0 O-C-N 120.181 -1.575 . . . . 73.200000000000003 110.767 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -118.47 -22.72 3.99 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-N 117.985 0.893 . . . . 64.409999999999997 111.138 -173.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.6 114.94 65.87 Favored Pre-proline 0 C--N 1.362 1.131 0 O-C-N 117.136 -3.478 . . . . 73.230000000000004 108.032 -174.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -76.92 167.19 25.64 Favored 'Trans proline' 0 C--N 1.364 1.39 0 CA-C-N 124.209 2.539 . . . . 74.299999999999997 112.016 -174.688 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.43 -61.56 1.62 Allowed 'General case' 0 C--N 1.357 0.934 0 N-CA-C 108.606 -0.887 . . . . 72.430000000000007 108.606 177.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.2 mt -146.32 -65.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.997 0 CA-C-O 118.435 -0.793 . . . . 74.510000000000005 108.896 -174.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.22 -120.64 2.71 Favored Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.236 -1.869 . . . . 72.140000000000001 108.761 -178.19 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -112.72 62.63 0.63 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-N 119.475 1.637 . . . . 75.200000000000003 107.258 -179.018 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.21 157.99 44.24 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 116.812 -1.566 . . . . 74.25 108.005 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -146.48 146.24 30.48 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.887 1.221 . . . . 55.020000000000003 110.425 -173.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -72.86 157.28 37.77 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.332 1.424 . . . . 72.400000000000006 110.015 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 . . . . . 0 C--N 1.356 0.876 0 CA-C-O 117.83 -1.081 . . . . 60.439999999999998 108.691 -178.54 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 N-CA-C 109.885 -1.286 . . . . 61.149999999999999 109.885 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 37.9 mt -129.2 39.46 3.76 Favored 'General case' 0 C--N 1.355 0.825 0 CA-C-N 117.855 0.827 . . . . 72.150000000000006 109.277 -175.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -160.76 -170.13 2.64 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 117.344 -1.313 . . . . 73.049999999999997 109.756 -170.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -119.86 51.51 1.18 Allowed 'General case' 0 C--N 1.36 1.062 0 CA-C-N 119.404 1.002 . . . . 71.120000000000005 110.956 -178.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.06 -141.99 1.41 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.763 . . . . 50.240000000000002 112.489 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.55 -30.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.801 0.334 . . . . 63.420000000000002 111.121 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -96.06 121.21 61.33 Favored Pre-proline 0 C--N 1.358 0.968 0 O-C-N 117.801 -3.062 . . . . 74.519999999999996 107.741 -175.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -78.56 168.12 21.72 Favored 'Trans proline' 0 C--N 1.362 1.269 0 CA-C-N 123.65 2.339 . . . . 74.219999999999999 111.328 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -102.21 -62.27 1.29 Allowed 'General case' 0 C--N 1.357 0.918 0 CA-C-O 117.915 -1.041 . . . . 72.349999999999994 108.351 174.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.1 mt -146.95 -64.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.092 0 CA-C-N 119.22 0.918 . . . . 75.310000000000002 109.293 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.57 -132.59 6.38 Favored Glycine 0 C--N 1.359 1.818 0 N-CA-C 107.918 -2.073 . . . . 50.420000000000002 107.918 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -93.99 62.51 3.11 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 120.131 1.966 . . . . 73.219999999999999 108.591 176.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.3 t -139.21 160.45 39.77 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 117.885 -1.055 . . . . 72.420000000000002 108.578 176.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -150.42 165.64 32.53 Favored 'General case' 0 C--N 1.352 0.697 0 CA-C-O 118.411 -0.804 . . . . 74.430000000000007 110.862 -170.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -81.97 174.98 10.75 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-N 119.004 0.82 . . . . 74.219999999999999 111.539 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -92.03 175.36 6.9 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-O 117.767 -1.111 . . . . 61.240000000000002 109.893 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -101.75 40.73 1.28 Allowed 'General case' 0 C--N 1.362 1.109 0 CA-C-N 119.371 0.987 . . . . 74.230000000000004 110.901 -178.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.88 158.18 36.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 51.130000000000003 110.876 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.501 -0.923 0 CA-C-N 116.143 -0.481 . . . . 72.150000000000006 110.908 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.766 0 N-CA-C 109.632 -1.387 . . . . 74.030000000000001 109.632 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.3 mt -132.49 41.43 3.2 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.996 0.898 . . . . 63.200000000000003 108.806 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.6 m -157.56 -169.92 3.04 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 117.589 -1.196 . . . . 63.100000000000001 109.215 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -120.6 51.45 1.23 Allowed 'General case' 0 C--N 1.358 0.962 0 CA-C-N 119.096 0.862 . . . . 72.319999999999993 110.888 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -142.0 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.694 -0.765 . . . . 62.009999999999998 112.477 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.54 -30.05 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.819 0.342 . . . . 71.519999999999996 111.105 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.62 121.63 59.31 Favored Pre-proline 0 C--N 1.358 0.972 0 O-C-N 117.774 -3.079 . . . . 74.109999999999999 107.736 -175.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.14 167.95 22.57 Favored 'Trans proline' 0 C--N 1.363 1.334 0 CA-C-N 123.7 2.357 . . . . 61.450000000000003 111.459 -176.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.17 -62.13 1.28 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.119 -0.943 . . . . 65.299999999999997 108.666 174.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.5 mt -148.22 -64.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.055 0 CA-C-N 119.106 0.866 . . . . 64.239999999999995 110.155 -174.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.2 -95.12 1.18 Allowed Glycine 0 C--N 1.357 1.737 0 N-CA-C 108.798 -1.721 . . . . 54.530000000000001 108.798 -174.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -136.54 54.09 1.89 Allowed 'General case' 0 C--N 1.355 0.827 0 N-CA-C 107.019 -1.474 . . . . 72.129999999999995 107.019 -178.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.2 t -138.13 163.85 30.63 Favored 'General case' 0 C--N 1.356 0.875 0 N-CA-C 107.602 -1.258 . . . . 70.519999999999996 107.602 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -149.38 165.48 31.92 Favored 'General case' 0 C--N 1.351 0.673 0 CA-C-N 119.232 0.924 . . . . 74.230000000000004 110.941 -171.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -81.02 174.41 11.64 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 118.127 -0.939 . . . . 74.319999999999993 111.545 -176.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.44 -179.35 5.57 Favored 'General case' 0 C--N 1.359 0.997 0 CA-C-O 118.054 -0.974 . . . . 72.540000000000006 109.48 -175.582 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -99.77 40.25 1.25 Allowed 'General case' 0 C--N 1.36 1.05 0 CA-C-N 119.108 0.867 . . . . 71.310000000000002 110.871 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.7 p -69.86 149.53 47.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 75.230000000000004 110.883 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.501 -0.929 0 CA-C-N 116.156 -0.475 . . . . 74.310000000000002 110.87 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.723 0 CA-C-O 118.241 -1.311 . . . . 55.119999999999997 109.915 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.0 mt -132.48 43.1 3.04 Favored 'General case' 0 C--N 1.355 0.81 0 CA-C-N 118.397 1.098 . . . . 73.420000000000002 108.689 -178.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -159.15 -171.6 3.43 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-O 117.397 -1.287 . . . . 52.520000000000003 109.576 -172.393 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -119.83 51.47 1.18 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-N 119.22 0.918 . . . . 74.439999999999998 110.901 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -141.99 1.37 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.744 -0.741 . . . . 62.140000000000001 112.513 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.58 -29.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.812 0.339 . . . . 62.32 111.107 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -97.52 120.65 60.27 Favored Pre-proline 0 C--N 1.359 1.018 0 O-C-N 117.568 -3.208 . . . . 60.409999999999997 107.773 -174.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.2 166.07 25.04 Favored 'Trans proline' 0 C--N 1.364 1.364 0 CA-C-N 123.653 2.34 . . . . 72.140000000000001 111.314 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -99.61 -62.2 1.27 Allowed 'General case' 0 C--N 1.358 0.953 0 N-CA-C 108.402 -0.962 . . . . 53.100000000000001 108.402 175.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.2 mt -148.03 -64.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.025 0 CA-C-O 118.39 -0.814 . . . . 55.299999999999997 109.683 -174.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.46 -114.25 1.89 Allowed Glycine 0 C--N 1.358 1.786 0 N-CA-C 108.488 -1.845 . . . . 74.310000000000002 108.488 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -114.37 55.89 0.73 Allowed 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.302 1.551 . . . . 74.530000000000001 106.966 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -137.23 162.11 34.38 Favored 'General case' 0 C--N 1.355 0.837 0 N-CA-C 108.117 -1.068 . . . . 54.149999999999999 108.117 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -149.27 165.62 31.37 Favored 'General case' 0 C--N 1.352 0.676 0 CA-C-O 118.309 -0.853 . . . . 73.409999999999997 110.407 -171.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -81.37 174.09 11.82 Favored 'General case' 0 C--N 1.358 0.962 0 CA-C-O 118.071 -0.966 . . . . 71.140000000000001 111.024 -177.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -89.59 159.7 17.04 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 117.809 -1.091 . . . . 61.340000000000003 110.926 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.26 40.44 1.53 Allowed 'General case' 0 C--N 1.362 1.124 0 CA-C-N 118.779 0.718 . . . . 54.130000000000003 110.88 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 51.9 m -69.86 163.76 25.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 65.439999999999998 110.886 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.501 -0.942 0 CA-C-N 116.122 -0.49 . . . . 74.129999999999995 110.882 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.557 -1.417 . . . . 63.439999999999998 109.557 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 51.7 mt -131.49 40.75 3.38 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 118.371 1.086 . . . . 65.230000000000004 108.884 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 m -155.72 -170.56 3.46 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 117.419 -1.277 . . . . 55.420000000000002 109.195 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -119.86 51.57 1.17 Allowed 'General case' 0 C--N 1.359 0.993 0 CA-C-N 119.313 0.96 . . . . 52.020000000000003 110.896 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.99 -141.95 1.38 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 55.409999999999997 112.478 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.62 -30.21 2.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.807 0.337 . . . . 72.140000000000001 111.126 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.29 121.95 59.04 Favored Pre-proline 0 C--N 1.359 0.981 0 O-C-N 117.763 -3.086 . . . . 73.030000000000001 107.731 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -77.91 166.96 24.43 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.773 2.383 . . . . 70.239999999999995 111.233 -176.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -100.71 -61.79 1.32 Allowed 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.328 -0.989 . . . . 62.140000000000001 108.328 174.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.1 mt -147.53 -64.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.013 0 CA-C-N 119.005 0.82 . . . . 71.519999999999996 109.717 -175.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.65 -115.99 2.32 Favored Glycine 0 C--N 1.357 1.74 0 N-CA-C 108.396 -1.881 . . . . 52.539999999999999 108.396 -177.437 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -112.22 58.98 0.63 Allowed 'General case' 0 C--N 1.357 0.909 0 CA-C-N 119.324 1.562 . . . . 74.5 106.93 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -140.56 160.02 40.92 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 117.806 -1.092 . . . . 70.349999999999994 108.218 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -148.84 165.45 31.47 Favored 'General case' 0 C--N 1.352 0.675 0 CA-C-O 118.342 -0.837 . . . . 64.510000000000005 110.526 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -80.97 174.87 11.19 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 119.265 0.939 . . . . 74.030000000000001 111.44 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -92.13 -177.16 4.6 Favored 'General case' 0 C--N 1.358 0.977 0 CA-C-O 117.865 -1.064 . . . . 74.239999999999995 108.857 -174.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -100.39 40.49 1.25 Allowed 'General case' 0 C--N 1.36 1.059 0 CA-C-N 119.546 1.066 . . . . 74.450000000000003 110.901 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -69.87 156.08 39.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 75.010000000000005 110.837 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.5 mtt180 . . . . . 0 CA--C 1.501 -0.939 0 CA-C-N 116.118 -0.492 . . . . 75.140000000000001 110.877 -179.952 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.776 0 N-CA-C 109.802 -1.319 . . . . 72.129999999999995 109.802 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 40.7 mt -126.73 39.27 3.96 Favored 'General case' 0 C--N 1.353 0.734 0 CA-C-N 118.17 0.985 . . . . 63.399999999999999 109.27 -175.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 m -160.39 -169.92 2.62 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 117.181 -1.39 . . . . 75.409999999999997 110.092 -170.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -120.28 51.45 1.21 Allowed 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.483 1.038 . . . . 63.340000000000003 110.873 -178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.92 -142.0 1.36 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 41.310000000000002 112.493 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.56 -30.58 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.75 0.31 . . . . 70.349999999999994 111.103 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.05 120.98 61.92 Favored Pre-proline 0 C--N 1.358 0.978 0 O-C-N 117.921 -2.987 . . . . 55.340000000000003 107.656 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -78.22 167.74 22.76 Favored 'Trans proline' 0 C--N 1.363 1.318 0 CA-C-N 123.76 2.378 . . . . 74.25 111.115 -175.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -101.42 -61.48 1.37 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 108.556 -0.905 . . . . 74.109999999999999 108.556 175.162 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.1 mt -146.63 -64.45 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.983 0 CA-C-O 118.378 -0.82 . . . . 70.430000000000007 109.576 -175.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.8 -112.75 2.54 Favored Glycine 0 C--N 1.357 1.748 0 N-CA-C 108.733 -1.747 . . . . 41.43 108.733 -177.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -114.15 56.03 0.72 Allowed 'General case' 0 C--N 1.355 0.838 0 N-CA-C 106.789 -1.559 . . . . 71.200000000000003 106.789 -177.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.9 t -140.61 162.26 35.8 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 117.995 -1.002 . . . . 72.230000000000004 108.64 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -151.01 166.82 29.53 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-O 118.294 -0.86 . . . . 73.120000000000005 110.693 -170.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -83.37 173.56 11.44 Favored 'General case' 0 C--N 1.358 0.944 0 CA-C-N 119.41 1.005 . . . . 73.540000000000006 111.89 -176.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -85.53 -178.05 6.58 Favored 'General case' 0 C--N 1.36 1.04 0 CA-C-N 119.168 0.894 . . . . 62.200000000000003 109.764 -177.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.9 pt-20 -103.27 40.34 1.42 Allowed 'General case' 0 C--N 1.361 1.093 0 C-N-CA 123.75 0.82 . . . . 62.25 110.855 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.95 150.64 46.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 74.109999999999999 110.808 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.906 0 CA-C-N 116.109 -0.496 . . . . 74.230000000000004 110.878 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.753 0 N-CA-C 109.855 -1.298 . . . . 53.32 109.855 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.7 mt -129.85 43.55 3.11 Favored 'General case' 0 C--N 1.353 0.722 0 CA-C-N 118.141 0.97 . . . . 63.210000000000001 108.78 -177.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.6 m -160.23 -171.62 3.26 Favored 'General case' 0 C--N 1.354 0.77 0 CA-C-O 117.398 -1.287 . . . . 35.439999999999998 109.855 -172.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.96 51.52 1.18 Allowed 'General case' 0 C--N 1.359 0.981 0 CA-C-N 119.213 0.915 . . . . 63.130000000000003 110.904 -178.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.11 -141.8 1.4 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.756 . . . . 62.020000000000003 112.482 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.7 -30.57 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 55.350000000000001 111.13 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.17 121.47 60.49 Favored Pre-proline 0 C--N 1.359 0.992 0 O-C-N 117.845 -3.034 . . . . 74.140000000000001 107.758 -175.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -78.17 166.79 24.2 Favored 'Trans proline' 0 C--N 1.364 1.363 0 CA-C-N 123.803 2.394 . . . . 75.420000000000002 111.25 -175.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -99.61 -61.24 1.39 Allowed 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.296 -1.001 . . . . 64.129999999999995 108.296 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 mt -146.77 -64.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.309 -0.853 . . . . 74.409999999999997 109.506 -175.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.2 -110.48 2.41 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 108.902 -1.679 . . . . 45.119999999999997 108.902 -177.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 51.1 mt-30 -115.8 54.04 0.83 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 106.717 -1.586 . . . . 74.019999999999996 106.717 -176.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.5 t -139.83 160.87 38.91 Favored 'General case' 0 C--N 1.354 0.783 0 N-CA-C 108.312 -0.995 . . . . 64.540000000000006 108.312 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -149.98 166.23 30.28 Favored 'General case' 0 C--N 1.351 0.674 0 CA-C-O 118.309 -0.853 . . . . 74.120000000000005 110.669 -170.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -82.19 174.38 11.24 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.04 0.837 . . . . 64.439999999999998 111.472 -176.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -91.55 -176.62 4.56 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.007 -0.997 . . . . 54.329999999999998 108.65 -175.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -102.16 40.5 1.33 Allowed 'General case' 0 C--N 1.359 1.0 0 CA-C-N 119.22 0.918 . . . . 61.119999999999997 110.906 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.9 m -69.88 155.17 40.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 61.210000000000001 110.891 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.927 0 CA-C-N 116.124 -0.489 . . . . 74.510000000000005 110.859 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.794 0 CA-C-O 118.525 -1.153 . . . . 72.329999999999998 113.872 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.0 mt -127.48 25.46 6.09 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.218 -0.896 . . . . 55.340000000000003 108.675 173.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.8 m -162.33 -168.21 1.8 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 116.594 -1.67 . . . . 73.030000000000001 109.577 -168.137 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -115.48 43.63 2.02 Favored 'General case' 0 C--N 1.362 1.12 0 CA-C-N 120.439 1.472 . . . . 61.329999999999998 110.925 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.57 1.0 Allowed Glycine 0 C--N 1.351 1.364 0 O-C-N 119.94 -1.725 . . . . 50.420000000000002 110.646 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.15 -21.96 4.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-N 117.659 0.73 . . . . 70.109999999999999 111.154 -173.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -98.37 115.8 65.67 Favored Pre-proline 0 C--N 1.361 1.098 0 O-C-N 117.543 -3.223 . . . . 74.299999999999997 108.044 -175.141 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -77.64 168.7 22.12 Favored 'Trans proline' 0 C--N 1.363 1.305 0 CA-C-N 124.07 2.489 . . . . 74.310000000000002 111.578 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.01 -61.42 1.66 Allowed 'General case' 0 C--N 1.359 0.979 0 N-CA-C 108.548 -0.908 . . . . 74.420000000000002 108.548 177.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.1 mt -146.37 -65.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.001 0 CA-C-O 118.397 -0.811 . . . . 63.450000000000003 109.271 -174.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.97 -107.81 1.27 Allowed Glycine 0 C--N 1.357 1.748 0 CA-C-O 117.457 -1.746 . . . . 71.439999999999998 109.124 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 tt0 -127.47 58.25 1.48 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 106.831 -1.544 . . . . 75.430000000000007 106.831 -178.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -139.02 159.57 41.84 Favored 'General case' 0 C--N 1.355 0.812 0 CA-C-O 117.023 -1.465 . . . . 62.340000000000003 107.871 -177.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.08 146.15 32.63 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-N 119.722 1.147 . . . . 75.129999999999995 110.881 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.13 160.16 32.93 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-N 120.135 1.334 . . . . 75.040000000000006 109.926 -178.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -91.53 169.52 10.69 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.082 -1.081 . . . . 75.140000000000001 108.082 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -100.04 40.0 1.28 Allowed 'General case' 0 C--N 1.357 0.91 0 CA-C-N 118.704 0.683 . . . . 72.329999999999998 110.897 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.93 166.53 19.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 65.519999999999996 110.845 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.8 ttt-85 . . . . . 0 CA--C 1.501 -0.91 0 CA-C-N 116.18 -0.464 . . . . 72.230000000000004 110.865 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.742 0 CA-C-O 118.398 -1.224 . . . . 61.25 114.48 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.2 mt -125.48 26.72 6.72 Favored 'General case' 0 C--N 1.354 0.773 0 CA-C-O 118.225 -0.893 . . . . 71.040000000000006 108.64 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.0 m -161.95 -170.12 2.43 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-O 116.76 -1.59 . . . . 75.349999999999994 109.852 -168.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -114.24 43.46 1.87 Allowed 'General case' 0 C--N 1.36 1.046 0 CA-C-N 120.119 1.327 . . . . 64.329999999999998 110.938 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.24 0.97 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 119.791 -1.818 . . . . 72.099999999999994 110.698 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.38 -22.77 4.33 Favored 'Isoleucine or valine' 0 C--N 1.357 0.892 0 CA-C-N 117.665 0.733 . . . . 72.239999999999995 111.164 -173.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.37 116.72 65.95 Favored Pre-proline 0 C--N 1.362 1.115 0 O-C-N 117.591 -3.193 . . . . 71.019999999999996 107.822 -174.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.11 168.79 21.37 Favored 'Trans proline' 0 C--N 1.363 1.338 0 CA-C-N 123.984 2.459 . . . . 70.430000000000007 111.593 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.48 -62.61 1.47 Allowed 'General case' 0 C--N 1.358 0.973 0 N-CA-C 108.419 -0.956 . . . . 74.109999999999999 108.419 177.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.3 mt -147.23 -66.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.979 0 CA-C-O 118.373 -0.822 . . . . 74.439999999999998 109.075 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.23 -105.26 1.09 Allowed Glycine 0 C--N 1.357 1.73 0 CA-C-O 117.637 -1.646 . . . . 74.019999999999996 109.338 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -129.29 60.19 1.57 Allowed 'General case' 0 C--N 1.357 0.92 0 N-CA-C 106.997 -1.483 . . . . 54.140000000000001 106.997 -177.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.95 163.7 32.08 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 117.117 -1.42 . . . . 73.140000000000001 108.445 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -146.6 148.06 31.72 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 117.885 -1.055 . . . . 52.32 111.005 -172.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -73.36 162.07 29.75 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-N 120.133 1.333 . . . . 75.510000000000005 110.041 -177.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.52 169.76 11.46 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 108.023 -1.103 . . . . 73.129999999999995 108.023 -178.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.1 pt-20 -99.81 40.96 1.19 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.049 0.84 . . . . 61.130000000000003 110.872 176.257 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.9 t -69.87 151.34 45.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 54.509999999999998 110.824 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.915 0 CA-C-N 116.14 -0.482 . . . . 62.32 110.879 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.685 0 CA-C-O 118.721 -1.044 . . . . 54.030000000000001 113.821 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 31.7 mt -129.35 23.12 5.55 Favored 'General case' 0 C--N 1.353 0.746 0 CA-C-O 118.217 -0.897 . . . . 71.519999999999996 109.171 172.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.4 m -158.64 -166.62 1.93 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-O 116.543 -1.694 . . . . 71.319999999999993 109.349 -169.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -115.37 43.57 2.01 Favored 'General case' 0 C--N 1.361 1.086 0 CA-C-N 120.553 1.524 . . . . 74.239999999999995 110.867 -177.08 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.2 -143.05 0.98 Allowed Glycine 0 C--N 1.351 1.395 0 O-C-N 120.076 -1.64 . . . . 72.349999999999994 110.713 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.94 -21.82 4.94 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 CA-C-N 117.634 0.717 . . . . 74.239999999999995 111.125 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.79 115.28 65.75 Favored Pre-proline 0 C--N 1.361 1.072 0 O-C-N 117.661 -3.149 . . . . 65.540000000000006 107.971 -175.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -77.34 168.5 22.85 Favored 'Trans proline' 0 C--N 1.363 1.297 0 CA-C-N 124.187 2.531 . . . . 75.150000000000006 111.58 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.12 -61.76 1.61 Allowed 'General case' 0 C--N 1.357 0.935 0 N-CA-C 108.328 -0.99 . . . . 75.340000000000003 108.328 177.012 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.4 mt -145.48 -65.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.971 0 CA-C-O 118.275 -0.869 . . . . 54.210000000000001 108.703 -174.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.82 -137.43 8.52 Favored Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.26 -1.855 . . . . 72.150000000000006 108.508 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -93.95 67.09 3.69 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.814 1.807 . . . . 74.430000000000007 107.854 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -141.91 154.6 45.22 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.057 -1.449 . . . . 75.409999999999997 108.228 177.664 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -144.0 143.58 31.27 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.592 1.087 . . . . 74.219999999999999 110.707 -171.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -69.07 161.14 29.66 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 120.072 1.305 . . . . 74.420000000000002 109.875 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -92.25 -179.44 5.24 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 107.327 -1.36 . . . . 71.150000000000006 107.327 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -100.67 40.81 1.23 Allowed 'General case' 0 C--N 1.356 0.856 0 CA-C-N 118.567 0.621 . . . . 70.109999999999999 110.883 177.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -69.98 140.14 52.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 73.239999999999995 110.822 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.3 ttm-85 . . . . . 0 CA--C 1.501 -0.933 0 CA-C-N 116.111 -0.495 . . . . 63.119999999999997 110.875 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.742 0 CA-C-O 118.682 -1.065 . . . . 51.340000000000003 113.87 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 29.4 mt -127.52 23.59 6.3 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.259 -0.877 . . . . 44.420000000000002 108.719 172.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.7 m -159.11 -167.18 2.01 Favored 'General case' 0 C--N 1.357 0.935 0 CA-C-O 116.511 -1.709 . . . . 40.240000000000002 109.79 -169.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -115.18 43.44 2.01 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-N 120.499 1.5 . . . . 75.319999999999993 110.915 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.11 -142.95 0.94 Allowed Glycine 0 C--N 1.35 1.355 0 O-C-N 119.96 -1.713 . . . . 54.409999999999997 110.856 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.95 -22.19 4.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.857 0 CA-C-N 117.76 0.78 . . . . 74.519999999999996 111.161 -173.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -97.47 116.09 65.82 Favored Pre-proline 0 C--N 1.361 1.08 0 O-C-N 117.656 -3.153 . . . . 74.439999999999998 107.952 -175.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -78.05 168.93 21.23 Favored 'Trans proline' 0 C--N 1.361 1.209 0 CA-C-N 124.086 2.495 . . . . 75.519999999999996 111.426 -175.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -110.39 -61.75 1.62 Allowed 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.687 -0.857 . . . . 64.239999999999995 108.687 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.05 -65.29 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.371 -0.823 . . . . 72.409999999999997 109.173 -174.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.15 -109.78 1.56 Allowed Glycine 0 C--N 1.357 1.714 0 CA-C-O 117.567 -1.685 . . . . 60.229999999999997 109.044 -177.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.6 tt0 -124.86 61.64 1.16 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 106.571 -1.64 . . . . 64.310000000000002 106.571 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.04 158.52 43.67 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 116.941 -1.504 . . . . 73.230000000000004 107.952 -178.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -144.08 144.36 31.58 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.844 1.202 . . . . 70.140000000000001 110.86 -172.076 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -70.05 159.47 33.78 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.331 1.423 . . . . 74.129999999999995 109.913 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.91 -178.56 5.5 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 107.85 -1.167 . . . . 73.219999999999999 107.85 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 20.8 pt-20 -101.15 40.11 1.33 Allowed 'General case' 0 C--N 1.356 0.882 0 CA-C-N 118.299 0.499 . . . . 62.32 110.874 176.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.9 t -69.94 172.3 8.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 63.509999999999998 110.832 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 11.1 mtt180 . . . . . 0 CA--C 1.501 -0.912 0 CA-C-N 116.105 -0.498 . . . . 71.129999999999995 110.92 -179.976 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.765 0 CA-C-O 118.667 -1.074 . . . . 24.440000000000001 113.145 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.4 mt -125.52 18.93 8.1 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 117.514 -1.231 . . . . 52.450000000000003 109.68 173.246 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.5 m -158.57 -164.27 1.42 Allowed 'General case' 0 C--N 1.358 0.969 0 CA-C-O 116.019 -1.944 . . . . 75.510000000000005 109.475 -169.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -116.05 43.36 2.16 Favored 'General case' 0 C--N 1.361 1.094 0 CA-C-N 121.269 1.85 . . . . 60.039999999999999 110.936 -174.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.8 -143.66 0.93 Allowed Glycine 0 C--N 1.35 1.349 0 O-C-N 120.149 -1.595 . . . . 73.349999999999994 110.738 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.42 -22.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-N 117.642 0.721 . . . . 65.0 111.14 -173.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.01 117.82 65.43 Favored Pre-proline 0 C--N 1.361 1.104 0 O-C-N 117.532 -3.23 . . . . 71.5 107.864 -175.163 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.08 170.41 18.81 Favored 'Trans proline' 0 C--N 1.363 1.296 0 CA-C-N 124.046 2.481 . . . . 75.319999999999993 111.325 -175.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.2 -62.14 1.61 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 108.524 -0.917 . . . . 74.299999999999997 108.524 177.3 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.28 -65.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.017 0 CA-C-O 118.336 -0.84 . . . . 72.230000000000004 108.972 -174.537 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.39 -109.19 1.57 Allowed Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.447 -1.752 . . . . 42.310000000000002 109.143 -177.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -124.66 61.33 1.15 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 106.931 -1.507 . . . . 63.240000000000002 106.931 -177.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -142.73 157.79 44.29 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 116.955 -1.498 . . . . 72.409999999999997 108.088 -178.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -144.36 143.67 31.07 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.782 1.174 . . . . 72.219999999999999 110.705 -171.478 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -70.68 157.67 37.58 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 120.034 1.288 . . . . 63.009999999999998 110.151 -176.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -83.66 152.87 24.55 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 117.368 -1.301 . . . . 75.0 108.748 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -103.98 39.9 1.55 Allowed 'General case' 0 C--N 1.358 0.967 0 CA-C-N 119.158 0.89 . . . . 71.409999999999997 110.842 176.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -69.88 169.21 13.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.19 -0.459 . . . . 73.209999999999994 110.87 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.7 ttt85 . . . . . 0 CA--C 1.501 -0.929 0 CA-C-N 116.138 -0.483 . . . . 71.209999999999994 110.897 -179.919 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.98 -0.9 . . . . 55.340000000000003 114.128 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.3 mt -131.29 28.81 4.67 Favored 'General case' 0 C--N 1.353 0.738 0 N-CA-C 108.613 -0.884 . . . . 63.450000000000003 108.613 171.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -161.78 -171.07 2.77 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 116.954 -1.498 . . . . 53.340000000000003 109.793 -169.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -114.2 43.36 1.88 Allowed 'General case' 0 C--N 1.36 1.044 0 CA-C-N 119.951 1.251 . . . . 74.409999999999997 110.89 -177.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.6 -143.76 0.9 Allowed Glycine 0 C--N 1.351 1.415 0 O-C-N 120.211 -1.555 . . . . 73.030000000000001 110.786 178.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.35 -22.93 4.38 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 CA-C-N 117.579 0.689 . . . . 71.420000000000002 111.133 -173.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -97.41 116.52 65.9 Favored Pre-proline 0 C--N 1.362 1.119 0 O-C-N 117.515 -3.241 . . . . 65.019999999999996 107.844 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.97 166.91 24.38 Favored 'Trans proline' 0 C--N 1.363 1.31 0 CA-C-N 123.995 2.463 . . . . 62.119999999999997 111.33 -174.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.16 -60.96 1.58 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.365 -0.976 . . . . 70.040000000000006 108.365 177.223 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.0 mt -145.29 -65.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.016 0 CA-C-O 118.168 -0.92 . . . . 74.299999999999997 108.897 -174.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.61 -115.31 3.54 Favored Glycine 0 C--N 1.358 1.75 0 CA-C-O 117.433 -1.759 . . . . 73.049999999999997 109.216 -177.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -110.78 63.14 0.61 Allowed 'General case' 0 C--N 1.358 0.953 0 CA-C-N 119.28 1.54 . . . . 63.210000000000001 107.871 -178.188 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -145.59 155.7 43.21 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 117.358 -1.306 . . . . 71.409999999999997 108.518 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -143.58 147.44 34.41 Favored 'General case' 0 C--N 1.354 0.795 0 CA-C-O 117.609 -1.186 . . . . 75.120000000000005 110.071 -172.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -73.38 159.96 32.51 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 120.183 1.356 . . . . 74.25 109.89 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -90.69 165.47 13.68 Favored 'General case' 0 C--N 1.356 0.85 0 CA-C-O 117.616 -1.183 . . . . 65.109999999999999 108.249 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -101.59 40.07 1.36 Allowed 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.076 0.853 . . . . 63.149999999999999 110.888 176.007 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 88.3 p -69.87 158.69 35.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.114 -0.493 . . . . 73.510000000000005 110.831 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.4 ttm-85 . . . . . 0 CA--C 1.501 -0.927 0 CA-C-N 116.119 -0.491 . . . . 72.150000000000006 110.855 -179.961 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.78 -1.011 . . . . 73.239999999999995 114.064 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 43.8 mt -130.32 28.51 4.97 Favored 'General case' 0 C--N 1.354 0.775 0 N-CA-C 108.618 -0.882 . . . . 74.439999999999998 108.618 171.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.8 m -161.25 -169.89 2.48 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 116.756 -1.592 . . . . 73.450000000000003 109.751 -169.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -114.9 43.39 1.98 Allowed 'General case' 0 C--N 1.359 1.001 0 CA-C-N 120.11 1.323 . . . . 72.030000000000001 110.864 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.99 -143.1 0.92 Allowed Glycine 0 C--N 1.351 1.404 0 O-C-N 120.033 -1.667 . . . . 62.229999999999997 110.776 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.82 -21.95 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.858 0 CA-C-N 117.667 0.733 . . . . 75.549999999999997 111.163 -173.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.89 115.31 65.76 Favored Pre-proline 0 C--N 1.361 1.097 0 O-C-N 117.612 -3.18 . . . . 74.099999999999994 107.837 -175.33 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -77.63 166.59 25.4 Favored 'Trans proline' 0 C--N 1.362 1.258 0 CA-C-N 124.143 2.515 . . . . 62.100000000000001 111.471 -175.329 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.95 -61.36 1.55 Allowed 'General case' 0 C--N 1.357 0.922 0 N-CA-C 108.573 -0.899 . . . . 62.130000000000003 108.573 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.7 mt -146.23 -65.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.946 0 N-CA-C 108.772 -0.825 . . . . 74.0 108.772 -174.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.81 -122.05 3.11 Favored Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.332 -1.815 . . . . 53.030000000000001 108.63 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -110.13 63.87 0.61 Allowed 'General case' 0 C--N 1.358 0.946 0 CA-C-N 119.365 1.582 . . . . 64.299999999999997 107.094 -179.021 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.0 t -142.53 157.07 45.12 Favored 'General case' 0 C--N 1.354 0.782 0 CA-C-O 117.088 -1.434 . . . . 73.120000000000005 108.118 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -144.13 146.79 32.99 Favored 'General case' 0 C--N 1.354 0.768 0 CA-C-O 117.694 -1.146 . . . . 75.219999999999999 110.541 -172.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -72.08 161.05 31.45 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-N 120.148 1.34 . . . . 71.420000000000002 109.961 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -91.49 169.78 10.49 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 107.856 -1.164 . . . . 61.219999999999999 107.856 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -101.12 40.0 1.34 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.967 0.803 . . . . 73.219999999999999 110.904 176.404 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 p -69.87 135.07 49.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 62.149999999999999 110.87 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 21.5 ttm180 . . . . . 0 CA--C 1.501 -0.923 0 CA-C-N 116.107 -0.497 . . . . 62.219999999999999 110.92 -179.948 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 118.618 -1.101 . . . . 54.009999999999998 114.048 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.2 mt -127.36 27.37 5.87 Favored 'General case' 0 C--N 1.353 0.754 0 N-CA-C 108.613 -0.884 . . . . 74.310000000000002 108.613 171.291 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -158.19 -169.94 2.96 Favored 'General case' 0 C--N 1.357 0.929 0 CA-C-O 116.786 -1.578 . . . . 32.450000000000003 109.697 -170.219 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -114.45 43.48 1.9 Allowed 'General case' 0 C--N 1.36 1.045 0 CA-C-N 120.132 1.333 . . . . 74.530000000000001 110.891 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.06 -143.16 0.94 Allowed Glycine 0 C--N 1.352 1.425 0 O-C-N 120.007 -1.683 . . . . 73.420000000000002 110.723 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.86 -22.38 4.63 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.617 0.708 . . . . 73.530000000000001 111.098 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -97.72 115.51 65.75 Favored Pre-proline 0 C--N 1.362 1.143 0 O-C-N 117.73 -3.106 . . . . 74.319999999999993 107.934 -175.129 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -77.81 166.94 24.62 Favored 'Trans proline' 0 C--N 1.364 1.369 0 CA-C-N 124.076 2.491 . . . . 60.409999999999997 111.722 -175.01 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.1 -61.9 1.48 Allowed 'General case' 0 C--N 1.357 0.912 0 N-CA-C 108.532 -0.914 . . . . 75.340000000000003 108.532 178.039 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.5 mt -147.23 -65.08 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.395 -0.812 . . . . 64.340000000000003 109.216 -174.186 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.44 -110.25 1.45 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.402 -1.777 . . . . 71.219999999999999 109.139 -176.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -123.44 58.96 1.11 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.815 -1.55 . . . . 61.329999999999998 106.815 -177.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -140.8 162.71 34.79 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 117.033 -1.461 . . . . 65.310000000000002 108.607 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -147.48 146.12 29.4 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.771 -1.109 . . . . 74.310000000000002 111.078 -171.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -72.94 159.5 33.6 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 120.207 1.367 . . . . 64.010000000000005 109.951 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -87.21 163.22 17.03 Favored 'General case' 0 C--N 1.356 0.869 0 CA-C-O 117.826 -1.083 . . . . 74.129999999999995 108.76 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.4 pt-20 -102.04 39.91 1.41 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 118.608 0.64 . . . . 32.32 110.856 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -69.87 171.23 9.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 72.400000000000006 110.876 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 63.7 mtt180 . . . . . 0 CA--C 1.501 -0.916 0 CA-C-N 116.14 -0.482 . . . . 70.420000000000002 110.886 -179.962 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 118.851 -0.972 . . . . 41.140000000000001 113.815 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.8 mt -129.91 26.73 5.22 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.678 -0.86 . . . . 55.219999999999999 108.678 171.014 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -158.05 -168.92 2.64 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-O 116.64 -1.647 . . . . 70.319999999999993 109.534 -170.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -114.96 43.61 1.94 Allowed 'General case' 0 C--N 1.36 1.06 0 CA-C-N 120.265 1.393 . . . . 74.340000000000003 110.869 -177.475 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.49 -143.9 0.89 Allowed Glycine 0 C--N 1.352 1.439 0 O-C-N 120.41 -1.431 . . . . 64.230000000000004 110.743 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.36 -22.24 4.79 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 117.554 0.677 . . . . 74.140000000000001 111.146 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.69 115.59 65.75 Favored Pre-proline 0 C--N 1.362 1.12 0 O-C-N 117.728 -3.107 . . . . 73.019999999999996 108.094 -175.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.26 167.14 25.2 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 124.122 2.508 . . . . 73.400000000000006 111.534 -175.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.96 -62.08 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 N-CA-C 108.393 -0.965 . . . . 71.099999999999994 108.393 177.123 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.9 mt -146.89 -64.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-O 118.409 -0.805 . . . . 45.43 108.867 -174.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.65 -122.72 2.57 Favored Glycine 0 C--N 1.359 1.817 0 CA-C-O 117.187 -1.896 . . . . 74.040000000000006 108.639 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.4 tt0 -111.04 61.5 0.61 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 119.437 1.618 . . . . 72.439999999999998 107.183 -179.407 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.9 t -139.78 157.48 45.67 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 117.132 -1.414 . . . . 64.409999999999997 108.101 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -144.57 142.83 30.46 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.815 -1.088 . . . . 71.450000000000003 110.603 -171.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -70.54 155.74 40.32 Favored 'General case' 0 C--N 1.359 1.004 0 CA-C-N 120.081 1.309 . . . . 62.450000000000003 109.513 -178.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -88.07 156.43 19.29 Favored 'General case' 0 C--N 1.357 0.906 0 CA-C-O 118.028 -0.987 . . . . 71.140000000000001 108.935 -179.129 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -105.62 39.97 1.65 Allowed 'General case' 0 C--N 1.357 0.933 0 O-C-N 123.76 0.663 . . . . 74.329999999999998 110.855 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.94 160.27 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 53.32 110.831 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.6 ttp180 . . . . . 0 CA--C 1.501 -0.91 0 CA-C-N 116.077 -0.51 . . . . 74.219999999999999 110.905 -179.951 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.776 0 CA-C-O 118.878 -0.957 . . . . 45.539999999999999 113.863 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.9 mt -129.59 27.61 5.24 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 108.596 -0.89 . . . . 42.049999999999997 108.596 170.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.8 m -159.5 -167.22 1.97 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-O 116.674 -1.631 . . . . 54.210000000000001 109.814 -171.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.8 43.31 2.13 Favored 'General case' 0 C--N 1.362 1.123 0 CA-C-N 120.278 1.399 . . . . 71.5 110.915 -177.417 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.71 -142.97 0.85 Allowed Glycine 0 C--N 1.351 1.394 0 O-C-N 119.992 -1.693 . . . . 65.319999999999993 110.707 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.88 -21.94 4.88 Favored 'Isoleucine or valine' 0 C--N 1.357 0.902 0 CA-C-N 117.556 0.678 . . . . 65.209999999999994 111.134 -173.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -98.75 115.09 65.93 Favored Pre-proline 0 C--N 1.362 1.135 0 O-C-N 117.632 -3.167 . . . . 71.129999999999995 107.789 -174.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -77.78 167.27 24.16 Favored 'Trans proline' 0 C--N 1.362 1.24 0 CA-C-N 123.967 2.453 . . . . 74.329999999999998 111.364 -174.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.33 -62.2 1.45 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.314 -0.995 . . . . 74.439999999999998 108.314 177.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.5 mt -146.56 -66.11 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.968 0 N-CA-C 108.757 -0.831 . . . . 54.439999999999998 108.757 -174.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.98 -117.79 1.8 Allowed Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.366 -1.797 . . . . 65.230000000000004 108.798 -177.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -115.91 62.14 0.7 Allowed 'General case' 0 C--N 1.357 0.924 0 N-CA-C 106.828 -1.545 . . . . 73.0 106.828 -178.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -142.05 157.97 44.3 Favored 'General case' 0 C--N 1.354 0.776 0 CA-C-O 117.214 -1.374 . . . . 65.120000000000005 108.234 -178.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -144.72 146.55 32.24 Favored 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.797 -1.097 . . . . 63.219999999999999 110.444 -172.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -72.55 158.92 34.78 Favored 'General case' 0 C--N 1.357 0.896 0 CA-C-N 120.143 1.338 . . . . 73.319999999999993 110.15 -177.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -87.66 174.0 8.69 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 107.437 -1.32 . . . . 73.030000000000001 107.437 178.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -101.68 40.08 1.36 Allowed 'General case' 0 C--N 1.356 0.868 0 C-N-CA 123.577 0.751 . . . . 64.329999999999998 110.857 174.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.85 159.35 33.8 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 64.319999999999993 110.905 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 . . . . . 0 CA--C 1.501 -0.931 0 CA-C-N 116.163 -0.471 . . . . 53.219999999999999 110.843 -179.924 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.45 -1.194 . . . . 74.010000000000005 113.499 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.7 mt -124.44 20.65 8.74 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.96 -1.019 . . . . 75.400000000000006 109.317 172.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -157.94 -164.29 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-O 116.223 -1.846 . . . . 74.420000000000002 109.557 -169.448 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -116.52 43.44 2.21 Favored 'General case' 0 C--N 1.361 1.089 0 CA-C-N 120.816 1.643 . . . . 71.349999999999994 110.917 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.59 -142.48 1.04 Allowed Glycine 0 C--N 1.35 1.326 0 O-C-N 119.859 -1.776 . . . . 61.219999999999999 110.682 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.13 -22.35 4.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 117.798 0.799 . . . . 63.310000000000002 111.16 -173.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -97.72 116.27 65.76 Favored Pre-proline 0 C--N 1.36 1.03 0 O-C-N 117.503 -3.248 . . . . 74.409999999999997 108.074 -174.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -77.71 169.42 20.84 Favored 'Trans proline' 0 C--N 1.362 1.26 0 CA-C-N 124.089 2.496 . . . . 73.310000000000002 111.6 -175.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.07 -61.99 1.61 Allowed 'General case' 0 C--N 1.357 0.932 0 N-CA-C 108.644 -0.872 . . . . 64.209999999999994 108.644 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.6 mt -146.71 -65.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.33 -0.843 . . . . 74.329999999999998 109.219 -174.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -107.81 1.28 Allowed Glycine 0 C--N 1.356 1.671 0 CA-C-O 117.492 -1.727 . . . . 74.400000000000006 109.112 -176.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -128.01 59.73 1.48 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 106.928 -1.508 . . . . 71.010000000000005 106.928 -177.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.4 t -140.83 159.93 41.14 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 116.898 -1.525 . . . . 54.009999999999998 107.733 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -144.61 142.77 30.39 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 120.052 1.296 . . . . 71.420000000000002 110.978 -171.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -68.14 161.08 27.74 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.99 1.268 . . . . 64.510000000000005 109.519 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -92.78 177.48 6.08 Favored 'General case' 0 C--N 1.353 0.745 0 N-CA-C 107.921 -1.14 . . . . 74.439999999999998 107.921 -177.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -101.95 40.75 1.29 Allowed 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.239 0.927 . . . . 72.010000000000005 110.903 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 73.3 m -69.91 163.12 26.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 71.310000000000002 110.865 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.8 ttp85 . . . . . 0 CA--C 1.501 -0.928 0 CA-C-N 116.118 -0.492 . . . . 72.329999999999998 110.89 -179.938 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.741 0 CA-C-O 118.647 -1.085 . . . . 52.210000000000001 113.751 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 mt -126.82 25.76 6.29 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 108.44 -0.948 . . . . 71.430000000000007 108.44 172.404 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.7 m -159.04 -169.35 2.64 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 116.857 -1.544 . . . . 55.109999999999999 109.622 -169.003 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -114.41 43.61 1.87 Allowed 'General case' 0 C--N 1.36 1.031 0 CA-C-N 120.081 1.31 . . . . 51.140000000000001 110.912 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.46 -142.29 0.99 Allowed Glycine 0 C--N 1.352 1.419 0 O-C-N 119.909 -1.745 . . . . 74.230000000000004 110.68 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.37 -22.67 4.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 117.69 0.745 . . . . 42.109999999999999 111.13 -173.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.38 117.07 65.92 Favored Pre-proline 0 C--N 1.362 1.122 0 O-C-N 117.62 -3.175 . . . . 61.240000000000002 108.012 -175.259 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -77.94 170.32 19.1 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 124.036 2.477 . . . . 54.119999999999997 111.541 -175.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.63 -62.19 1.59 Allowed 'General case' 0 C--N 1.359 0.995 0 N-CA-C 108.479 -0.934 . . . . 53.119999999999997 108.479 177.552 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt -146.71 -65.41 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.998 0 CA-C-O 118.375 -0.821 . . . . 75.409999999999997 109.213 -174.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.21 -108.39 1.16 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.407 -1.774 . . . . 63.130000000000003 108.96 -177.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -127.49 59.85 1.43 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.255 1.527 . . . . 75.25 106.909 -178.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -139.69 158.93 43.3 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 116.923 -1.513 . . . . 65.230000000000004 107.897 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -143.9 147.36 33.91 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-N 119.772 1.169 . . . . 71.329999999999998 110.738 -171.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-N 120.152 1.342 . . . . 74.299999999999997 110.43 -177.201 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -80.48 161.91 24.64 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 117.774 -1.108 . . . . 73.340000000000003 108.988 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -100.57 40.33 1.27 Allowed 'General case' 0 C--N 1.358 0.942 0 CA-C-N 118.821 0.737 . . . . 71.319999999999993 110.916 175.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.4 p -69.85 126.86 30.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.125 -0.489 . . . . 73.109999999999999 110.902 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 . . . . . 0 CA--C 1.501 -0.92 0 CA-C-N 116.152 -0.476 . . . . 73.120000000000005 110.91 -179.946 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.763 0 CA-C-O 118.688 -1.062 . . . . 53.420000000000002 114.032 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.5 mt -128.29 25.49 5.81 Favored 'General case' 0 C--N 1.354 0.774 0 N-CA-C 108.712 -0.848 . . . . 74.340000000000003 108.712 172.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.8 m -162.33 -168.96 2.0 Allowed 'General case' 0 C--N 1.358 0.936 0 CA-C-O 116.645 -1.645 . . . . 62.32 109.745 -167.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -115.09 43.56 1.97 Allowed 'General case' 0 C--N 1.36 1.058 0 CA-C-N 120.382 1.446 . . . . 72.329999999999998 110.906 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.41 -142.87 1.03 Allowed Glycine 0 C--N 1.351 1.373 0 O-C-N 119.963 -1.71 . . . . 73.239999999999995 110.682 179.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.01 -21.9 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.68 0.74 . . . . 61.340000000000003 111.124 -173.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -98.45 116.04 65.59 Favored Pre-proline 0 C--N 1.361 1.093 0 O-C-N 117.474 -3.266 . . . . 72.030000000000001 107.954 -175.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -77.83 168.63 21.97 Favored 'Trans proline' 0 C--N 1.363 1.341 0 CA-C-N 123.983 2.458 . . . . 52.119999999999997 111.577 -175.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.59 -61.41 1.64 Allowed 'General case' 0 C--N 1.357 0.911 0 N-CA-C 108.597 -0.89 . . . . 74.519999999999996 108.597 178.069 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.9 mt -145.8 -65.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.986 0 CA-C-O 118.513 -0.756 . . . . 64.209999999999994 109.065 -174.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.02 -110.18 1.75 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 117.519 -1.712 . . . . 52.509999999999998 109.001 -176.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -124.01 62.35 1.08 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.81 -1.552 . . . . 71.219999999999999 106.81 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.31 158.57 43.57 Favored 'General case' 0 C--N 1.354 0.801 0 CA-C-O 116.969 -1.491 . . . . 72.299999999999997 107.888 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -143.57 147.13 33.95 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-N 119.859 1.208 . . . . 73.310000000000002 110.711 -172.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.53 160.78 31.72 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 120.143 1.338 . . . . 74.430000000000007 109.963 -178.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -88.76 173.71 8.41 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 108.13 -1.063 . . . . 64.409999999999997 108.13 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -100.41 40.76 1.22 Allowed 'General case' 0 C--N 1.356 0.884 0 CA-C-N 118.812 0.733 . . . . 54.229999999999997 110.872 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.92 149.01 48.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 72.319999999999993 110.843 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.925 0 CA-C-N 116.173 -0.467 . . . . 73.340000000000003 110.879 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.78 0 CA-C-O 118.738 -1.035 . . . . 60.109999999999999 113.596 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.4 mt -127.39 25.51 6.11 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.347 -0.835 . . . . 74.150000000000006 108.996 170.425 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.9 m -157.31 -173.36 4.39 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 117.145 -1.407 . . . . 75.129999999999995 109.666 -170.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -109.08 41.48 1.61 Allowed 'General case' 0 C--N 1.359 1.011 0 CA-C-N 119.745 1.157 . . . . 71.329999999999998 110.917 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -72.1 -140.64 0.32 Allowed Glycine 0 C--N 1.35 1.337 0 O-C-N 120.181 -1.575 . . . . 73.200000000000003 110.767 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -118.47 -22.72 3.99 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-N 117.985 0.893 . . . . 64.409999999999997 111.138 -173.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.6 114.94 65.87 Favored Pre-proline 0 C--N 1.362 1.131 0 O-C-N 117.136 -3.478 . . . . 73.230000000000004 108.032 -174.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -76.92 167.19 25.64 Favored 'Trans proline' 0 C--N 1.364 1.39 0 CA-C-N 124.209 2.539 . . . . 74.299999999999997 112.016 -174.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.43 -61.56 1.62 Allowed 'General case' 0 C--N 1.357 0.934 0 N-CA-C 108.606 -0.887 . . . . 72.430000000000007 108.606 177.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.2 mt -146.32 -65.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.997 0 CA-C-O 118.435 -0.793 . . . . 74.510000000000005 108.896 -174.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.22 -120.64 2.71 Favored Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.236 -1.869 . . . . 72.140000000000001 108.761 -178.19 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -112.72 62.63 0.63 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-N 119.475 1.637 . . . . 75.200000000000003 107.258 -179.018 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.21 157.99 44.24 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 116.812 -1.566 . . . . 74.25 108.005 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -146.48 146.24 30.48 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.887 1.221 . . . . 55.020000000000003 110.425 -173.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -72.86 157.28 37.77 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.332 1.424 . . . . 72.400000000000006 110.015 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -86.68 170.06 12.12 Favored 'General case' 0 C--N 1.356 0.876 0 CA-C-O 117.83 -1.081 . . . . 60.439999999999998 108.691 -178.54 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -99.98 40.36 1.25 Allowed 'General case' 0 C--N 1.358 0.937 0 CA-C-N 119.021 0.828 . . . . 74.140000000000001 110.918 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.6 m -69.86 147.32 50.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 73.140000000000001 110.89 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 . . . . . 0 CA--C 1.501 -0.922 0 CA-C-N 116.163 -0.472 . . . . 74.120000000000005 110.888 -179.953 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 37.9 mt . . . . . 0 CA--C 1.513 -0.446 0 N-CA-C 109.277 -0.638 . . . . 72.15 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -160.76 -170.13 2.64 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 117.344 -1.313 . . . . 73.05 109.756 -170.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -119.86 51.51 1.18 Allowed 'General case' 0 C--N 1.36 1.062 0 CA-C-N 119.404 1.002 . . . . 71.12 110.956 -178.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.06 -141.99 1.41 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.763 . . . . 50.24 112.489 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.55 -30.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.801 0.334 . . . . 63.42 111.121 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -96.06 121.21 61.33 Favored Pre-proline 0 C--N 1.358 0.968 0 O-C-N 117.801 -3.062 . . . . 74.52 107.741 -175.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -78.56 168.12 21.72 Favored 'Trans proline' 0 C--N 1.362 1.269 0 CA-C-N 123.65 2.339 . . . . 74.22 111.328 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -102.21 -62.27 1.29 Allowed 'General case' 0 C--N 1.357 0.918 0 CA-C-O 117.915 -1.041 . . . . 72.35 108.351 174.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.1 mt -146.95 -64.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.092 0 CA-C-N 119.22 0.918 . . . . 75.31 109.293 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.57 -132.59 6.38 Favored Glycine 0 C--N 1.359 1.818 0 N-CA-C 107.918 -2.073 . . . . 50.42 107.918 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -93.99 62.51 3.11 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 120.131 1.966 . . . . 73.22 108.591 176.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.3 t -139.21 160.45 39.77 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 117.885 -1.055 . . . . 72.42 108.578 176.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -150.42 165.64 32.53 Favored 'General case' 0 C--N 1.352 0.697 0 CA-C-O 118.411 -0.804 . . . . 74.43 110.862 -170.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -81.97 174.98 10.75 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-N 119.004 0.82 . . . . 74.22 111.539 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 . . . . . 0 C--N 1.358 0.945 0 CA-C-O 117.767 -1.111 . . . . 61.24 109.893 -175.98 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.3 mt . . . . . 0 CA--C 1.514 -0.424 0 N-CA-C 108.806 -0.813 . . . . 63.2 108.806 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.6 m -157.56 -169.92 3.04 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 117.589 -1.196 . . . . 63.1 109.215 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -120.6 51.45 1.23 Allowed 'General case' 0 C--N 1.358 0.962 0 CA-C-N 119.096 0.862 . . . . 72.32 110.888 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -142.0 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.694 -0.765 . . . . 62.01 112.477 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.54 -30.05 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.819 0.342 . . . . 71.52 111.105 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.62 121.63 59.31 Favored Pre-proline 0 C--N 1.358 0.972 0 O-C-N 117.774 -3.079 . . . . 74.11 107.736 -175.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.14 167.95 22.57 Favored 'Trans proline' 0 C--N 1.363 1.334 0 CA-C-N 123.7 2.357 . . . . 61.45 111.459 -176.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.17 -62.13 1.28 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.119 -0.943 . . . . 65.3 108.666 174.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.5 mt -148.22 -64.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.055 0 CA-C-N 119.106 0.866 . . . . 64.24 110.155 -174.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.2 -95.12 1.18 Allowed Glycine 0 C--N 1.357 1.737 0 N-CA-C 108.798 -1.721 . . . . 54.53 108.798 -174.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -136.54 54.09 1.89 Allowed 'General case' 0 C--N 1.355 0.827 0 N-CA-C 107.019 -1.474 . . . . 72.13 107.019 -178.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.2 t -138.13 163.85 30.63 Favored 'General case' 0 C--N 1.356 0.875 0 N-CA-C 107.602 -1.258 . . . . 70.52 107.602 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -149.38 165.48 31.92 Favored 'General case' 0 C--N 1.351 0.673 0 CA-C-N 119.232 0.924 . . . . 74.23 110.941 -171.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -81.02 174.41 11.64 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 118.127 -0.939 . . . . 74.32 111.545 -176.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.359 0.997 0 CA-C-O 118.054 -0.974 . . . . 72.54 109.48 -175.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.0 mt . . . . . 0 CA--C 1.515 -0.401 0 N-CA-C 108.689 -0.856 . . . . 73.42 108.689 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -159.15 -171.6 3.43 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-O 117.397 -1.287 . . . . 52.52 109.576 -172.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -119.83 51.47 1.18 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-N 119.22 0.918 . . . . 74.44 110.901 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -141.99 1.37 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.744 -0.741 . . . . 62.14 112.513 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.58 -29.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.812 0.339 . . . . 62.32 111.107 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -97.52 120.65 60.27 Favored Pre-proline 0 C--N 1.359 1.018 0 O-C-N 117.568 -3.208 . . . . 60.41 107.773 -174.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.2 166.07 25.04 Favored 'Trans proline' 0 C--N 1.364 1.364 0 CA-C-N 123.653 2.34 . . . . 72.14 111.314 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -99.61 -62.2 1.27 Allowed 'General case' 0 C--N 1.358 0.953 0 N-CA-C 108.402 -0.962 . . . . 53.1 108.402 175.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.2 mt -148.03 -64.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.025 0 CA-C-O 118.39 -0.814 . . . . 55.3 109.683 -174.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.46 -114.25 1.89 Allowed Glycine 0 C--N 1.358 1.786 0 N-CA-C 108.488 -1.845 . . . . 74.31 108.488 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -114.37 55.89 0.73 Allowed 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.302 1.551 . . . . 74.53 106.966 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -137.23 162.11 34.38 Favored 'General case' 0 C--N 1.355 0.837 0 N-CA-C 108.117 -1.068 . . . . 54.15 108.117 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -149.27 165.62 31.37 Favored 'General case' 0 C--N 1.352 0.676 0 CA-C-O 118.309 -0.853 . . . . 73.41 110.407 -171.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -81.37 174.09 11.82 Favored 'General case' 0 C--N 1.358 0.962 0 CA-C-O 118.071 -0.966 . . . . 71.14 111.024 -177.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 . . . . . 0 C--N 1.358 0.939 0 CA-C-O 117.809 -1.091 . . . . 61.34 110.926 -176.344 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 51.7 mt . . . . . 0 CA--C 1.514 -0.41 0 N-CA-C 108.884 -0.784 . . . . 65.23 108.884 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 m -155.72 -170.56 3.46 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 117.419 -1.277 . . . . 55.42 109.195 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -119.86 51.57 1.17 Allowed 'General case' 0 C--N 1.359 0.993 0 CA-C-N 119.313 0.96 . . . . 52.02 110.896 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.99 -141.95 1.38 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 55.41 112.478 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.62 -30.21 2.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.807 0.337 . . . . 72.14 111.126 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.29 121.95 59.04 Favored Pre-proline 0 C--N 1.359 0.981 0 O-C-N 117.763 -3.086 . . . . 73.03 107.731 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -77.91 166.96 24.43 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.773 2.383 . . . . 70.24 111.233 -176.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -100.71 -61.79 1.32 Allowed 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.328 -0.989 . . . . 62.14 108.328 174.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.1 mt -147.53 -64.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.013 0 CA-C-N 119.005 0.82 . . . . 71.52 109.717 -175.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.65 -115.99 2.32 Favored Glycine 0 C--N 1.357 1.74 0 N-CA-C 108.396 -1.881 . . . . 52.54 108.396 -177.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -112.22 58.98 0.63 Allowed 'General case' 0 C--N 1.357 0.909 0 CA-C-N 119.324 1.562 . . . . 74.5 106.93 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -140.56 160.02 40.92 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 117.806 -1.092 . . . . 70.35 108.218 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -148.84 165.45 31.47 Favored 'General case' 0 C--N 1.352 0.675 0 CA-C-O 118.342 -0.837 . . . . 64.51 110.526 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -80.97 174.87 11.19 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 119.265 0.939 . . . . 74.03 111.44 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 . . . . . 0 C--N 1.358 0.977 0 CA-C-O 117.865 -1.064 . . . . 74.24 108.857 -174.926 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 40.7 mt . . . . . 0 CA--C 1.513 -0.455 0 N-CA-C 109.27 -0.641 . . . . 63.4 109.27 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 m -160.39 -169.92 2.62 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 117.181 -1.39 . . . . 75.41 110.092 -170.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -120.28 51.45 1.21 Allowed 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.483 1.038 . . . . 63.34 110.873 -178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.92 -142.0 1.36 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 41.31 112.493 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.56 -30.58 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.75 0.31 . . . . 70.35 111.103 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.05 120.98 61.92 Favored Pre-proline 0 C--N 1.358 0.978 0 O-C-N 117.921 -2.987 . . . . 55.34 107.656 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -78.22 167.74 22.76 Favored 'Trans proline' 0 C--N 1.363 1.318 0 CA-C-N 123.76 2.378 . . . . 74.25 111.115 -175.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -101.42 -61.48 1.37 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 108.556 -0.905 . . . . 74.11 108.556 175.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.1 mt -146.63 -64.45 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.983 0 CA-C-O 118.378 -0.82 . . . . 70.43 109.576 -175.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.8 -112.75 2.54 Favored Glycine 0 C--N 1.357 1.748 0 N-CA-C 108.733 -1.747 . . . . 41.43 108.733 -177.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -114.15 56.03 0.72 Allowed 'General case' 0 C--N 1.355 0.838 0 N-CA-C 106.789 -1.559 . . . . 71.2 106.789 -177.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.9 t -140.61 162.26 35.8 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 117.995 -1.002 . . . . 72.23 108.64 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -151.01 166.82 29.53 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-O 118.294 -0.86 . . . . 73.12 110.693 -170.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -83.37 173.56 11.44 Favored 'General case' 0 C--N 1.358 0.944 0 CA-C-N 119.41 1.005 . . . . 73.54 111.89 -176.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 . . . . . 0 C--N 1.36 1.04 0 CA-C-N 119.168 0.894 . . . . 62.2 109.764 -177.259 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.7 mt . . . . . 0 CA--C 1.513 -0.451 0 N-CA-C 108.78 -0.822 . . . . 63.21 108.78 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.6 m -160.23 -171.62 3.26 Favored 'General case' 0 C--N 1.354 0.77 0 CA-C-O 117.398 -1.287 . . . . 35.44 109.855 -172.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.96 51.52 1.18 Allowed 'General case' 0 C--N 1.359 0.981 0 CA-C-N 119.213 0.915 . . . . 63.13 110.904 -178.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.11 -141.8 1.4 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.756 . . . . 62.02 112.482 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.7 -30.57 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 55.35 111.13 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.17 121.47 60.49 Favored Pre-proline 0 C--N 1.359 0.992 0 O-C-N 117.845 -3.034 . . . . 74.14 107.758 -175.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -78.17 166.79 24.2 Favored 'Trans proline' 0 C--N 1.364 1.363 0 CA-C-N 123.803 2.394 . . . . 75.42 111.25 -175.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -99.61 -61.24 1.39 Allowed 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.296 -1.001 . . . . 64.13 108.296 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 mt -146.77 -64.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.309 -0.853 . . . . 74.41 109.506 -175.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.2 -110.48 2.41 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 108.902 -1.679 . . . . 45.12 108.902 -177.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 51.1 mt-30 -115.8 54.04 0.83 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 106.717 -1.586 . . . . 74.02 106.717 -176.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.5 t -139.83 160.87 38.91 Favored 'General case' 0 C--N 1.354 0.783 0 N-CA-C 108.312 -0.995 . . . . 64.54 108.312 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -149.98 166.23 30.28 Favored 'General case' 0 C--N 1.351 0.674 0 CA-C-O 118.309 -0.853 . . . . 74.12 110.669 -170.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -82.19 174.38 11.24 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.04 0.837 . . . . 64.44 111.472 -176.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 . . . . . 0 C--N 1.358 0.96 0 CA-C-O 118.007 -0.997 . . . . 54.33 108.65 -175.292 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.0 mt . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.218 -0.896 . . . . 55.34 108.675 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.8 m -162.33 -168.21 1.8 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 116.594 -1.67 . . . . 73.03 109.577 -168.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -115.48 43.63 2.02 Favored 'General case' 0 C--N 1.362 1.12 0 CA-C-N 120.439 1.472 . . . . 61.33 110.925 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.57 1.0 Allowed Glycine 0 C--N 1.351 1.364 0 O-C-N 119.94 -1.725 . . . . 50.42 110.646 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.15 -21.96 4.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-N 117.659 0.73 . . . . 70.11 111.154 -173.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -98.37 115.8 65.67 Favored Pre-proline 0 C--N 1.361 1.098 0 O-C-N 117.543 -3.223 . . . . 74.3 108.044 -175.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -77.64 168.7 22.12 Favored 'Trans proline' 0 C--N 1.363 1.305 0 CA-C-N 124.07 2.489 . . . . 74.31 111.578 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.01 -61.42 1.66 Allowed 'General case' 0 C--N 1.359 0.979 0 N-CA-C 108.548 -0.908 . . . . 74.42 108.548 177.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.1 mt -146.37 -65.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.001 0 CA-C-O 118.397 -0.811 . . . . 63.45 109.271 -174.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.97 -107.81 1.27 Allowed Glycine 0 C--N 1.357 1.748 0 CA-C-O 117.457 -1.746 . . . . 71.44 109.124 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 tt0 -127.47 58.25 1.48 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 106.831 -1.544 . . . . 75.43 106.831 -178.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -139.02 159.57 41.84 Favored 'General case' 0 C--N 1.355 0.812 0 CA-C-O 117.023 -1.465 . . . . 62.34 107.871 -177.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.08 146.15 32.63 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-N 119.722 1.147 . . . . 75.13 110.881 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.13 160.16 32.93 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-N 120.135 1.334 . . . . 75.04 109.926 -178.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 . . . . . 0 C--N 1.356 0.866 0 N-CA-C 108.082 -1.081 . . . . 75.14 108.082 -178.798 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.2 mt . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.225 -0.893 . . . . 71.04 108.64 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.0 m -161.95 -170.12 2.43 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-O 116.76 -1.59 . . . . 75.35 109.852 -168.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -114.24 43.46 1.87 Allowed 'General case' 0 C--N 1.36 1.046 0 CA-C-N 120.119 1.327 . . . . 64.33 110.938 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.24 0.97 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 119.791 -1.818 . . . . 72.1 110.698 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.38 -22.77 4.33 Favored 'Isoleucine or valine' 0 C--N 1.357 0.892 0 CA-C-N 117.665 0.733 . . . . 72.24 111.164 -173.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.37 116.72 65.95 Favored Pre-proline 0 C--N 1.362 1.115 0 O-C-N 117.591 -3.193 . . . . 71.02 107.822 -174.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.11 168.79 21.37 Favored 'Trans proline' 0 C--N 1.363 1.338 0 CA-C-N 123.984 2.459 . . . . 70.43 111.593 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.48 -62.61 1.47 Allowed 'General case' 0 C--N 1.358 0.973 0 N-CA-C 108.419 -0.956 . . . . 74.11 108.419 177.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.3 mt -147.23 -66.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.979 0 CA-C-O 118.373 -0.822 . . . . 74.44 109.075 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.23 -105.26 1.09 Allowed Glycine 0 C--N 1.357 1.73 0 CA-C-O 117.637 -1.646 . . . . 74.02 109.338 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -129.29 60.19 1.57 Allowed 'General case' 0 C--N 1.357 0.92 0 N-CA-C 106.997 -1.483 . . . . 54.14 106.997 -177.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.95 163.7 32.08 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 117.117 -1.42 . . . . 73.14 108.445 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -146.6 148.06 31.72 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 117.885 -1.055 . . . . 52.32 111.005 -172.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -73.36 162.07 29.75 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-N 120.133 1.333 . . . . 75.51 110.041 -177.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 . . . . . 0 C--N 1.357 0.896 0 N-CA-C 108.023 -1.103 . . . . 73.13 108.023 -178.969 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 31.7 mt . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.217 -0.897 . . . . 71.52 109.171 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.4 m -158.64 -166.62 1.93 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-O 116.543 -1.694 . . . . 71.32 109.349 -169.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -115.37 43.57 2.01 Favored 'General case' 0 C--N 1.361 1.086 0 CA-C-N 120.553 1.524 . . . . 74.24 110.867 -177.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.2 -143.05 0.98 Allowed Glycine 0 C--N 1.351 1.395 0 O-C-N 120.076 -1.64 . . . . 72.35 110.713 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.94 -21.82 4.94 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 CA-C-N 117.634 0.717 . . . . 74.24 111.125 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.79 115.28 65.75 Favored Pre-proline 0 C--N 1.361 1.072 0 O-C-N 117.661 -3.149 . . . . 65.54 107.971 -175.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -77.34 168.5 22.85 Favored 'Trans proline' 0 C--N 1.363 1.297 0 CA-C-N 124.187 2.531 . . . . 75.15 111.58 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.12 -61.76 1.61 Allowed 'General case' 0 C--N 1.357 0.935 0 N-CA-C 108.328 -0.99 . . . . 75.34 108.328 177.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.4 mt -145.48 -65.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.971 0 CA-C-O 118.275 -0.869 . . . . 54.21 108.703 -174.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.82 -137.43 8.52 Favored Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.26 -1.855 . . . . 72.15 108.508 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -93.95 67.09 3.69 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.814 1.807 . . . . 74.43 107.854 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -141.91 154.6 45.22 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.057 -1.449 . . . . 75.41 108.228 177.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -144.0 143.58 31.27 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.592 1.087 . . . . 74.22 110.707 -171.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -69.07 161.14 29.66 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 120.072 1.305 . . . . 74.42 109.875 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 C--N 1.355 0.825 0 N-CA-C 107.327 -1.36 . . . . 71.15 107.327 -178.91 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 29.4 mt . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 118.259 -0.877 . . . . 44.42 108.719 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.7 m -159.11 -167.18 2.01 Favored 'General case' 0 C--N 1.357 0.935 0 CA-C-O 116.511 -1.709 . . . . 40.24 109.79 -169.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -115.18 43.44 2.01 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-N 120.499 1.5 . . . . 75.32 110.915 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.11 -142.95 0.94 Allowed Glycine 0 C--N 1.35 1.355 0 O-C-N 119.96 -1.713 . . . . 54.41 110.856 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.95 -22.19 4.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.857 0 CA-C-N 117.76 0.78 . . . . 74.52 111.161 -173.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -97.47 116.09 65.82 Favored Pre-proline 0 C--N 1.361 1.08 0 O-C-N 117.656 -3.153 . . . . 74.44 107.952 -175.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -78.05 168.93 21.23 Favored 'Trans proline' 0 C--N 1.361 1.209 0 CA-C-N 124.086 2.495 . . . . 75.52 111.426 -175.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -110.39 -61.75 1.62 Allowed 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.687 -0.857 . . . . 64.24 108.687 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.05 -65.29 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.371 -0.823 . . . . 72.41 109.173 -174.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.15 -109.78 1.56 Allowed Glycine 0 C--N 1.357 1.714 0 CA-C-O 117.567 -1.685 . . . . 60.23 109.044 -177.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.6 tt0 -124.86 61.64 1.16 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 106.571 -1.64 . . . . 64.31 106.571 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.04 158.52 43.67 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 116.941 -1.504 . . . . 73.23 107.952 -178.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -144.08 144.36 31.58 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.844 1.202 . . . . 70.14 110.86 -172.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -70.05 159.47 33.78 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.331 1.423 . . . . 74.13 109.913 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.354 0.804 0 N-CA-C 107.85 -1.167 . . . . 73.22 107.85 -179.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.4 mt . . . . . 0 C--O 1.221 -0.396 0 CA-C-O 117.514 -1.231 . . . . 52.45 109.68 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.5 m -158.57 -164.27 1.42 Allowed 'General case' 0 C--N 1.358 0.969 0 CA-C-O 116.019 -1.944 . . . . 75.51 109.475 -169.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -116.05 43.36 2.16 Favored 'General case' 0 C--N 1.361 1.094 0 CA-C-N 121.269 1.85 . . . . 60.04 110.936 -174.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.8 -143.66 0.93 Allowed Glycine 0 C--N 1.35 1.349 0 O-C-N 120.149 -1.595 . . . . 73.35 110.738 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.42 -22.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-N 117.642 0.721 . . . . 65.0 111.14 -173.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.01 117.82 65.43 Favored Pre-proline 0 C--N 1.361 1.104 0 O-C-N 117.532 -3.23 . . . . 71.5 107.864 -175.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.08 170.41 18.81 Favored 'Trans proline' 0 C--N 1.363 1.296 0 CA-C-N 124.046 2.481 . . . . 75.32 111.325 -175.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.2 -62.14 1.61 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 108.524 -0.917 . . . . 74.3 108.524 177.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.28 -65.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.017 0 CA-C-O 118.336 -0.84 . . . . 72.23 108.972 -174.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.39 -109.19 1.57 Allowed Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.447 -1.752 . . . . 42.31 109.143 -177.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -124.66 61.33 1.15 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 106.931 -1.507 . . . . 63.24 106.931 -177.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -142.73 157.79 44.29 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 116.955 -1.498 . . . . 72.41 108.088 -178.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -144.36 143.67 31.07 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.782 1.174 . . . . 72.22 110.705 -171.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -70.68 157.67 37.58 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 120.034 1.288 . . . . 63.01 110.151 -176.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 C--N 1.355 0.847 0 CA-C-O 117.368 -1.301 . . . . 75.0 108.748 -179.497 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.3 mt . . . . . 0 C--O 1.221 -0.412 0 N-CA-C 108.613 -0.884 . . . . 63.45 108.613 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -161.78 -171.07 2.77 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 116.954 -1.498 . . . . 53.34 109.793 -169.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -114.2 43.36 1.88 Allowed 'General case' 0 C--N 1.36 1.044 0 CA-C-N 119.951 1.251 . . . . 74.41 110.89 -177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.6 -143.76 0.9 Allowed Glycine 0 C--N 1.351 1.415 0 O-C-N 120.211 -1.555 . . . . 73.03 110.786 178.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.35 -22.93 4.38 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 CA-C-N 117.579 0.689 . . . . 71.42 111.133 -173.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -97.41 116.52 65.9 Favored Pre-proline 0 C--N 1.362 1.119 0 O-C-N 117.515 -3.241 . . . . 65.02 107.844 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.97 166.91 24.38 Favored 'Trans proline' 0 C--N 1.363 1.31 0 CA-C-N 123.995 2.463 . . . . 62.12 111.33 -174.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.16 -60.96 1.58 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.365 -0.976 . . . . 70.04 108.365 177.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.0 mt -145.29 -65.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.016 0 CA-C-O 118.168 -0.92 . . . . 74.3 108.897 -174.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.61 -115.31 3.54 Favored Glycine 0 C--N 1.358 1.75 0 CA-C-O 117.433 -1.759 . . . . 73.05 109.216 -177.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -110.78 63.14 0.61 Allowed 'General case' 0 C--N 1.358 0.953 0 CA-C-N 119.28 1.54 . . . . 63.21 107.871 -178.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -145.59 155.7 43.21 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 117.358 -1.306 . . . . 71.41 108.518 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -143.58 147.44 34.41 Favored 'General case' 0 C--N 1.354 0.795 0 CA-C-O 117.609 -1.186 . . . . 75.12 110.071 -172.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -73.38 159.96 32.51 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 120.183 1.356 . . . . 74.25 109.89 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 . . . . . 0 C--N 1.356 0.85 0 CA-C-O 117.616 -1.183 . . . . 65.11 108.249 -179.407 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 43.8 mt . . . . . 0 C--O 1.221 -0.412 0 N-CA-C 108.618 -0.882 . . . . 74.44 108.618 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.8 m -161.25 -169.89 2.48 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 116.756 -1.592 . . . . 73.45 109.751 -169.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -114.9 43.39 1.98 Allowed 'General case' 0 C--N 1.359 1.001 0 CA-C-N 120.11 1.323 . . . . 72.03 110.864 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.99 -143.1 0.92 Allowed Glycine 0 C--N 1.351 1.404 0 O-C-N 120.033 -1.667 . . . . 62.23 110.776 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.82 -21.95 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.858 0 CA-C-N 117.667 0.733 . . . . 75.55 111.163 -173.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.89 115.31 65.76 Favored Pre-proline 0 C--N 1.361 1.097 0 O-C-N 117.612 -3.18 . . . . 74.1 107.837 -175.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -77.63 166.59 25.4 Favored 'Trans proline' 0 C--N 1.362 1.258 0 CA-C-N 124.143 2.515 . . . . 62.1 111.471 -175.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.95 -61.36 1.55 Allowed 'General case' 0 C--N 1.357 0.922 0 N-CA-C 108.573 -0.899 . . . . 62.13 108.573 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.7 mt -146.23 -65.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.946 0 N-CA-C 108.772 -0.825 . . . . 74.0 108.772 -174.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.81 -122.05 3.11 Favored Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.332 -1.815 . . . . 53.03 108.63 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -110.13 63.87 0.61 Allowed 'General case' 0 C--N 1.358 0.946 0 CA-C-N 119.365 1.582 . . . . 64.3 107.094 -179.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.0 t -142.53 157.07 45.12 Favored 'General case' 0 C--N 1.354 0.782 0 CA-C-O 117.088 -1.434 . . . . 73.12 108.118 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -144.13 146.79 32.99 Favored 'General case' 0 C--N 1.354 0.768 0 CA-C-O 117.694 -1.146 . . . . 75.22 110.541 -172.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -72.08 161.05 31.45 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-N 120.148 1.34 . . . . 71.42 109.961 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 . . . . . 0 C--N 1.355 0.834 0 N-CA-C 107.856 -1.164 . . . . 61.22 107.856 -179.471 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.2 mt . . . . . 0 C--O 1.221 -0.397 0 N-CA-C 108.613 -0.884 . . . . 74.31 108.613 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -158.19 -169.94 2.96 Favored 'General case' 0 C--N 1.357 0.929 0 CA-C-O 116.786 -1.578 . . . . 32.45 109.697 -170.219 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -114.45 43.48 1.9 Allowed 'General case' 0 C--N 1.36 1.045 0 CA-C-N 120.132 1.333 . . . . 74.53 110.891 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.06 -143.16 0.94 Allowed Glycine 0 C--N 1.352 1.425 0 O-C-N 120.007 -1.683 . . . . 73.42 110.723 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.86 -22.38 4.63 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.617 0.708 . . . . 73.53 111.098 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -97.72 115.51 65.75 Favored Pre-proline 0 C--N 1.362 1.143 0 O-C-N 117.73 -3.106 . . . . 74.32 107.934 -175.129 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -77.81 166.94 24.62 Favored 'Trans proline' 0 C--N 1.364 1.369 0 CA-C-N 124.076 2.491 . . . . 60.41 111.722 -175.01 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.1 -61.9 1.48 Allowed 'General case' 0 C--N 1.357 0.912 0 N-CA-C 108.532 -0.914 . . . . 75.34 108.532 178.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.5 mt -147.23 -65.08 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.395 -0.812 . . . . 64.34 109.216 -174.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.44 -110.25 1.45 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.402 -1.777 . . . . 71.22 109.139 -176.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -123.44 58.96 1.11 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.815 -1.55 . . . . 61.33 106.815 -177.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -140.8 162.71 34.79 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 117.033 -1.461 . . . . 65.31 108.607 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -147.48 146.12 29.4 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.771 -1.109 . . . . 74.31 111.078 -171.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -72.94 159.5 33.6 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 120.207 1.367 . . . . 64.01 109.951 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 . . . . . 0 C--N 1.356 0.869 0 CA-C-O 117.826 -1.083 . . . . 74.13 108.76 -179.724 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.8 mt . . . . . 0 C--O 1.221 -0.429 0 N-CA-C 108.678 -0.86 . . . . 55.22 108.678 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -158.05 -168.92 2.64 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-O 116.64 -1.647 . . . . 70.32 109.534 -170.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -114.96 43.61 1.94 Allowed 'General case' 0 C--N 1.36 1.06 0 CA-C-N 120.265 1.393 . . . . 74.34 110.869 -177.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.49 -143.9 0.89 Allowed Glycine 0 C--N 1.352 1.439 0 O-C-N 120.41 -1.431 . . . . 64.23 110.743 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.36 -22.24 4.79 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 117.554 0.677 . . . . 74.14 111.146 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.69 115.59 65.75 Favored Pre-proline 0 C--N 1.362 1.12 0 O-C-N 117.728 -3.107 . . . . 73.02 108.094 -175.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.26 167.14 25.2 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 124.122 2.508 . . . . 73.4 111.534 -175.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.96 -62.08 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 N-CA-C 108.393 -0.965 . . . . 71.1 108.393 177.123 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.9 mt -146.89 -64.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-O 118.409 -0.805 . . . . 45.43 108.867 -174.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.65 -122.72 2.57 Favored Glycine 0 C--N 1.359 1.817 0 CA-C-O 117.187 -1.896 . . . . 74.04 108.639 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.4 tt0 -111.04 61.5 0.61 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 119.437 1.618 . . . . 72.44 107.183 -179.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.9 t -139.78 157.48 45.67 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 117.132 -1.414 . . . . 64.41 108.101 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -144.57 142.83 30.46 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.815 -1.088 . . . . 71.45 110.603 -171.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -70.54 155.74 40.32 Favored 'General case' 0 C--N 1.359 1.004 0 CA-C-N 120.081 1.309 . . . . 62.45 109.513 -178.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--N 1.357 0.906 0 CA-C-O 118.028 -0.987 . . . . 71.14 108.935 -179.129 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.9 mt . . . . . 0 C--O 1.221 -0.406 0 N-CA-C 108.596 -0.89 . . . . 42.05 108.596 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.8 m -159.5 -167.22 1.97 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-O 116.674 -1.631 . . . . 54.21 109.814 -171.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.8 43.31 2.13 Favored 'General case' 0 C--N 1.362 1.123 0 CA-C-N 120.278 1.399 . . . . 71.5 110.915 -177.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.71 -142.97 0.85 Allowed Glycine 0 C--N 1.351 1.394 0 O-C-N 119.992 -1.693 . . . . 65.32 110.707 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.88 -21.94 4.88 Favored 'Isoleucine or valine' 0 C--N 1.357 0.902 0 CA-C-N 117.556 0.678 . . . . 65.21 111.134 -173.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -98.75 115.09 65.93 Favored Pre-proline 0 C--N 1.362 1.135 0 O-C-N 117.632 -3.167 . . . . 71.13 107.789 -174.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -77.78 167.27 24.16 Favored 'Trans proline' 0 C--N 1.362 1.24 0 CA-C-N 123.967 2.453 . . . . 74.33 111.364 -174.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.33 -62.2 1.45 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.314 -0.995 . . . . 74.44 108.314 177.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.5 mt -146.56 -66.11 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.968 0 N-CA-C 108.757 -0.831 . . . . 54.44 108.757 -174.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.98 -117.79 1.8 Allowed Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.366 -1.797 . . . . 65.23 108.798 -177.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -115.91 62.14 0.7 Allowed 'General case' 0 C--N 1.357 0.924 0 N-CA-C 106.828 -1.545 . . . . 73.0 106.828 -178.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -142.05 157.97 44.3 Favored 'General case' 0 C--N 1.354 0.776 0 CA-C-O 117.214 -1.374 . . . . 65.12 108.234 -178.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -144.72 146.55 32.24 Favored 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.797 -1.097 . . . . 63.22 110.444 -172.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -72.55 158.92 34.78 Favored 'General case' 0 C--N 1.357 0.896 0 CA-C-N 120.143 1.338 . . . . 73.32 110.15 -177.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 . . . . . 0 C--N 1.356 0.876 0 N-CA-C 107.437 -1.32 . . . . 73.03 107.437 178.359 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.7 mt . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.96 -1.019 . . . . 75.4 109.317 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -157.94 -164.29 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-O 116.223 -1.846 . . . . 74.42 109.557 -169.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -116.52 43.44 2.21 Favored 'General case' 0 C--N 1.361 1.089 0 CA-C-N 120.816 1.643 . . . . 71.35 110.917 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.59 -142.48 1.04 Allowed Glycine 0 C--N 1.35 1.326 0 O-C-N 119.859 -1.776 . . . . 61.22 110.682 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.13 -22.35 4.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 117.798 0.799 . . . . 63.31 111.16 -173.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -97.72 116.27 65.76 Favored Pre-proline 0 C--N 1.36 1.03 0 O-C-N 117.503 -3.248 . . . . 74.41 108.074 -174.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -77.71 169.42 20.84 Favored 'Trans proline' 0 C--N 1.362 1.26 0 CA-C-N 124.089 2.496 . . . . 73.31 111.6 -175.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.07 -61.99 1.61 Allowed 'General case' 0 C--N 1.357 0.932 0 N-CA-C 108.644 -0.872 . . . . 64.21 108.644 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.6 mt -146.71 -65.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.33 -0.843 . . . . 74.33 109.219 -174.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -107.81 1.28 Allowed Glycine 0 C--N 1.356 1.671 0 CA-C-O 117.492 -1.727 . . . . 74.4 109.112 -176.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -128.01 59.73 1.48 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 106.928 -1.508 . . . . 71.01 106.928 -177.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.4 t -140.83 159.93 41.14 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 116.898 -1.525 . . . . 54.01 107.733 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -144.61 142.77 30.39 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 120.052 1.296 . . . . 71.42 110.978 -171.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -68.14 161.08 27.74 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.99 1.268 . . . . 64.51 109.519 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 . . . . . 0 C--N 1.353 0.745 0 N-CA-C 107.921 -1.14 . . . . 74.44 107.921 -177.426 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 mt . . . . . 0 C--O 1.221 -0.431 0 N-CA-C 108.44 -0.948 . . . . 71.43 108.44 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.7 m -159.04 -169.35 2.64 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 116.857 -1.544 . . . . 55.11 109.622 -169.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -114.41 43.61 1.87 Allowed 'General case' 0 C--N 1.36 1.031 0 CA-C-N 120.081 1.31 . . . . 51.14 110.912 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.46 -142.29 0.99 Allowed Glycine 0 C--N 1.352 1.419 0 O-C-N 119.909 -1.745 . . . . 74.23 110.68 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.37 -22.67 4.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 117.69 0.745 . . . . 42.11 111.13 -173.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.38 117.07 65.92 Favored Pre-proline 0 C--N 1.362 1.122 0 O-C-N 117.62 -3.175 . . . . 61.24 108.012 -175.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -77.94 170.32 19.1 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 124.036 2.477 . . . . 54.12 111.541 -175.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.63 -62.19 1.59 Allowed 'General case' 0 C--N 1.359 0.995 0 N-CA-C 108.479 -0.934 . . . . 53.12 108.479 177.552 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt -146.71 -65.41 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.998 0 CA-C-O 118.375 -0.821 . . . . 75.41 109.213 -174.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.21 -108.39 1.16 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.407 -1.774 . . . . 63.13 108.96 -177.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -127.49 59.85 1.43 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.255 1.527 . . . . 75.25 106.909 -178.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -139.69 158.93 43.3 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 116.923 -1.513 . . . . 65.23 107.897 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -143.9 147.36 33.91 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-N 119.772 1.169 . . . . 71.33 110.738 -171.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-N 120.152 1.342 . . . . 74.3 110.43 -177.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 . . . . . 0 C--N 1.355 0.845 0 CA-C-O 117.774 -1.108 . . . . 73.34 108.988 -179.892 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.5 mt . . . . . 0 C--O 1.221 -0.431 0 N-CA-C 108.712 -0.848 . . . . 74.34 108.712 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.8 m -162.33 -168.96 2.0 Allowed 'General case' 0 C--N 1.358 0.936 0 CA-C-O 116.645 -1.645 . . . . 62.32 109.745 -167.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -115.09 43.56 1.97 Allowed 'General case' 0 C--N 1.36 1.058 0 CA-C-N 120.382 1.446 . . . . 72.33 110.906 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.41 -142.87 1.03 Allowed Glycine 0 C--N 1.351 1.373 0 O-C-N 119.963 -1.71 . . . . 73.24 110.682 179.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.01 -21.9 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.68 0.74 . . . . 61.34 111.124 -173.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -98.45 116.04 65.59 Favored Pre-proline 0 C--N 1.361 1.093 0 O-C-N 117.474 -3.266 . . . . 72.03 107.954 -175.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -77.83 168.63 21.97 Favored 'Trans proline' 0 C--N 1.363 1.341 0 CA-C-N 123.983 2.458 . . . . 52.12 111.577 -175.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.59 -61.41 1.64 Allowed 'General case' 0 C--N 1.357 0.911 0 N-CA-C 108.597 -0.89 . . . . 74.52 108.597 178.069 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.9 mt -145.8 -65.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.986 0 CA-C-O 118.513 -0.756 . . . . 64.21 109.065 -174.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.02 -110.18 1.75 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 117.519 -1.712 . . . . 52.51 109.001 -176.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -124.01 62.35 1.08 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.81 -1.552 . . . . 71.22 106.81 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.31 158.57 43.57 Favored 'General case' 0 C--N 1.354 0.801 0 CA-C-O 116.969 -1.491 . . . . 72.3 107.888 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -143.57 147.13 33.95 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-N 119.859 1.208 . . . . 73.31 110.711 -172.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.53 160.78 31.72 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 120.143 1.338 . . . . 74.43 109.963 -178.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 . . . . . 0 C--N 1.356 0.848 0 N-CA-C 108.13 -1.063 . . . . 64.41 108.13 -178.806 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.4 mt . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 118.347 -0.835 . . . . 74.15 108.996 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.9 m -157.31 -173.36 4.39 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 117.145 -1.407 . . . . 75.13 109.666 -170.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -109.08 41.48 1.61 Allowed 'General case' 0 C--N 1.359 1.011 0 CA-C-N 119.745 1.157 . . . . 71.33 110.917 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -72.1 -140.64 0.32 Allowed Glycine 0 C--N 1.35 1.337 0 O-C-N 120.181 -1.575 . . . . 73.2 110.767 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -118.47 -22.72 3.99 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-N 117.985 0.893 . . . . 64.41 111.138 -173.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.6 114.94 65.87 Favored Pre-proline 0 C--N 1.362 1.131 0 O-C-N 117.136 -3.478 . . . . 73.23 108.032 -174.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -76.92 167.19 25.64 Favored 'Trans proline' 0 C--N 1.364 1.39 0 CA-C-N 124.209 2.539 . . . . 74.3 112.016 -174.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.43 -61.56 1.62 Allowed 'General case' 0 C--N 1.357 0.934 0 N-CA-C 108.606 -0.887 . . . . 72.43 108.606 177.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.2 mt -146.32 -65.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.997 0 CA-C-O 118.435 -0.793 . . . . 74.51 108.896 -174.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.22 -120.64 2.71 Favored Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.236 -1.869 . . . . 72.14 108.761 -178.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -112.72 62.63 0.63 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-N 119.475 1.637 . . . . 75.2 107.258 -179.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.21 157.99 44.24 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 116.812 -1.566 . . . . 74.25 108.005 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -146.48 146.24 30.48 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.887 1.221 . . . . 55.02 110.425 -173.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -72.86 157.28 37.77 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.332 1.424 . . . . 72.4 110.015 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 . . . . . 0 C--N 1.356 0.876 0 CA-C-O 117.83 -1.081 . . . . 60.44 108.691 -178.54 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.731 0 N-CA-C 109.885 -1.286 . . . . 61.15 109.885 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 37.9 mt -129.2 39.46 3.76 Favored 'General case' 0 C--N 1.355 0.825 0 CA-C-N 117.855 0.827 . . . . 72.15 109.277 -175.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -160.76 -170.13 2.64 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 117.344 -1.313 . . . . 73.05 109.756 -170.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.3 pt20 -119.86 51.51 1.18 Allowed 'General case' 0 C--N 1.36 1.062 0 CA-C-N 119.404 1.002 . . . . 71.12 110.956 -178.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.06 -141.99 1.41 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.697 -0.763 . . . . 50.24 112.489 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.55 -30.6 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.801 0.334 . . . . 63.42 111.121 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -96.06 121.21 61.33 Favored Pre-proline 0 C--N 1.358 0.968 0 O-C-N 117.801 -3.062 . . . . 74.52 107.741 -175.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -78.56 168.12 21.72 Favored 'Trans proline' 0 C--N 1.362 1.269 0 CA-C-N 123.65 2.339 . . . . 74.22 111.328 -175.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -102.21 -62.27 1.29 Allowed 'General case' 0 C--N 1.357 0.918 0 CA-C-O 117.915 -1.041 . . . . 72.35 108.351 174.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.1 mt -146.95 -64.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.361 1.092 0 CA-C-N 119.22 0.918 . . . . 75.31 109.293 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.57 -132.59 6.38 Favored Glycine 0 C--N 1.359 1.818 0 N-CA-C 107.918 -2.073 . . . . 50.42 107.918 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -93.99 62.51 3.11 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 120.131 1.966 . . . . 73.22 108.591 176.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.3 t -139.21 160.45 39.77 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 117.885 -1.055 . . . . 72.42 108.578 176.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 40.0 m-85 -150.42 165.64 32.53 Favored 'General case' 0 C--N 1.352 0.697 0 CA-C-O 118.411 -0.804 . . . . 74.43 110.862 -170.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -81.97 174.98 10.75 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-N 119.004 0.82 . . . . 74.22 111.539 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -92.03 175.36 6.9 Favored 'General case' 0 C--N 1.358 0.945 0 CA-C-O 117.767 -1.111 . . . . 61.24 109.893 -175.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -101.75 40.73 1.28 Allowed 'General case' 0 C--N 1.362 1.109 0 CA-C-N 119.371 0.987 . . . . 74.23 110.901 -178.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -69.88 158.18 36.03 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 51.13 110.876 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.501 -0.923 0 CA-C-N 116.143 -0.481 . . . . 72.15 110.908 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.766 0 N-CA-C 109.632 -1.387 . . . . 74.03 109.632 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 56.3 mt -132.49 41.43 3.2 Favored 'General case' 0 C--N 1.352 0.712 0 CA-C-N 117.996 0.898 . . . . 63.2 108.806 -179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.6 m -157.56 -169.92 3.04 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 117.589 -1.196 . . . . 63.1 109.215 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.9 pm0 -120.6 51.45 1.23 Allowed 'General case' 0 C--N 1.358 0.962 0 CA-C-N 119.096 0.862 . . . . 72.32 110.888 -178.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -142.0 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.694 -0.765 . . . . 62.01 112.477 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.54 -30.05 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.819 0.342 . . . . 71.52 111.105 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.62 121.63 59.31 Favored Pre-proline 0 C--N 1.358 0.972 0 O-C-N 117.774 -3.079 . . . . 74.11 107.736 -175.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.14 167.95 22.57 Favored 'Trans proline' 0 C--N 1.363 1.334 0 CA-C-N 123.7 2.357 . . . . 61.45 111.459 -176.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -101.17 -62.13 1.28 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.119 -0.943 . . . . 65.3 108.666 174.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.5 mt -148.22 -64.87 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.055 0 CA-C-N 119.106 0.866 . . . . 64.24 110.155 -174.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.2 -95.12 1.18 Allowed Glycine 0 C--N 1.357 1.737 0 N-CA-C 108.798 -1.721 . . . . 54.53 108.798 -174.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.3 tt0 -136.54 54.09 1.89 Allowed 'General case' 0 C--N 1.355 0.827 0 N-CA-C 107.019 -1.474 . . . . 72.13 107.019 -178.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 12.2 t -138.13 163.85 30.63 Favored 'General case' 0 C--N 1.356 0.875 0 N-CA-C 107.602 -1.258 . . . . 70.52 107.602 -179.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -149.38 165.48 31.92 Favored 'General case' 0 C--N 1.351 0.673 0 CA-C-N 119.232 0.924 . . . . 74.23 110.941 -171.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -81.02 174.41 11.64 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 118.127 -0.939 . . . . 74.32 111.545 -176.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.44 -179.35 5.57 Favored 'General case' 0 C--N 1.359 0.997 0 CA-C-O 118.054 -0.974 . . . . 72.54 109.48 -175.582 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -99.77 40.25 1.25 Allowed 'General case' 0 C--N 1.36 1.05 0 CA-C-N 119.108 0.867 . . . . 71.31 110.871 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.7 p -69.86 149.53 47.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.473 . . . . 75.23 110.883 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.501 -0.929 0 CA-C-N 116.156 -0.475 . . . . 74.31 110.87 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.723 0 CA-C-O 118.241 -1.311 . . . . 55.12 109.915 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 53.0 mt -132.48 43.1 3.04 Favored 'General case' 0 C--N 1.355 0.81 0 CA-C-N 118.397 1.098 . . . . 73.42 108.689 -178.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.0 m -159.15 -171.6 3.43 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-O 117.397 -1.287 . . . . 52.52 109.576 -172.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -119.83 51.47 1.18 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-N 119.22 0.918 . . . . 74.44 110.901 -178.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.95 -141.99 1.37 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.744 -0.741 . . . . 62.14 112.513 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.58 -29.59 2.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.812 0.339 . . . . 62.32 111.107 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -97.52 120.65 60.27 Favored Pre-proline 0 C--N 1.359 1.018 0 O-C-N 117.568 -3.208 . . . . 60.41 107.773 -174.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -78.2 166.07 25.04 Favored 'Trans proline' 0 C--N 1.364 1.364 0 CA-C-N 123.653 2.34 . . . . 72.14 111.314 -175.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -99.61 -62.2 1.27 Allowed 'General case' 0 C--N 1.358 0.953 0 N-CA-C 108.402 -0.962 . . . . 53.1 108.402 175.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 16.2 mt -148.03 -64.27 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.36 1.025 0 CA-C-O 118.39 -0.814 . . . . 55.3 109.683 -174.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.46 -114.25 1.89 Allowed Glycine 0 C--N 1.358 1.786 0 N-CA-C 108.488 -1.845 . . . . 74.31 108.488 -177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 16.5 tt0 -114.37 55.89 0.73 Allowed 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.302 1.551 . . . . 74.53 106.966 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -137.23 162.11 34.38 Favored 'General case' 0 C--N 1.355 0.837 0 N-CA-C 108.117 -1.068 . . . . 54.15 108.117 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 41.1 m-85 -149.27 165.62 31.37 Favored 'General case' 0 C--N 1.352 0.676 0 CA-C-O 118.309 -0.853 . . . . 73.41 110.407 -171.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.7 m-85 -81.37 174.09 11.82 Favored 'General case' 0 C--N 1.358 0.962 0 CA-C-O 118.071 -0.966 . . . . 71.14 111.024 -177.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -89.59 159.7 17.04 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 117.809 -1.091 . . . . 61.34 110.926 -176.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.26 40.44 1.53 Allowed 'General case' 0 C--N 1.362 1.124 0 CA-C-N 118.779 0.718 . . . . 54.13 110.88 -178.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 51.9 m -69.86 163.76 25.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 65.44 110.886 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.501 -0.942 0 CA-C-N 116.122 -0.49 . . . . 74.13 110.882 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.725 0 N-CA-C 109.557 -1.417 . . . . 63.44 109.557 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 51.7 mt -131.49 40.75 3.38 Favored 'General case' 0 C--N 1.353 0.729 0 CA-C-N 118.371 1.086 . . . . 65.23 108.884 -179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 m -155.72 -170.56 3.46 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 117.419 -1.277 . . . . 55.42 109.195 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 -119.86 51.57 1.17 Allowed 'General case' 0 C--N 1.359 0.993 0 CA-C-N 119.313 0.96 . . . . 52.02 110.896 -179.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.99 -141.95 1.38 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 55.41 112.478 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.62 -30.21 2.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.807 0.337 . . . . 72.14 111.126 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -96.29 121.95 59.04 Favored Pre-proline 0 C--N 1.359 0.981 0 O-C-N 117.763 -3.086 . . . . 73.03 107.731 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -77.91 166.96 24.43 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.773 2.383 . . . . 70.24 111.233 -176.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -100.71 -61.79 1.32 Allowed 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.328 -0.989 . . . . 62.14 108.328 174.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.1 mt -147.53 -64.49 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.013 0 CA-C-N 119.005 0.82 . . . . 71.52 109.717 -175.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.65 -115.99 2.32 Favored Glycine 0 C--N 1.357 1.74 0 N-CA-C 108.396 -1.881 . . . . 52.54 108.396 -177.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 19.0 tt0 -112.22 58.98 0.63 Allowed 'General case' 0 C--N 1.357 0.909 0 CA-C-N 119.324 1.562 . . . . 74.5 106.93 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 t -140.56 160.02 40.92 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 117.806 -1.092 . . . . 70.35 108.218 179.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -148.84 165.45 31.47 Favored 'General case' 0 C--N 1.352 0.675 0 CA-C-O 118.342 -0.837 . . . . 64.51 110.526 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -80.97 174.87 11.19 Favored 'General case' 0 C--N 1.356 0.882 0 CA-C-N 119.265 0.939 . . . . 74.03 111.44 -176.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 11.1 tt0 -92.13 -177.16 4.6 Favored 'General case' 0 C--N 1.358 0.977 0 CA-C-O 117.865 -1.064 . . . . 74.24 108.857 -174.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.8 pt-20 -100.39 40.49 1.25 Allowed 'General case' 0 C--N 1.36 1.059 0 CA-C-N 119.546 1.066 . . . . 74.45 110.901 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -69.87 156.08 39.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 75.01 110.837 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.5 mtt180 . . . . . 0 CA--C 1.501 -0.939 0 CA-C-N 116.118 -0.492 . . . . 75.14 110.877 -179.952 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.776 0 N-CA-C 109.802 -1.319 . . . . 72.13 109.802 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 40.7 mt -126.73 39.27 3.96 Favored 'General case' 0 C--N 1.353 0.734 0 CA-C-N 118.17 0.985 . . . . 63.4 109.27 -175.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 m -160.39 -169.92 2.62 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 117.181 -1.39 . . . . 75.41 110.092 -170.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -120.28 51.45 1.21 Allowed 'General case' 0 C--N 1.36 1.029 0 CA-C-N 119.483 1.038 . . . . 63.34 110.873 -178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -76.92 -142.0 1.36 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 41.31 112.493 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.56 -30.58 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.75 0.31 . . . . 70.35 111.103 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.05 120.98 61.92 Favored Pre-proline 0 C--N 1.358 0.978 0 O-C-N 117.921 -2.987 . . . . 55.34 107.656 -175.047 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -78.22 167.74 22.76 Favored 'Trans proline' 0 C--N 1.363 1.318 0 CA-C-N 123.76 2.378 . . . . 74.25 111.115 -175.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -101.42 -61.48 1.37 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 108.556 -0.905 . . . . 74.11 108.556 175.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 19.1 mt -146.63 -64.45 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.983 0 CA-C-O 118.378 -0.82 . . . . 70.43 109.576 -175.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -94.8 -112.75 2.54 Favored Glycine 0 C--N 1.357 1.748 0 N-CA-C 108.733 -1.747 . . . . 41.43 108.733 -177.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 11.9 mt-30 -114.15 56.03 0.72 Allowed 'General case' 0 C--N 1.355 0.838 0 N-CA-C 106.789 -1.559 . . . . 71.2 106.789 -177.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.9 t -140.61 162.26 35.8 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 117.995 -1.002 . . . . 72.23 108.64 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -151.01 166.82 29.53 Favored 'General case' 0 C--N 1.353 0.735 0 CA-C-O 118.294 -0.86 . . . . 73.12 110.693 -170.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -83.37 173.56 11.44 Favored 'General case' 0 C--N 1.358 0.944 0 CA-C-N 119.41 1.005 . . . . 73.54 111.89 -176.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -85.53 -178.05 6.58 Favored 'General case' 0 C--N 1.36 1.04 0 CA-C-N 119.168 0.894 . . . . 62.2 109.764 -177.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.9 pt-20 -103.27 40.34 1.42 Allowed 'General case' 0 C--N 1.361 1.093 0 C-N-CA 123.75 0.82 . . . . 62.25 110.855 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.95 150.64 46.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 74.11 110.808 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.906 0 CA-C-N 116.109 -0.496 . . . . 74.23 110.878 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.753 0 N-CA-C 109.855 -1.298 . . . . 53.32 109.855 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 52.7 mt -129.85 43.55 3.11 Favored 'General case' 0 C--N 1.353 0.722 0 CA-C-N 118.141 0.97 . . . . 63.21 108.78 -177.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.6 m -160.23 -171.62 3.26 Favored 'General case' 0 C--N 1.354 0.77 0 CA-C-O 117.398 -1.287 . . . . 35.44 109.855 -172.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.96 51.52 1.18 Allowed 'General case' 0 C--N 1.359 0.981 0 CA-C-N 119.213 0.915 . . . . 63.13 110.904 -178.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -77.11 -141.8 1.4 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.756 . . . . 62.02 112.482 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -111.7 -30.57 2.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 55.35 111.13 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -96.17 121.47 60.49 Favored Pre-proline 0 C--N 1.359 0.992 0 O-C-N 117.845 -3.034 . . . . 74.14 107.758 -175.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -78.17 166.79 24.2 Favored 'Trans proline' 0 C--N 1.364 1.363 0 CA-C-N 123.803 2.394 . . . . 75.42 111.25 -175.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -99.61 -61.24 1.39 Allowed 'General case' 0 C--N 1.356 0.88 0 N-CA-C 108.296 -1.001 . . . . 64.13 108.296 174.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 mt -146.77 -64.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.309 -0.853 . . . . 74.41 109.506 -175.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -95.2 -110.48 2.41 Favored Glycine 0 C--N 1.356 1.672 0 N-CA-C 108.902 -1.679 . . . . 45.12 108.902 -177.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 51.1 mt-30 -115.8 54.04 0.83 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 106.717 -1.586 . . . . 74.02 106.717 -176.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.5 t -139.83 160.87 38.91 Favored 'General case' 0 C--N 1.354 0.783 0 N-CA-C 108.312 -0.995 . . . . 64.54 108.312 -179.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -149.98 166.23 30.28 Favored 'General case' 0 C--N 1.351 0.674 0 CA-C-O 118.309 -0.853 . . . . 74.12 110.669 -170.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -82.19 174.38 11.24 Favored 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.04 0.837 . . . . 64.44 111.472 -176.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -91.55 -176.62 4.56 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.007 -0.997 . . . . 54.33 108.65 -175.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -102.16 40.5 1.33 Allowed 'General case' 0 C--N 1.359 1.0 0 CA-C-N 119.22 0.918 . . . . 61.12 110.906 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.9 m -69.88 155.17 40.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.148 -0.478 . . . . 61.21 110.891 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.501 -0.927 0 CA-C-N 116.124 -0.489 . . . . 74.51 110.859 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.219 -0.794 0 CA-C-O 118.525 -1.153 . . . . 72.33 113.872 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 28.0 mt -127.48 25.46 6.09 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 118.218 -0.896 . . . . 55.34 108.675 173.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.8 m -162.33 -168.21 1.8 Allowed 'General case' 0 C--N 1.358 0.952 0 CA-C-O 116.594 -1.67 . . . . 73.03 109.577 -168.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 9.6 pt20 -115.48 43.63 2.02 Favored 'General case' 0 C--N 1.362 1.12 0 CA-C-N 120.439 1.472 . . . . 61.33 110.925 -177.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.57 1.0 Allowed Glycine 0 C--N 1.351 1.364 0 O-C-N 119.94 -1.725 . . . . 50.42 110.646 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.15 -21.96 4.83 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-N 117.659 0.73 . . . . 70.11 111.154 -173.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -98.37 115.8 65.67 Favored Pre-proline 0 C--N 1.361 1.098 0 O-C-N 117.543 -3.223 . . . . 74.3 108.044 -175.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -77.64 168.7 22.12 Favored 'Trans proline' 0 C--N 1.363 1.305 0 CA-C-N 124.07 2.489 . . . . 74.31 111.578 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.01 -61.42 1.66 Allowed 'General case' 0 C--N 1.359 0.979 0 N-CA-C 108.548 -0.908 . . . . 74.42 108.548 177.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.1 mt -146.37 -65.57 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.001 0 CA-C-O 118.397 -0.811 . . . . 63.45 109.271 -174.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.97 -107.81 1.27 Allowed Glycine 0 C--N 1.357 1.748 0 CA-C-O 117.457 -1.746 . . . . 71.44 109.124 -176.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.0 tt0 -127.47 58.25 1.48 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 106.831 -1.544 . . . . 75.43 106.831 -178.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -139.02 159.57 41.84 Favored 'General case' 0 C--N 1.355 0.812 0 CA-C-O 117.023 -1.465 . . . . 62.34 107.871 -177.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.08 146.15 32.63 Favored 'General case' 0 C--N 1.355 0.828 0 CA-C-N 119.722 1.147 . . . . 75.13 110.881 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.13 160.16 32.93 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-N 120.135 1.334 . . . . 75.04 109.926 -178.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -91.53 169.52 10.69 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.082 -1.081 . . . . 75.14 108.082 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -100.04 40.0 1.28 Allowed 'General case' 0 C--N 1.357 0.91 0 CA-C-N 118.704 0.683 . . . . 72.33 110.897 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.93 166.53 19.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 65.52 110.845 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 1.8 ttt-85 . . . . . 0 CA--C 1.501 -0.91 0 CA-C-N 116.18 -0.464 . . . . 72.23 110.865 -179.921 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.742 0 CA-C-O 118.398 -1.224 . . . . 61.25 114.48 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.2 mt -125.48 26.72 6.72 Favored 'General case' 0 C--N 1.354 0.773 0 CA-C-O 118.225 -0.893 . . . . 71.04 108.64 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.0 m -161.95 -170.12 2.43 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-O 116.76 -1.59 . . . . 75.35 109.852 -168.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -114.24 43.46 1.87 Allowed 'General case' 0 C--N 1.36 1.046 0 CA-C-N 120.119 1.327 . . . . 64.33 110.938 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.43 -142.24 0.97 Allowed Glycine 0 C--N 1.352 1.426 0 O-C-N 119.791 -1.818 . . . . 72.1 110.698 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.38 -22.77 4.33 Favored 'Isoleucine or valine' 0 C--N 1.357 0.892 0 CA-C-N 117.665 0.733 . . . . 72.24 111.164 -173.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.37 116.72 65.95 Favored Pre-proline 0 C--N 1.362 1.115 0 O-C-N 117.591 -3.193 . . . . 71.02 107.822 -174.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -78.11 168.79 21.37 Favored 'Trans proline' 0 C--N 1.363 1.338 0 CA-C-N 123.984 2.459 . . . . 70.43 111.593 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.48 -62.61 1.47 Allowed 'General case' 0 C--N 1.358 0.973 0 N-CA-C 108.419 -0.956 . . . . 74.11 108.419 177.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 64.3 mt -147.23 -66.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.979 0 CA-C-O 118.373 -0.822 . . . . 74.44 109.075 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.23 -105.26 1.09 Allowed Glycine 0 C--N 1.357 1.73 0 CA-C-O 117.637 -1.646 . . . . 74.02 109.338 -176.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -129.29 60.19 1.57 Allowed 'General case' 0 C--N 1.357 0.92 0 N-CA-C 106.997 -1.483 . . . . 54.14 106.997 -177.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.95 163.7 32.08 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 117.117 -1.42 . . . . 73.14 108.445 -177.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -146.6 148.06 31.72 Favored 'General case' 0 C--N 1.355 0.805 0 CA-C-O 117.885 -1.055 . . . . 52.32 111.005 -172.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -73.36 162.07 29.75 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-N 120.133 1.333 . . . . 75.51 110.041 -177.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -88.52 169.76 11.46 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 108.023 -1.103 . . . . 73.13 108.023 -178.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 18.1 pt-20 -99.81 40.96 1.19 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.049 0.84 . . . . 61.13 110.872 176.257 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 45.9 t -69.87 151.34 45.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 54.51 110.824 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.915 0 CA-C-N 116.14 -0.482 . . . . 62.32 110.879 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.685 0 CA-C-O 118.721 -1.044 . . . . 54.03 113.821 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 31.7 mt -129.35 23.12 5.55 Favored 'General case' 0 C--N 1.353 0.746 0 CA-C-O 118.217 -0.897 . . . . 71.52 109.171 172.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.4 m -158.64 -166.62 1.93 Allowed 'General case' 0 C--N 1.359 0.985 0 CA-C-O 116.543 -1.694 . . . . 71.32 109.349 -169.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.8 pm0 -115.37 43.57 2.01 Favored 'General case' 0 C--N 1.361 1.086 0 CA-C-N 120.553 1.524 . . . . 74.24 110.867 -177.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.2 -143.05 0.98 Allowed Glycine 0 C--N 1.351 1.395 0 O-C-N 120.076 -1.64 . . . . 72.35 110.713 179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.94 -21.82 4.94 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 CA-C-N 117.634 0.717 . . . . 74.24 111.125 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.79 115.28 65.75 Favored Pre-proline 0 C--N 1.361 1.072 0 O-C-N 117.661 -3.149 . . . . 65.54 107.971 -175.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -77.34 168.5 22.85 Favored 'Trans proline' 0 C--N 1.363 1.297 0 CA-C-N 124.187 2.531 . . . . 75.15 111.58 -175.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.12 -61.76 1.61 Allowed 'General case' 0 C--N 1.357 0.935 0 N-CA-C 108.328 -0.99 . . . . 75.34 108.328 177.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.4 mt -145.48 -65.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.971 0 CA-C-O 118.275 -0.869 . . . . 54.21 108.703 -174.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.82 -137.43 8.52 Favored Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.26 -1.855 . . . . 72.15 108.508 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -93.95 67.09 3.69 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.814 1.807 . . . . 74.43 107.854 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -141.91 154.6 45.22 Favored 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.057 -1.449 . . . . 75.41 108.228 177.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.8 m-85 -144.0 143.58 31.27 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-N 119.592 1.087 . . . . 74.22 110.707 -171.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -69.07 161.14 29.66 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 120.072 1.305 . . . . 74.42 109.875 -178.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 4.0 tt0 -92.25 -179.44 5.24 Favored 'General case' 0 C--N 1.355 0.825 0 N-CA-C 107.327 -1.36 . . . . 71.15 107.327 -178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -100.67 40.81 1.23 Allowed 'General case' 0 C--N 1.356 0.856 0 CA-C-N 118.567 0.621 . . . . 70.11 110.883 177.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -69.98 140.14 52.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 73.24 110.822 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.3 ttm-85 . . . . . 0 CA--C 1.501 -0.933 0 CA-C-N 116.111 -0.495 . . . . 63.12 110.875 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.742 0 CA-C-O 118.682 -1.065 . . . . 51.34 113.87 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 29.4 mt -127.52 23.59 6.3 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.259 -0.877 . . . . 44.42 108.719 172.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.7 m -159.11 -167.18 2.01 Favored 'General case' 0 C--N 1.357 0.935 0 CA-C-O 116.511 -1.709 . . . . 40.24 109.79 -169.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -115.18 43.44 2.01 Favored 'General case' 0 C--N 1.361 1.091 0 CA-C-N 120.499 1.5 . . . . 75.32 110.915 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.11 -142.95 0.94 Allowed Glycine 0 C--N 1.35 1.355 0 O-C-N 119.96 -1.713 . . . . 54.41 110.856 179.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.95 -22.19 4.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.857 0 CA-C-N 117.76 0.78 . . . . 74.52 111.161 -173.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -97.47 116.09 65.82 Favored Pre-proline 0 C--N 1.361 1.08 0 O-C-N 117.656 -3.153 . . . . 74.44 107.952 -175.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.7 Cg_endo -78.05 168.93 21.23 Favored 'Trans proline' 0 C--N 1.361 1.209 0 CA-C-N 124.086 2.495 . . . . 75.52 111.426 -175.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -110.39 -61.75 1.62 Allowed 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.687 -0.857 . . . . 64.24 108.687 177.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.05 -65.29 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.371 -0.823 . . . . 72.41 109.173 -174.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.15 -109.78 1.56 Allowed Glycine 0 C--N 1.357 1.714 0 CA-C-O 117.567 -1.685 . . . . 60.23 109.044 -177.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.6 tt0 -124.86 61.64 1.16 Allowed 'General case' 0 C--N 1.356 0.864 0 N-CA-C 106.571 -1.64 . . . . 64.31 106.571 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.04 158.52 43.67 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 116.941 -1.504 . . . . 73.23 107.952 -178.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -144.08 144.36 31.58 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.844 1.202 . . . . 70.14 110.86 -172.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -70.05 159.47 33.78 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.331 1.423 . . . . 74.13 109.913 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.91 -178.56 5.5 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 107.85 -1.167 . . . . 73.22 107.85 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 20.8 pt-20 -101.15 40.11 1.33 Allowed 'General case' 0 C--N 1.356 0.882 0 CA-C-N 118.299 0.499 . . . . 62.32 110.874 176.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.9 t -69.94 172.3 8.02 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 63.51 110.832 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 11.1 mtt180 . . . . . 0 CA--C 1.501 -0.912 0 CA-C-N 116.105 -0.498 . . . . 71.13 110.92 -179.976 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.765 0 CA-C-O 118.667 -1.074 . . . . 24.44 113.145 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 33.4 mt -125.52 18.93 8.1 Favored 'General case' 0 C--N 1.353 0.749 0 CA-C-O 117.514 -1.231 . . . . 52.45 109.68 173.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.5 m -158.57 -164.27 1.42 Allowed 'General case' 0 C--N 1.358 0.969 0 CA-C-O 116.019 -1.944 . . . . 75.51 109.475 -169.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -116.05 43.36 2.16 Favored 'General case' 0 C--N 1.361 1.094 0 CA-C-N 121.269 1.85 . . . . 60.04 110.936 -174.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.8 -143.66 0.93 Allowed Glycine 0 C--N 1.35 1.349 0 O-C-N 120.149 -1.595 . . . . 73.35 110.738 178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.42 -22.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.356 0.875 0 CA-C-N 117.642 0.721 . . . . 65.0 111.14 -173.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.01 117.82 65.43 Favored Pre-proline 0 C--N 1.361 1.104 0 O-C-N 117.532 -3.23 . . . . 71.5 107.864 -175.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.08 170.41 18.81 Favored 'Trans proline' 0 C--N 1.363 1.296 0 CA-C-N 124.046 2.481 . . . . 75.32 111.325 -175.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.2 -62.14 1.61 Allowed 'General case' 0 C--N 1.357 0.926 0 N-CA-C 108.524 -0.917 . . . . 74.3 108.524 177.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.0 mt -146.28 -65.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.017 0 CA-C-O 118.336 -0.84 . . . . 72.23 108.972 -174.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -91.39 -109.19 1.57 Allowed Glycine 0 C--N 1.358 1.769 0 CA-C-O 117.447 -1.752 . . . . 42.31 109.143 -177.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 54.3 tt0 -124.66 61.33 1.15 Allowed 'General case' 0 C--N 1.357 0.909 0 N-CA-C 106.931 -1.507 . . . . 63.24 106.931 -177.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -142.73 157.79 44.29 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 116.955 -1.498 . . . . 72.41 108.088 -178.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -144.36 143.67 31.07 Favored 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.782 1.174 . . . . 72.22 110.705 -171.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -70.68 157.67 37.58 Favored 'General case' 0 C--N 1.357 0.934 0 CA-C-N 120.034 1.288 . . . . 63.01 110.151 -176.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -83.66 152.87 24.55 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 117.368 -1.301 . . . . 75.0 108.748 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -103.98 39.9 1.55 Allowed 'General case' 0 C--N 1.358 0.967 0 CA-C-N 119.158 0.89 . . . . 71.41 110.842 176.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -69.88 169.21 13.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.19 -0.459 . . . . 73.21 110.87 -179.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.7 ttt85 . . . . . 0 CA--C 1.501 -0.929 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.897 -179.919 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.98 -0.9 . . . . 55.34 114.128 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 41.3 mt -131.29 28.81 4.67 Favored 'General case' 0 C--N 1.353 0.738 0 N-CA-C 108.613 -0.884 . . . . 63.45 108.613 171.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.3 m -161.78 -171.07 2.77 Favored 'General case' 0 C--N 1.357 0.916 0 CA-C-O 116.954 -1.498 . . . . 53.34 109.793 -169.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -114.2 43.36 1.88 Allowed 'General case' 0 C--N 1.36 1.044 0 CA-C-N 119.951 1.251 . . . . 74.41 110.89 -177.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.6 -143.76 0.9 Allowed Glycine 0 C--N 1.351 1.415 0 O-C-N 120.211 -1.555 . . . . 73.03 110.786 178.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.35 -22.93 4.38 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 CA-C-N 117.579 0.689 . . . . 71.42 111.133 -173.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -97.41 116.52 65.9 Favored Pre-proline 0 C--N 1.362 1.119 0 O-C-N 117.515 -3.241 . . . . 65.02 107.844 -175.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -77.97 166.91 24.38 Favored 'Trans proline' 0 C--N 1.363 1.31 0 CA-C-N 123.995 2.463 . . . . 62.12 111.33 -174.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.16 -60.96 1.58 Allowed 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.365 -0.976 . . . . 70.04 108.365 177.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.0 mt -145.29 -65.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.016 0 CA-C-O 118.168 -0.92 . . . . 74.3 108.897 -174.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -98.61 -115.31 3.54 Favored Glycine 0 C--N 1.358 1.75 0 CA-C-O 117.433 -1.759 . . . . 73.05 109.216 -177.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -110.78 63.14 0.61 Allowed 'General case' 0 C--N 1.358 0.953 0 CA-C-N 119.28 1.54 . . . . 63.21 107.871 -178.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.2 t -145.59 155.7 43.21 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 117.358 -1.306 . . . . 71.41 108.518 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -143.58 147.44 34.41 Favored 'General case' 0 C--N 1.354 0.795 0 CA-C-O 117.609 -1.186 . . . . 75.12 110.071 -172.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -73.38 159.96 32.51 Favored 'General case' 0 C--N 1.356 0.883 0 CA-C-N 120.183 1.356 . . . . 74.25 109.89 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -90.69 165.47 13.68 Favored 'General case' 0 C--N 1.356 0.85 0 CA-C-O 117.616 -1.183 . . . . 65.11 108.249 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -101.59 40.07 1.36 Allowed 'General case' 0 C--N 1.357 0.934 0 CA-C-N 119.076 0.853 . . . . 63.15 110.888 176.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 88.3 p -69.87 158.69 35.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.114 -0.493 . . . . 73.51 110.831 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 6.4 ttm-85 . . . . . 0 CA--C 1.501 -0.927 0 CA-C-N 116.119 -0.491 . . . . 72.15 110.855 -179.961 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.78 -1.011 . . . . 73.24 114.064 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 43.8 mt -130.32 28.51 4.97 Favored 'General case' 0 C--N 1.354 0.775 0 N-CA-C 108.618 -0.882 . . . . 74.44 108.618 171.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.8 m -161.25 -169.89 2.48 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 116.756 -1.592 . . . . 73.45 109.751 -169.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -114.9 43.39 1.98 Allowed 'General case' 0 C--N 1.359 1.001 0 CA-C-N 120.11 1.323 . . . . 72.03 110.864 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.99 -143.1 0.92 Allowed Glycine 0 C--N 1.351 1.404 0 O-C-N 120.033 -1.667 . . . . 62.23 110.776 178.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.82 -21.95 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.858 0 CA-C-N 117.667 0.733 . . . . 75.55 111.163 -173.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -97.89 115.31 65.76 Favored Pre-proline 0 C--N 1.361 1.097 0 O-C-N 117.612 -3.18 . . . . 74.1 107.837 -175.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_endo -77.63 166.59 25.4 Favored 'Trans proline' 0 C--N 1.362 1.258 0 CA-C-N 124.143 2.515 . . . . 62.1 111.471 -175.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.95 -61.36 1.55 Allowed 'General case' 0 C--N 1.357 0.922 0 N-CA-C 108.573 -0.899 . . . . 62.13 108.573 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.7 mt -146.23 -65.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.946 0 N-CA-C 108.772 -0.825 . . . . 74.0 108.772 -174.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.81 -122.05 3.11 Favored Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.332 -1.815 . . . . 53.03 108.63 -178.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -110.13 63.87 0.61 Allowed 'General case' 0 C--N 1.358 0.946 0 CA-C-N 119.365 1.582 . . . . 64.3 107.094 -179.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.0 t -142.53 157.07 45.12 Favored 'General case' 0 C--N 1.354 0.782 0 CA-C-O 117.088 -1.434 . . . . 73.12 108.118 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -144.13 146.79 32.99 Favored 'General case' 0 C--N 1.354 0.768 0 CA-C-O 117.694 -1.146 . . . . 75.22 110.541 -172.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -72.08 161.05 31.45 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-N 120.148 1.34 . . . . 71.42 109.961 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -91.49 169.78 10.49 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 107.856 -1.164 . . . . 61.22 107.856 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -101.12 40.0 1.34 Allowed 'General case' 0 C--N 1.357 0.922 0 CA-C-N 118.967 0.803 . . . . 73.22 110.904 176.404 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 p -69.87 135.07 49.15 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 62.15 110.87 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 21.5 ttm180 . . . . . 0 CA--C 1.501 -0.923 0 CA-C-N 116.107 -0.497 . . . . 62.22 110.92 -179.948 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.771 0 CA-C-O 118.618 -1.101 . . . . 54.01 114.048 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 49.2 mt -127.36 27.37 5.87 Favored 'General case' 0 C--N 1.353 0.754 0 N-CA-C 108.613 -0.884 . . . . 74.31 108.613 171.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -158.19 -169.94 2.96 Favored 'General case' 0 C--N 1.357 0.929 0 CA-C-O 116.786 -1.578 . . . . 32.45 109.697 -170.219 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -114.45 43.48 1.9 Allowed 'General case' 0 C--N 1.36 1.045 0 CA-C-N 120.132 1.333 . . . . 74.53 110.891 -178.038 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.06 -143.16 0.94 Allowed Glycine 0 C--N 1.352 1.425 0 O-C-N 120.007 -1.683 . . . . 73.42 110.723 179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.86 -22.38 4.63 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.617 0.708 . . . . 73.53 111.098 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -97.72 115.51 65.75 Favored Pre-proline 0 C--N 1.362 1.143 0 O-C-N 117.73 -3.106 . . . . 74.32 107.934 -175.129 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -77.81 166.94 24.62 Favored 'Trans proline' 0 C--N 1.364 1.369 0 CA-C-N 124.076 2.491 . . . . 60.41 111.722 -175.01 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.1 -61.9 1.48 Allowed 'General case' 0 C--N 1.357 0.912 0 N-CA-C 108.532 -0.914 . . . . 75.34 108.532 178.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.5 mt -147.23 -65.08 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 1.0 0 CA-C-O 118.395 -0.812 . . . . 64.34 109.216 -174.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.44 -110.25 1.45 Allowed Glycine 0 C--N 1.358 1.768 0 CA-C-O 117.402 -1.777 . . . . 71.22 109.139 -176.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 55.7 tt0 -123.44 58.96 1.11 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.815 -1.55 . . . . 61.33 106.815 -177.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -140.8 162.71 34.79 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 117.033 -1.461 . . . . 65.31 108.607 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -147.48 146.12 29.4 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.771 -1.109 . . . . 74.31 111.078 -171.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -72.94 159.5 33.6 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 120.207 1.367 . . . . 64.01 109.951 -178.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 16.0 tt0 -87.21 163.22 17.03 Favored 'General case' 0 C--N 1.356 0.869 0 CA-C-O 117.826 -1.083 . . . . 74.13 108.76 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 19.4 pt-20 -102.04 39.91 1.41 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 118.608 0.64 . . . . 32.32 110.856 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -69.87 171.23 9.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.48 . . . . 72.4 110.876 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 63.7 mtt180 . . . . . 0 CA--C 1.501 -0.916 0 CA-C-N 116.14 -0.482 . . . . 70.42 110.886 -179.962 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.749 0 CA-C-O 118.851 -0.972 . . . . 41.14 113.815 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 46.8 mt -129.91 26.73 5.22 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 108.678 -0.86 . . . . 55.22 108.678 171.014 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.5 m -158.05 -168.92 2.64 Favored 'General case' 0 C--N 1.357 0.907 0 CA-C-O 116.64 -1.647 . . . . 70.32 109.534 -170.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -114.96 43.61 1.94 Allowed 'General case' 0 C--N 1.36 1.06 0 CA-C-N 120.265 1.393 . . . . 74.34 110.869 -177.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.49 -143.9 0.89 Allowed Glycine 0 C--N 1.352 1.439 0 O-C-N 120.41 -1.431 . . . . 64.23 110.743 179.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -115.36 -22.24 4.79 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 CA-C-N 117.554 0.677 . . . . 74.14 111.146 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -97.69 115.59 65.75 Favored Pre-proline 0 C--N 1.362 1.12 0 O-C-N 117.728 -3.107 . . . . 73.02 108.094 -175.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -77.26 167.14 25.2 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 124.122 2.508 . . . . 73.4 111.534 -175.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.96 -62.08 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 N-CA-C 108.393 -0.965 . . . . 71.1 108.393 177.123 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 49.9 mt -146.89 -64.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-O 118.409 -0.805 . . . . 45.43 108.867 -174.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.65 -122.72 2.57 Favored Glycine 0 C--N 1.359 1.817 0 CA-C-O 117.187 -1.896 . . . . 74.04 108.639 -178.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 17.4 tt0 -111.04 61.5 0.61 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 119.437 1.618 . . . . 72.44 107.183 -179.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.9 t -139.78 157.48 45.67 Favored 'General case' 0 C--N 1.355 0.806 0 CA-C-O 117.132 -1.414 . . . . 64.41 108.101 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -144.57 142.83 30.46 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.815 -1.088 . . . . 71.45 110.603 -171.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -70.54 155.74 40.32 Favored 'General case' 0 C--N 1.359 1.004 0 CA-C-N 120.081 1.309 . . . . 62.45 109.513 -178.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 -88.07 156.43 19.29 Favored 'General case' 0 C--N 1.357 0.906 0 CA-C-O 118.028 -0.987 . . . . 71.14 108.935 -179.129 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -105.62 39.97 1.65 Allowed 'General case' 0 C--N 1.357 0.933 0 O-C-N 123.76 0.663 . . . . 74.33 110.855 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.94 160.27 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.475 . . . . 53.32 110.831 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.6 ttp180 . . . . . 0 CA--C 1.501 -0.91 0 CA-C-N 116.077 -0.51 . . . . 74.22 110.905 -179.951 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.776 0 CA-C-O 118.878 -0.957 . . . . 45.54 113.863 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.9 mt -129.59 27.61 5.24 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 108.596 -0.89 . . . . 42.05 108.596 170.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.8 m -159.5 -167.22 1.97 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-O 116.674 -1.631 . . . . 54.21 109.814 -171.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -115.8 43.31 2.13 Favored 'General case' 0 C--N 1.362 1.123 0 CA-C-N 120.278 1.399 . . . . 71.5 110.915 -177.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -74.71 -142.97 0.85 Allowed Glycine 0 C--N 1.351 1.394 0 O-C-N 119.992 -1.693 . . . . 65.32 110.707 179.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -115.88 -21.94 4.88 Favored 'Isoleucine or valine' 0 C--N 1.357 0.902 0 CA-C-N 117.556 0.678 . . . . 65.21 111.134 -173.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -98.75 115.09 65.93 Favored Pre-proline 0 C--N 1.362 1.135 0 O-C-N 117.632 -3.167 . . . . 71.13 107.789 -174.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -77.78 167.27 24.16 Favored 'Trans proline' 0 C--N 1.362 1.24 0 CA-C-N 123.967 2.453 . . . . 74.33 111.364 -174.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.33 -62.2 1.45 Allowed 'General case' 0 C--N 1.358 0.966 0 N-CA-C 108.314 -0.995 . . . . 74.44 108.314 177.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 67.5 mt -146.56 -66.11 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.968 0 N-CA-C 108.757 -0.831 . . . . 54.44 108.757 -174.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.98 -117.79 1.8 Allowed Glycine 0 C--N 1.358 1.764 0 CA-C-O 117.366 -1.797 . . . . 65.23 108.798 -177.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.7 tt0 -115.91 62.14 0.7 Allowed 'General case' 0 C--N 1.357 0.924 0 N-CA-C 106.828 -1.545 . . . . 73.0 106.828 -178.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -142.05 157.97 44.3 Favored 'General case' 0 C--N 1.354 0.776 0 CA-C-O 117.214 -1.374 . . . . 65.12 108.234 -178.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -144.72 146.55 32.24 Favored 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.797 -1.097 . . . . 63.22 110.444 -172.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -72.55 158.92 34.78 Favored 'General case' 0 C--N 1.357 0.896 0 CA-C-N 120.143 1.338 . . . . 73.32 110.15 -177.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -87.66 174.0 8.69 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 107.437 -1.32 . . . . 73.03 107.437 178.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -101.68 40.08 1.36 Allowed 'General case' 0 C--N 1.356 0.868 0 C-N-CA 123.577 0.751 . . . . 64.33 110.857 174.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -69.85 159.35 33.8 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.16 -0.473 . . . . 64.32 110.905 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 8.4 ttt180 . . . . . 0 CA--C 1.501 -0.931 0 CA-C-N 116.163 -0.471 . . . . 53.22 110.843 -179.924 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.45 -1.194 . . . . 74.01 113.499 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 32.7 mt -124.44 20.65 8.74 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 117.96 -1.019 . . . . 75.4 109.317 172.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -157.94 -164.29 1.49 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-O 116.223 -1.846 . . . . 74.42 109.557 -169.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -116.52 43.44 2.21 Favored 'General case' 0 C--N 1.361 1.089 0 CA-C-N 120.816 1.643 . . . . 71.35 110.917 -175.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.59 -142.48 1.04 Allowed Glycine 0 C--N 1.35 1.326 0 O-C-N 119.859 -1.776 . . . . 61.22 110.682 179.228 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.13 -22.35 4.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.872 0 CA-C-N 117.798 0.799 . . . . 63.31 111.16 -173.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -97.72 116.27 65.76 Favored Pre-proline 0 C--N 1.36 1.03 0 O-C-N 117.503 -3.248 . . . . 74.41 108.074 -174.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -77.71 169.42 20.84 Favored 'Trans proline' 0 C--N 1.362 1.26 0 CA-C-N 124.089 2.496 . . . . 73.31 111.6 -175.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.07 -61.99 1.61 Allowed 'General case' 0 C--N 1.357 0.932 0 N-CA-C 108.644 -0.872 . . . . 64.21 108.644 178.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.6 mt -146.71 -65.3 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.358 0.97 0 CA-C-O 118.33 -0.843 . . . . 74.33 109.219 -174.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -90.02 -107.81 1.28 Allowed Glycine 0 C--N 1.356 1.671 0 CA-C-O 117.492 -1.727 . . . . 74.4 109.112 -176.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -128.01 59.73 1.48 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 106.928 -1.508 . . . . 71.01 106.928 -177.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.4 t -140.83 159.93 41.14 Favored 'General case' 0 C--N 1.354 0.794 0 CA-C-O 116.898 -1.525 . . . . 54.01 107.733 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -144.61 142.77 30.39 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 120.052 1.296 . . . . 71.42 110.978 -171.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -68.14 161.08 27.74 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.99 1.268 . . . . 64.51 109.519 -178.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.7 tt0 -92.78 177.48 6.08 Favored 'General case' 0 C--N 1.353 0.745 0 N-CA-C 107.921 -1.14 . . . . 74.44 107.921 -177.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -101.95 40.75 1.29 Allowed 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.239 0.927 . . . . 72.01 110.903 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 73.3 m -69.91 163.12 26.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 71.31 110.865 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.8 ttp85 . . . . . 0 CA--C 1.501 -0.928 0 CA-C-N 116.118 -0.492 . . . . 72.33 110.89 -179.938 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.741 0 CA-C-O 118.647 -1.085 . . . . 52.21 113.751 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 27.5 mt -126.82 25.76 6.29 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 108.44 -0.948 . . . . 71.43 108.44 172.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.7 m -159.04 -169.35 2.64 Favored 'General case' 0 C--N 1.358 0.942 0 CA-C-O 116.857 -1.544 . . . . 55.11 109.622 -169.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -114.41 43.61 1.87 Allowed 'General case' 0 C--N 1.36 1.031 0 CA-C-N 120.081 1.31 . . . . 51.14 110.912 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.46 -142.29 0.99 Allowed Glycine 0 C--N 1.352 1.419 0 O-C-N 119.909 -1.745 . . . . 74.23 110.68 179.32 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.37 -22.67 4.39 Favored 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 117.69 0.745 . . . . 42.11 111.13 -173.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -97.38 117.07 65.92 Favored Pre-proline 0 C--N 1.362 1.122 0 O-C-N 117.62 -3.175 . . . . 61.24 108.012 -175.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -77.94 170.32 19.1 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 124.036 2.477 . . . . 54.12 111.541 -175.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -111.63 -62.19 1.59 Allowed 'General case' 0 C--N 1.359 0.995 0 N-CA-C 108.479 -0.934 . . . . 53.12 108.479 177.552 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt -146.71 -65.41 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.998 0 CA-C-O 118.375 -0.821 . . . . 75.41 109.213 -174.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -89.21 -108.39 1.16 Allowed Glycine 0 C--N 1.358 1.76 0 CA-C-O 117.407 -1.774 . . . . 63.13 108.96 -177.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 20.8 tt0 -127.49 59.85 1.43 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-N 119.255 1.527 . . . . 75.25 106.909 -178.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -139.69 158.93 43.3 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 116.923 -1.513 . . . . 65.23 107.897 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -143.9 147.36 33.91 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-N 119.772 1.169 . . . . 71.33 110.738 -171.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.358 0.964 0 CA-C-N 120.152 1.342 . . . . 74.3 110.43 -177.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -80.48 161.91 24.64 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 117.774 -1.108 . . . . 73.34 108.988 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -100.57 40.33 1.27 Allowed 'General case' 0 C--N 1.358 0.942 0 CA-C-N 118.821 0.737 . . . . 71.32 110.916 175.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.4 p -69.85 126.86 30.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.125 -0.489 . . . . 73.11 110.902 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.4 mtp180 . . . . . 0 CA--C 1.501 -0.92 0 CA-C-N 116.152 -0.476 . . . . 73.12 110.91 -179.946 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.763 0 CA-C-O 118.688 -1.062 . . . . 53.42 114.032 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 30.5 mt -128.29 25.49 5.81 Favored 'General case' 0 C--N 1.354 0.774 0 N-CA-C 108.712 -0.848 . . . . 74.34 108.712 172.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.8 m -162.33 -168.96 2.0 Allowed 'General case' 0 C--N 1.358 0.936 0 CA-C-O 116.645 -1.645 . . . . 62.32 109.745 -167.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -115.09 43.56 1.97 Allowed 'General case' 0 C--N 1.36 1.058 0 CA-C-N 120.382 1.446 . . . . 72.33 110.906 -177.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -75.41 -142.87 1.03 Allowed Glycine 0 C--N 1.351 1.373 0 O-C-N 119.963 -1.71 . . . . 73.24 110.682 179.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.9 m -116.01 -21.9 4.88 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 117.68 0.74 . . . . 61.34 111.124 -173.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -98.45 116.04 65.59 Favored Pre-proline 0 C--N 1.361 1.093 0 O-C-N 117.474 -3.266 . . . . 72.03 107.954 -175.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -77.83 168.63 21.97 Favored 'Trans proline' 0 C--N 1.363 1.341 0 CA-C-N 123.983 2.458 . . . . 52.12 111.577 -175.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.59 -61.41 1.64 Allowed 'General case' 0 C--N 1.357 0.911 0 N-CA-C 108.597 -0.89 . . . . 74.52 108.597 178.069 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 50.9 mt -145.8 -65.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.986 0 CA-C-O 118.513 -0.756 . . . . 64.21 109.065 -174.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.02 -110.18 1.75 Allowed Glycine 0 C--N 1.357 1.71 0 CA-C-O 117.519 -1.712 . . . . 52.51 109.001 -176.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 22.6 tt0 -124.01 62.35 1.08 Allowed 'General case' 0 C--N 1.357 0.898 0 N-CA-C 106.81 -1.552 . . . . 71.22 106.81 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.6 t -142.31 158.57 43.57 Favored 'General case' 0 C--N 1.354 0.801 0 CA-C-O 116.969 -1.491 . . . . 72.3 107.888 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -143.57 147.13 33.95 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-N 119.859 1.208 . . . . 73.31 110.711 -172.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -72.53 160.78 31.72 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 120.143 1.338 . . . . 74.43 109.963 -178.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -88.76 173.71 8.41 Favored 'General case' 0 C--N 1.356 0.848 0 N-CA-C 108.13 -1.063 . . . . 64.41 108.13 -178.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -100.41 40.76 1.22 Allowed 'General case' 0 C--N 1.356 0.884 0 CA-C-N 118.812 0.733 . . . . 54.23 110.872 177.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.92 149.01 48.26 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 72.32 110.843 -179.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.501 -0.925 0 CA-C-N 116.173 -0.467 . . . . 73.34 110.879 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.78 0 CA-C-O 118.738 -1.035 . . . . 60.11 113.596 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 44.4 mt -127.39 25.51 6.11 Favored 'General case' 0 C--N 1.354 0.793 0 CA-C-O 118.347 -0.835 . . . . 74.15 108.996 170.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.9 m -157.31 -173.36 4.39 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 117.145 -1.407 . . . . 75.13 109.666 -170.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -109.08 41.48 1.61 Allowed 'General case' 0 C--N 1.359 1.011 0 CA-C-N 119.745 1.157 . . . . 71.33 110.917 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -72.1 -140.64 0.32 Allowed Glycine 0 C--N 1.35 1.337 0 O-C-N 120.181 -1.575 . . . . 73.2 110.767 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.8 m -118.47 -22.72 3.99 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-N 117.985 0.893 . . . . 64.41 111.138 -173.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -98.6 114.94 65.87 Favored Pre-proline 0 C--N 1.362 1.131 0 O-C-N 117.136 -3.478 . . . . 73.23 108.032 -174.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -76.92 167.19 25.64 Favored 'Trans proline' 0 C--N 1.364 1.39 0 CA-C-N 124.209 2.539 . . . . 74.3 112.016 -174.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.43 -61.56 1.62 Allowed 'General case' 0 C--N 1.357 0.934 0 N-CA-C 108.606 -0.887 . . . . 72.43 108.606 177.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 51.2 mt -146.32 -65.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.359 0.997 0 CA-C-O 118.435 -0.793 . . . . 74.51 108.896 -174.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.22 -120.64 2.71 Favored Glycine 0 C--N 1.358 1.751 0 CA-C-O 117.236 -1.869 . . . . 72.14 108.761 -178.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLN . . . . . . . . . . . . . 18.4 tt0 -112.72 62.63 0.63 Allowed 'General case' 0 C--N 1.357 0.921 0 CA-C-N 119.475 1.637 . . . . 75.2 107.258 -179.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.8 t -142.21 157.99 44.24 Favored 'General case' 0 C--N 1.353 0.76 0 CA-C-O 116.812 -1.566 . . . . 74.25 108.005 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -146.48 146.24 30.48 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.887 1.221 . . . . 55.02 110.425 -173.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -72.86 157.28 37.77 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 120.332 1.424 . . . . 72.4 110.015 -178.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 18.2 tt0 -86.68 170.06 12.12 Favored 'General case' 0 C--N 1.356 0.876 0 CA-C-O 117.83 -1.081 . . . . 60.44 108.691 -178.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -99.98 40.36 1.25 Allowed 'General case' 0 C--N 1.358 0.937 0 CA-C-N 119.021 0.828 . . . . 74.14 110.918 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.6 m -69.86 147.32 50.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 73.14 110.89 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.3 mtm180 . . . . . 0 CA--C 1.501 -0.922 0 CA-C-N 116.163 -0.472 . . . . 74.12 110.888 -179.953 . . . . . . . . 0 0 . 1 stop_ save_